

Review Article

Biochemistry, pharmacology and *in vivo* function of arginases

Sophia K. Heuser^{1*}, Junjie Li^{1*}, Silke Pudewell², Anthea LoBue¹, Zhixin Li¹, Miriam M. Cortese-Krott^{1,3#}

¹Myocardial Infarction Research Laboratory, Department of Cardiology, Pulmonology, and Angiology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany; ²Department of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany; ³CARID, Cardiovascular Research Institute Düsseldorf; ³Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden

*Contributed equally

Manuscript pages: 77 pages

Figures: 8 Figures

Table: 5 Table

Word count Abstract: 233 words

Word Count Significance Statement: 55 words

#Correspondence to:

Miriam M. Cortese-Krott, PhD

Myocardial Infarction Research Laboratory,

Department of Cardiology, Pulmonology, and Vascular Medicine,

Medical Faculty, Heinrich-Heine-University of Düsseldorf

Postfach 1108, Moorenstraße 5, 40225 Düsseldorf, Germany

E-Mail: Miriam.cortese@hhu.de

Tel.: +49 (0) 211 81 15115

Abstract

Arginase catalyzes the hydrolysis of L-arginine into L-ornithine and urea. The two existing isoforms Arg1 and Arg2 show different cellular localizations and metabolic functions. Arginase activity is crucial for nitrogen detoxification in the urea cycle, synthesis of polyamines, and control of L-arginine bioavailability and nitric oxide (NO) production. Despite significant progress in the understanding of the biochemistry and function of arginases, several open questions remain. Recent studies have revealed that the regulation and function of Arg1 and Arg2 are cell-type-specific, species-specific, and profoundly different in mice and humans. The main differences were found in the distribution and function of Arg1 and Arg2 in immune and erythroid cells. Contrary to what was previously thought, Arg1 activity appears to be only partially related to vascular NO signaling under homeostatic conditions in the vascular wall, but its expression is increased under disease conditions and may be targeted by treatment with arginase inhibitors. Arg2 appears to be mainly a catabolic enzyme involved in the synthesis of L-ornithine, polyamine, and L-proline but may play a putative role in blood pressure control, at least in mice. The immunosuppressive role of arginase-mediated arginine depletion is a promising target for cancer treatment. This review critically revises and discusses the biochemistry, pharmacology, and *in vivo* function of arginases, focusing on the insights gained from the analysis of cell-specific Arg1 and Arg2 knockout mice and human studies using arginase inhibitors or pegylated recombinant arginase.

Significance statement. The review emphasizes the need for further research to deepen our understanding of the regulation of Arg1 and Arg 2 in different cell types under consideration of their localization, species-specificity, and multiple biochemical and physiological roles. This will lead to better pharmacological strategies to target arginase activity in liver, cardiovascular, hematological, immune/infection diseases and cancer.

Running title: Pharmacology of arginases

Keywords: Arginase inhibitors, enzymatic catalysis of arginase, endothelial dysfunction, liver disease, red blood cells

Table of Contents

Abstract	2
Table of Contents	4
Abbreviations.....	6
I. Introduction	7
II. Biochemistry and regulation of arginase expression and activity	9
A. Genetic characteristics and regulation	9
B. Protein structure and catalysis	11
C. Summary.....	13
III. Biochemical assays for the determination of arginase activity and L-arginine metabolomics 14	
A. The urea assay: colorimetric determination of urea formation in cells and tissues	14
B. Colorimetric determination of L-ornithine	15
C. The radioactive assay: Conversion of ¹⁴ C-L-arginine into L-ornithine and ¹⁴ C-urea.....	15
D. Systemic analysis of L-arginine bioavailability and L-arginine metabolism.	17
E. Summary	18
IV. The biological role of arginase in cells and tissues	19
A. Role of arginase in the liver	19
B. Role of arginase in the immune system.....	21
C. Role of arginase in red blood cells	25
D. Role of arginase in the vasculature	28
E. Role of arginase in the heart.....	31
F. L-Arginine metabolism and role of arginase in the kidney	32
G. Summary and outlook	35
V. L-Arginine metabolism and arginase activity in human disease	38
A. Measurements of arginase expression and activity in human disease.....	38

B. Measurement of L-arginine bioavailability in human cohorts with cardiometabolic disease	41
C. Arginase as a pharmacological target	42
D. L-arginine/L-arginine metabolites supplementation	44
E. Summary and outlook.....	45
VI. Conclusion and outlook.....	46
VII. References	48
VIII. Tables	65
IX. Footnotes.....	76
Authorship contribution	76
Acknowledgements	76
Data Availability Statement	76
X. Legend of figures.....	77

Abbreviations

2-(S)-amino-5-borono-hexanoic acid, ABH; Arginase 1, Arg1; Arginase 2, Arg2; asymmetric dimethylarginine, ADMA; coronary artery disease, CAD; cardiovascular disease, CVD; endothelial cells, ECs; endothelial nitric oxide synthase, eNOS; endothelium-dependent vasodilation, EDV; global L-arginine bioavailability ratio, GABR; hepatic stellate cells, HSC; inducible nitric oxide synthase, iNOS; interleukin, IL; ischemia reperfusion, I/R; isonitrosopropiophenone ISPF;; maximum reaction rate, V_{max} ; Michaelis constant, K_m ; mitogen activated protein kinase, MAPK; mass spectrometry, MS; Myeloid-derived suppressor cells, MDSC; myocardial infarction, MI; nitric oxide synthase, NOS; nitric oxide, NO; N ω -hydroxy-nor-arginine, nor-NOHA; red blood cells, RBCs; polymorphonuclear neutrophils, PMN; sickle cell disease, SCD; signal transducer and activator of transcription, STAT; solute carrier family 25 member 29, SLC25A29; streptozotocin, STZ; type 2 diabetes mellitus, T2DM; T cell receptor

1 I. Introduction

2 The enzyme arginase (L-arginine-urea hydrolase; EC 3.5.3.1) catalyzes the hydrolysis of L-
3 arginine to L-ornithine and urea and thereby participates in the final step of the urea cycle
4 (**Fig. 1**). In mammals there are two isoforms of arginase, defined as arginase 1 (Arg1) and
5 arginase 2 (Arg2), which are codified by independent genes (Arg1 6q23; Arg2 14q24.1-24.3)
6 (Sparkes et al., 1986, Gotoh et al., 1997). The two isoenzymes differ substantially in
7 subcellular localization and function. Arg1 is mainly localized in the cytoplasm and is highly
8 expressed in hepatocytes in the liver and participates in the urea cycle. Instead, Arg2 is a
9 mitochondrial enzyme that was first identified in the kidney (Kaysen and Strecker, 1973), but
10 its function in the kidney and elsewhere has been unclear for many years.

11 Arg1 was found to regulate L-arginine bioavailability and nitric oxide (NO) synthesis from
12 nitric oxide synthases (NOSs) in the immune system and the cardiovascular system
13 (Durante et al., 2007); therefore, Arg1 was proposed to modulate macrophage M1/M2
14 polarization, suppress T-cell responses and regulate vascular endothelial function and NO-
15 mediated cardioprotection. However, There is accumulating evidence from cell-specific mice
16 and multiomics studies demonstrating that some of these mechanisms are instead
17 modulated by Arg2, depend on the cell type or health/disease conditions, are species-
18 specific and, in many cases, profoundly different in mouse and man.

19 Moreover, by synthesizing L-ornithine, arginases are also crucial for the generation and
20 intracellular availability of polyamines, such as putrescine, spermidine, and spermine (**Fig. 2**)
21 Notably, polyamines have been shown to be involved in the promotion of stem cell self-
22 renewal (James et al., 2018), the induction of autophagy (Hofer et al., 2022), the protection
23 against neurological disorders (Ghosh et al., 2020), immune cell functions, and immune
24 suppression in the tumor microenvironment (Hayes et al., 2014).

25 This review will summarize the current state of knowledge on the biochemistry,
26 pharmacology, and *in vivo* function of arginases, focusing on *in vivo* data obtained from the

27 analysis of cell-specific Arg1 knockout (Arg1^{-/-}) and Arg2 knockout (Arg2^{-/-}) mice, and from
28 human studies. Specifically, we will summarize the biochemistry, genetics, and cellular
29 biology of arginases; their cell-specific and species-specific role in the liver, vasculature,
30 bone marrow, blood (immune cells, red blood cells (RBCs)), and kidney; and summarize the
31 current pharmacological strategies, and the results of human studies using recombinant
32 arginase and arginase inhibitors.

33 The careful characterization of the cell-specific role of Arg1 and Arg2 in mouse models,
34 human cells/organoids, and human cohorts with single-cell and multiomics approaches will
35 allow a deeper understanding of the role of arginase in specific cells and tissues, thus
36 proving better diagnostic, prognostic, and therapeutic strategies to address cardiovascular,
37 hematological, inflammatory, and genetic diseases related to L-arginine metabolism and
38 cancer.

39 **II. Biochemistry and regulation of arginase expression and activity**

40 **A. Genetic characteristics and regulation**

41 The enzyme arginase catalyzes the hydrolysis of L-arginine to L-ornithine and urea (**Fig. 1**).

42 In mammals, there are two isoforms of arginase, defined as arginase 1 (Arg1) and arginase

43 2 (Arg2), which are codified by independent genes. In humans, Arg1 and Arg2 show 58%

44 sequence homology (Morris et al., 1997, Perozich et al., 1998). Human ARG1 gene was

45 cloned by independently by the groups of Cederbaum and Mori in the 1980s and mapped to

46 chromosome 6q23 (Dizikes et al., 1986, Sparkes et al., 1986, Haraguchi et al., 1987).

47 Human ARG2 was cloned by the same groups 10 years later and mapped on chromosome

48 14q24.1–24.3 (Gotoh et al., 1996, Vockley et al., 1996, Gotoh et al., 1997). The gene

49 sequence presents highly conserved residues among species (Jenkinson et al., 1996) (**Tab.**

50 **1**). Structural studies identified high similarity (50%) and sequence homology in encoded

51 genes of arginase of different species (Jenkinson et al., 1996, Perozich et al., 1998) (**Tab.**

52 **1**).

53 Evolutionary, it is most likely that the two paralogues ARG1 and ARG2 genes originated by

54 gene duplication before amphibians and mammals diverged (Patterton and Shi, 1994, Morris

55 et al., 1997). Among all species, arginase and other ureohydrolases share multiple

56 conserved residues, which play crucial roles in protein folding, binding of manganese-ions,

57 and substrate interaction (Kanyo et al., 1996, Perozich et al., 1998). The sequence around

58 the catalytic site of both Arg1 and Arg2 is highly conserved, which makes it difficult to

59 synthesize isoform-specific arginase inhibitors. Current arginase inhibitors resemble its

60 substrate L-arginine, are mostly unselective, and display similar K_i or IC_{50} values (Adams et

61 al., 2017). However, there is currently an effort for synthesizing isoform-specific drugs (Gzik

62 et al., 2024) (see also Chapter VI B).

63 The human Arg1 protein exists in three isoforms obtained by alternative splicing (**Tab.1; Fig.**

64 **3**). The canonical isoform 1 (P05089-1) comprises 8 exons that encode 322 amino acids.

65 The isoform 2 (P05089-2) includes an 8 amino acids insertion and therefore consists of 330
66 amino acids (**Fig. 3**). The isoform 3 (P05089-3) lacks exons 4 and 5, which encode for the
67 amino acids 204-289 and therefore make a total of 236 amino acids. Only one sequence is
68 known for Arg2, which is built up of 8 exons as well and comprises 354 amino acids (Sayers
69 et al., 2022).

70 Apart from several similarities between Arg1 and Arg2, the localization, cellular function, and
71 tissue- or cell-specific expression are rather diverse. In humans and rodents, Arg1 is found
72 constitutively expressed at high levels in the liver, particularly in the cytosol of hepatocytes,
73 where it is responsible for catalyzing the last step of the urea cycle. This is also the reason
74 why it was called "liver arginase" (Morris et al., 1997). The functions of Arg1, besides its role
75 in the urea cycle, are less characterized and profoundly different in mice and man. In human,
76 Arg1 is also expressed to a lower extent in the bone marrow, the blood, and the skin (Morris
77 et al., 1997, Kim et al., 2002, Bruch-Gerharz et al., 2003, Munder et al., 2005). In rodents,
78 Arg1 is constitutively expressed in multiple tissues, mainly in the liver and gastrointestinal
79 tract, but also in the uterus and the skin (Yu et al., 2003, Choi et al., 2012).

80 At the cellular level, Arg1 is constitutively expressed in hepatocytes and inflammatory cells
81 (M2 macrophages) in all species; in other cell types including vascular endothelial cells,
82 smooth muscle cells, cardiomyocytes is expressed constitutively is species-specific way and
83 in general at very low level; but its expression is induced in disease conditions (Morris et al.,
84 1997, Teupser et al., 2006, Gonon et al., 2012, Caldwell et al., 2015), as described in detail
85 in the next chapters. In humans, polymorphonuclear neutrophils (PMN) constitutively
86 express Arg1, which is localized in granules and can be released under pro-inflammatory
87 conditions (Rotondo et al., 2011). Interestingly, human and primate erythrocytes
88 constitutively express higher levels of Arg1 and display increased arginase activity, while
89 rodent erythrocytes express very low levels (Spector et al., 1985).

90 The regulation of the expression either isozyme is cell type-specific and can be influenced by
91 health/disease conditions and by the presence of pro-inflammatory (Th1) or anti-
92 inflammatory (Th2) cytokines. In the mouse, Arg1 expression was shown to be induced upon
93 Th2 cytokines like interleukin (IL)-4 and -6 stimulation in M2 macrophages via signal
94 transducer and activator of transcription (STAT) 6 signaling, by mitogen-activated protein
95 kinase (MAPK) - activating transcription factor-2 (ATF-2) signaling pathway, by
96 CCAAT/enhancer binding protein (C/EBP) β , and by the transcription factor forkhead box O4
97 (FoxO4) (Gray et al., 2005, Sheldon et al., 2013, Shatanawi et al., 2015, Zhu et al., 2015,
98 Schmok et al., 2017, Caldwell et al., 2018)

99 In contrast, Arg2 is mainly localized in the mitochondria and is constitutively expressed at
100 higher levels in the kidney, the urinary bladder, the prostate but also in human skeletal
101 muscle (Vockley et al., 1996, Morris et al., 1997, Rath et al., 2014), but a lower constitutive
102 expression of Arg2 was found in almost all cells of the body. The expression of Arg2 can be
103 upregulated in inflammatory or disease conditions in different cell types and in a species-
104 specific way. For example it was shown to be up-regulated by interferon regulatory factor 3
105 in Jurkat cells (Grandvaux et al., 2005), by the hypoxia-inducible factor-2 in HUVECs
106 (Krotova et al., 2010), by activation of the ERK5 (extracellular signal-regulated kinase 5)-
107 CREB (cyclic AMP-responsive element-binding protein) pathway in human Jurkat cells and
108 mouse monocytes, (Barra et al., 2011) and by IL-10 stimulation likely via signal transducer
109 and activator of transcription 3 activation in the mouse. It is therefore generally different from
110 the regulation of Arg1 (Grandvaux et al., 2005, Krotova et al., 2010, Barra et al., 2011,
111 Dowling et al., 2021).

112 **B. Protein structure and catalysis**

113 Human Arg1 and Arg2 show a similar trimeric structure and catalytical mechanisms (Cama
114 et al., 2003, Di Costanzo et al., 2005). Each monomer of arginase exhibits a typical
115 Rossmann-fold structure, where β -sheets are wrapped by α -helices (Li et al., 2022a). The
116 molecular weight of each monomer varies among isoforms and species ranging from 30 to

117 40 kDa (**Tab. 1**) (Li et al., 2022a). The crystal structure of human Arg1 was characterized by
118 Di Costanzo et al. (Di Costanzo et al., 2005). The catalytic center of each arginase monomer
119 contains a Mn^{2+} coordinated to one His and 3 Asp (**Fig. 4**). The spin-coupled Mn^{2+} - Mn^{2+}
120 structure is formed in the catalytic center and activates arginase (**Fig. 4**) (Li et al., 2022a).
121 Mn^{2+} is required as a cofactor for converting L-arginine to L-ornithine and urea. Interestingly,
122 if Mn^{2+} is replaced with Co^{2+} the catalytic efficiency (k_{cat}/K_M) of Arg1 is increased (Stone et al.,
123 2010).

124 Interestingly, the kinetics of the hydrolysis of L-arginine to L-ornithine and urea catalyzed by
125 isolated/recombinant arginase is dramatically different when compared to the enzyme
126 expressed in cellular compartments. Purified rat liver arginase is characterized by a
127 Michaelis constant (K_m) of 1 mM and a maximum rate (V_{max}) of 4380 $\mu\text{mol}/\text{min}/\text{mg}$ in the
128 presence of 10 mM $MnCl_2$ at pH of 7.5 (Reczkowski and Ash, 1994). In contrast,
129 recombinant human Arg1 and Arg2 expressed in HEK293T cells are characterized by a K_m
130 of 3.3 mM and V_{max} of 34 nmol/min/mg and a K_m of 1.9 mM and V_{max} of 883 pmol/min/mg
131 respectively at physiological pH value of 7.4 (Tommasi et al., 2018). These differences need
132 to be taken into consideration for pharmaceutical preparations containing recombinant
133 arginase, like the pegylated-arginases, which was recently approved for treating
134 hyperarginemia in patients with genetic deficiency of arginase (see chapter VI).

135 Interestingly, it was proposed that arginase kinetics in cells is modified by the presence of
136 binding partners that regulates the catalytical activity of the enzyme. Examples of binding
137 partners regulating arginase activity are human flotillin, which was proposed to bind Arg1 in
138 human RBCs (Jiang et al., 2006) or the embryonic stem cell-expressed Ras, which was
139 found to interact with Arg1 in hepatic stellate cells (HSC) (Pudewell et al., 2022).

140 Also, the concentration and availability of L-arginine may contribute to regulate the kinetic
141 activity of arginase enzymes. For example, in cultured RAW 264.7 cells and primary murine
142 alveolar macrophages, Arg2 or Arg1, respectively, were described to compete for L-arginine

143 bioavailability with the inducible nitric oxide synthase (iNOS), which catalyzes the oxidation
144 of L-arginine to L-citrulline and leads to high-output nitric oxide (NO) synthesis (Wang et al.,
145 1995, Hey et al., 1997, Sonoki et al., 1997, Momma and Ottaviani, 2022). Therefore, Arg1
146 was proposed to control L-arginine bioavailability and NO production by iNOS in murine
147 alveolar macrophages and other cell types co-expressing iNOS during pro-inflammatory
148 conditions (Sonoki et al., 1997, Rath et al., 2014), which also include for example human
149 keratinocytes (Bruch-Gerharz et al., 2003). However, the intracellular L-arginine
150 concentrations (approx. 100 μ M) and the K_m of iNOS (2.8 μ M) are much lower than the K_m
151 for Arg1 (2 mM) (Garganta and Bond, 1986, Stuehr et al., 1991)

152 Arg1 was also proposed to compete with eNOS for the common substrate L-arginine in ECs.
153 The intracellular concentration of L-arginine in ECs is ca. 100 μ M, which should saturate
154 eNOS; however, paradoxically, NO production by eNOS in ECs can be still increased by
155 increasing extracellular L-arginine concentration. It remains unclear how excess extracellular
156 L-arginine can increase eNOS activity. The ability of extracellular L-arginine to increase NO
157 production in the presence of arginase was defined as “the L-arginine paradox” and it is still
158 partially unresolved (Girerd et al., 1990, Lundberg and Weitzberg, 2022).

159 **C. Summary**

160 To summarize, the two isoenzymes Arg1 and Arg2 catalyze the same reaction and their
161 tertiary and quaternary structure are similar. The kinetics of the reaction are affected by the
162 cell type, sub-localization in the cells (cytoplasm, granula, mitochondria), the presence of a
163 binding partner (flotillin), and the availability of L-arginine for the reaction.

164 **III. Biochemical assays for the determination of arginase activity** 165 **and L-arginine metabolomics**

166 Biochemical assays for determination of arginase activity and the new metabolomics
167 approaches have been playing a crucial role in understanding arginase function and its
168 involvement in different cellular processes. This chapter will discuss the various biochemical
169 assays used to determine arginase activity and arginine bioavailability, and their applications
170 for studying its role in systemic L-arginine metabolism in humans.

171 **A. The urea assay: colorimetric determination of urea formation in cells and tissues**

172 The first method to determine arginase activity was developed in 1945. The arginase activity
173 in liver or RBCs was quantified colorimetrically as formation of urea by derivatization with α -
174 isonitrosopropiophenone (ISPF) (Archibald, 1945, Van Slyke and Archibald, 1946). Later on,
175 it was modified by others for fitting a 96-well plate format and applied for determination of
176 arginase activity in leucocytes with a detection limit of 0.02 μmol urea (Corraliza et al.,
177 1994). Then the method was further improved and adapted by other groups for other sample
178 types (Romero et al., 2008, Yang et al., 2013, Bhatta et al., 2017, Heuser et al., 2022,
179 Pudewell et al., 2022).

180 In this assay, the samples (cells or tissue lysates) are pre-incubated at 58-60 °C with 7-10
181 mM MnCl_2 as cofactor for the activation of arginase. Afterwards, a millimolar concentration of
182 L-arginine (500 mM) is added into the mixture incubated for 1 min - 1 hour or more at 37 °C
183 according to specific arginase activity (i.e. activity/mg protein) expected in the specific
184 cell/tissue of interest. The enzymatic reaction is terminated by adding an acidic mix
185 composed of H_2SO_4 , H_3PO_4 , and H_2O , in v/v/v, 1:3:7 to denature the proteins in the sample
186 and to allow the derivatization reaction, which requires acidic conditions. Then a solution of
187 ISPF (9% in ethanol) is added to the samples and incubated at least 30 - 45 min at 100 °C.
188 Urea concentration in the samples is then determined colorimetrically by measuring the
189 absorbance of the pink ISPF-adduct with urea at 540 nm and quantified by comparing the

190 absorbance of a standard curve prepared by using standard concentrations of urea. Based
191 on this method, the arginase-dependent urea production in different cells and tissues
192 including kidney, liver, and brain was determined and compared among health and disease
193 conditions as well as different species (Iwata et al., 2002, Romero et al., 2008, Bagnost et
194 al., 2009, Bhatta et al., 2017, Heuser et al., 2022, Pudewell et al., 2022).

195 The main disadvantage of the urea assay for analysis of arginase activity in cells and tissues
196 is the lower sensitivity and signal-to-noise ratio due to the presence of urea and other
197 colored contaminants (like heme) in biological samples. For example, in plasma urea
198 concentration is very high and can be removed by size exclusion centrifugation filters. This
199 procedure is however not always applicable to tissues or cell lysates, thus limiting the
200 accuracy of the assay for samples with very low specific activity. An example of cells with
201 low specific activity of arginase are rodent RBCs or platelets (see below paragraph II.C.).

202 **B. Colorimetric determination of L-ornithine**

203 In 1952 Chinard et al. described a single cuvette assay based on the colorimetric reaction of
204 ninhydrin reagent with L-ornithine at very low pH (Chinard, 1952). Later on, the method was
205 optimized for microplates for the detection of arginase activity by analyzing the production of
206 L-ornithine in human hemolysates and cultured erythroleukemic cells (K562 cells) (Iyamu et
207 al., 2008). If applied for determination of arginase activity in cells and tissues, this method
208 has some major disadvantages including the interference of endogenous L-ornithine found in
209 sample at the steady state, as well as its complex trafficking and metabolism, which also
210 includes the formation of downstream products like polyamine.

211 **C. The radioactive assay: Conversion of ^{14}C -L-arginine into L-ornithine and ^{14}C -urea**

212 Rüegg and Russell first proposed the determination of arginase activity in bovine liver, calf
213 serum, and murine macrophage extract by applying L-[guanido- ^{14}C]-arginine (Rüegg and
214 Russell, 1980). Before application into the assay the substrate, L-[^{14}C]-arginine was purified
215 by using an ion exchange column prepared by using a Dowex 50W X8 (hydrogen form)

216 resin, which removes potential contaminants (including spontaneously hydrolyzed arginine)
217 and leads to a very low background. According to their method, 1 volume of glycine buffer
218 containing 75 mM glycine, 2 mM MnCl_2 , and 0.02% thymol blue at pH 9.7 was premixed with
219 7 volumes of 1 M L-arginine solution containing L-[^{14}C]-arginine and water (v/v, 1:6) and 10
220 mM MnCl_2 , and then incubated at 56 °C, pH 7.5. The reaction was terminated by adding
221 acetic acid with 7 M urea, 10 mM L-arginine, and 0.001% methyl red at pH 4.5 in each
222 sample. The time-dependent formation of ^{14}C -urea was measured by scintillation counting at
223 different time points from 2 to 120 min (Ruegg and Russell, 1980).

224 By using L-[guanido- ^{14}C]-arginine Spector et al. established a similar assay for the detection
225 of arginase activity in erythrocyte lysate (Spector et al., 1980). The produced ^{14}C -urea was
226 converted into ammonia and $^{14}\text{CO}_2$ by Jackbean urease, which was trapped by filter paper
227 soaked with NaOH as $\text{Na}_2^{14}\text{CO}_3$ followed by scintillation counting. By using this method, the
228 authors compared arginase activity in RBCs of different species, including humans and
229 primates, rats, rabbits, cats, and dogs; the arginase activity was normalized as μmol L-
230 arginine hydrolyzed per gram hemoglobin per hour (Spector et al., 1985). They found less
231 than 1 μmol urea/g hemoglobin/h of RBCs from Blab/c mouse, rat, rabbit, cat, and dog; in
232 contrast to more than 900 μmol urea/g hemoglobin/h of that in humans.

233 A further optimization of this method was carried out by Morris Jr. et al. later on (Morris et al.,
234 1998). This assay was applied by many authors to analyze arginase activity in cells, tissues,
235 and blood, and it is still one of the most sensitive and accurate assays. By applying this
236 assay, they found that the arginase activity in the plasma and RBCs of individuals with sickle
237 cell disease (SCD) were significantly higher than those in healthy controls (humans with
238 SCD vs healthy controls, 37.7 ± 2.9 vs 23.5 ± 1.7 nmol/mg/min in plasma and 2.1 ± 2.1 vs
239 0.4 ± 0.2 $\mu\text{mol}/\text{mL}/\text{h}$ in RBCs) (Morris et al., 2005a).

240 **D. Systemic analysis of L-arginine bioavailability and L-arginine metabolism.**

241 With the discovery that upregulation of arginase activity may play an important role in
242 disease conditions, there has been a growing interest in the analysis of arginase activity and
243 L-arginine bioavailability in human cohorts and in pre-clinical studies in experimental
244 animals. As mentioned above, L-arginine is the common substrate for arginase and the NOS
245 enzymes; therefore, systemic L-arginine bioavailability is thought to be dependent on the
246 relative activity of both enzyme classes, their expression, and the compartmentalization of L-
247 arginine (Elms et al., 2013). For the analysis of L-arginine bioavailability, the “global L-
248 arginine bioavailability ratio” (GABR) was proposed. GABR is calculated as the ratio
249 between L-arginine level and the levels of L-ornithine and L-citrulline ($GABR = L\text{-arginine}/(L\text{-}$
250 $ornithine + L\text{-citrulline})$), which are metabolic products respectively of arginase and NOS
251 activity (Tang et al., 2009). Further studies have investigated the levels of L-arginine, L-
252 ornithine, and L-citrulline in plasma of human cohorts (Kovamees et al., 2016b, De Santo et
253 al., 2018, Burrage et al., 2019, Fan et al., 2021).

254 Alternatively, for determination of serum levels of L-arginine, L-ornithine, L-citrulline,
255 asymmetric dimethylarginine (ADMA), and symmetric dimethylarginine (SDMA), some
256 authors applied an HPLC method based on fluorescent derivatization with 6-aminoquinolyl-
257 N-hydroxysuccinimidyl carbamate (AccQ-Fluor™) (Heresztyn et al., 2004, Miyazaki et al.,
258 2018).

259 L-arginine, L-ornithine and L-citrulline, and the derived GABR were also measured directly in
260 plasma of subjects with coronary artery disease (CAD) by electrospray ionization tandem
261 mass spectrometry (LC/ESI/MS/MS) online with an API 365 triple quadrupole mass
262 spectrometer using $^{13}C_6$ -arginine as the internal standard for the quantitation (Tang et al.,
263 2009).

264 Metabolomics approaches were also established to investigate the L-arginine metabolism
265 and its corresponding regulation *in vivo* by using LC-qTOF-MS. One example is a method for

266 the determination of 16 amino acids, amino acid derivatives, and related compounds in
267 plasma to identify potential biomarkers in pediatric chronic kidney disease (Benito et al.,
268 2016). The metabolites comprised L-homoarginine, L-homocysteine, L-arginine, symmetric
269 dimethylarginine (SDMA), ADMA, dimethylglycine, S-adenosylhomocysteine, S-
270 adenosylmethionine, L-citrulline, betaine, creatine, creatinine, glutathione, methionine,
271 glycine, and cysteine (Benito et al., 2016). Another example is the quantitative analysis of L-
272 arginine metabolites, polyamines, and acetylated polyamines in various biological matrices
273 such as liver, muscle, adrenal glands, and brain in mice (Langner et al., 2022). Further
274 examples of applications of the analysis of arginase metabolites in human cohorts are
275 discussed in Chapter IV and summarized in the related **Tab. 4**.

276 **E. Summary**

277 To summarize, the arginase activity in cells and tissues was analyzed by measuring the
278 production of urea by derivatization and colorimetric assay, which has limitations due to
279 interference with endogenous urea (e.g. in plasma) or heme-containing proteins (hemoglobin
280 in RBCs). A more accurate method is the detection of the conversion of isotope-labeled (^{13}C
281 or ^{14}C) L-arginine into their enzymatic products ^{13}C or ^{14}C -L-ornithine/urea from arginases or
282 ^{13}C or ^{14}C -L-citrulline from NOS by scintillation or for nonradioactive isotopes by MS. MS has
283 the advantage that can be applied for metabolic analysis of L-arginine metabolites on a
284 larger scale and does not require the use of radioactive compounds.

285 **IV. The biological role of arginase in cells and tissues**

286 In this section, we aim to review and discuss the cell-specific role of arginase in the liver,
287 immune cells, vasculature, RBCs, and the kidney and to highlight their significance in health
288 and disease. Specifically, we will explore the diverse function of Arg1 and Arg2 in the tissues
289 and point on the species-specific differences, their function, and regulation in rodents and
290 humans. These differences are particularly important when pharmacological therapies are
291 tested in pre-clinical models. The available cell-specific mice models and their phenotypes
292 are summarized in **Tab. 2**.

293 **A. Role of arginase in the liver**

294 The liver is built up out of four major cell types: hepatocytes (~70%), HSCs (~13%),
295 sinusoidal endothelial cells (~10%), and liver resident macrophages named Kupffer cells
296 (~7%), (Racanelli and Rehermann, 2006, Chen and Tian, 2021). Interestingly, all of these
297 cells express Arg1 and are of major importance to maintain liver homeostasis (MacParland
298 et al., 2018).

299 Arg1, the so-called liver-type arginase, is predominantly and constitutively expressed in the
300 liver, especially in hepatocytes (MacParland et al., 2018). The main role of arginase in the
301 liver is the detoxification of the body from ammonia, which is produced as a result of the
302 catabolism of amino acids and is potentially neurotoxic. Ammonia is detoxified in the urea
303 cycle by forming urea, which can be then excreted by the kidney (Krebs and Henseleit,
304 1932, Strong et al., 2021) (**Fig. 5**).

305 The urea cycle can be divided into five enzymatic steps. The first two steps are located in
306 the mitochondria, the last three in the cytoplasm of hepatocytes: (1) Ammonium, carbon
307 dioxide, and two ATP are converted into carbamoylphosphate by the carbamoylphosphate
308 synthetase I; (2) carbamoylphosphate is combined with L-ornithine to L-citrulline; (3) L-
309 citrulline and aspartate are condensed to argininosuccinate by the argininosuccinate
310 synthetase using one ATP; (4) argininosuccinate is cleaved into L-arginine and fumarate by

311 the argininosuccinase; and finally (5) Arg1 hydrolyzes L-arginine into L-ornithine and urea
312 (Pelley, 2012, Barmore et al., 2024). Urea is exported from the hepatocytes towards the
313 kidney where it is excreted in the urine.

314 The transport of L-ornithine and L-citrulline in and outside of the mitochondria is carried out
315 by L-ornithine carrier 1 and 2 and the solute carrier family 25 member A29 (SLC25A29)
316 (Fiermonte et al., 2003, Porcelli et al., 2014). However, the expression of SLC25A29 is lower
317 as compared to the other transporters. Therefore, the role of SLC25A29 in the urea cycle is
318 likely limited (Camacho and Rioseco-Camacho, 2009).

319 Besides the urea cycle, L-arginine can also be consumed by eNOS or iNOS to produce L-
320 citrulline and NO in liver ECs (Poisson et al., 2017), but also in hepatocytes, HSC, and
321 Kupfer cells macrophages (Cunningham and Porat-Shliom, 2021, Pudewell et al., 2022).
322 Furthermore, in the liver L-arginine can be converted into agmatine or creatine, whereas L-
323 ornithine can be further catabolized into polyamines, L-proline, or glutamate. The urea cycle
324 and its intermediates are tightly regulated (Wu and Morris, 1998). In individuals carrying a
325 genetic mutation of liver Arg1 the levels of L-arginine in plasma are elevated (Diez-
326 Fernandez et al., 2018), indicating that the higher arginase activity in the liver limits the
327 export of L-arginine in plasma. In line with those findings, global constitutive Arg1^{-/-} mice
328 display hyperarginemia and die between day 10 and 14 after birth because of
329 hyperammonemia (Iyer et al., 2002).

330 Conditional mouse models of Arg1 deficiency (Arg1^{flox/flox} mice) were generated by targeting
331 exons 7-8 (El Kasmi et al., 2008) or exon 4 (Van den Bossche et al., 2012). Late-onset
332 global Arg1^{-/-} mice or hepatocyte-specific Arg1^{-/-} mice showed a similar phenotype
333 characterized by hyperarginemia, hyperammonemia, and dysregulation of amino acid
334 metabolism, but without any increase in L-ornithine (Kasten et al., 2013, Sin et al., 2013).
335 Interestingly, the same phenotype was found in another study in hepatocyte-specific Arg1^{-/-}
336 mice (Ballantyne et al., 2016), demonstrating that Arg1 in hepatocytes plays a major role in

337 regulating the systemic levels of ammonia and L-arginine. Other pathways that metabolize L-
338 arginine, like NO production by eNOS or iNOS, are mainly influenced by the extracellular L-
339 arginine concentration (MacKenzie and Wadsworth, 2003, Shin et al., 2011).

340 Polyamines play an important role in liver regeneration and homeostasis and are regulated
341 by arginase levels, import and export of polyamines and amino acids, as well as the
342 expression of the rate-limiting enzyme L-ornithine decarboxylase that converts L-ornithine to
343 putrescine (Luk, 1986, Dayoub et al., 2006, Uemura and Gerner, 2011, Okumura et al.,
344 2016, Sagar et al., 2021). Recently, it was shown that in HSC, Arg1 plays a major role in the
345 maintenance of quiescence, suggesting an effect of downstream polyamine synthesis
346 (Pudewell et al., 2022). The detailed role of arginase in sinusoidal liver endothelial cells is
347 less known. The consequence of EC-Arg1 knockout in mice was not specifically studied for
348 the liver in detail. However, mice lacking EC Arg1 did not show specific liver phenotype (at
349 least in our hands) (Heuser et al., 2022) and other authors did not mention any liver
350 phenotype in similar models (**Tab 2**) (Bhatta et al., 2017). Arg1 is also expressed in resident
351 liver macrophages (or Kupfer cells) in mouse liver. Although the canonical role of arginase in
352 mouse bone marrow and alveolar macrophages has been well studied (see paragraph IV.
353 B), cell-specific analysis of the effects of arginase in Kupfer cells on liver pathophysiology is
354 still lacking.

355 **B. Role of arginase in the immune system**

356 Arginases are crucially involved in various aspects of inflammation and immunomodulation
357 both in health and disease conditions. Increased arginase activity has been involved in
358 inflammation-triggered immune dysfunction, tumor immune escape, fibrosis,
359 immunosuppression, and immunopathology of infectious diseases (Bronte and Zanovello,
360 2005, Munder, 2009, Murray, 2016, Martí and Reith, 2021). The regulatory role of Arg1 and
361 Arg2 in the immune response profoundly differs between mice and humans.

362 According to a classical view, mouse macrophages can be classified as belonging to two
363 subtypes named M1 and M2 based on their role in inflammatory response and their
364 expression of iNOS (M1) or Arg1 (M2) (**Fig. 6**) (Thomas and Mattila, 2014, Murray, 2017). In
365 this model, the balance between arginase and iNOS activity in macrophages dictates the
366 outcome of immune responses. M1 macrophages preferentially metabolize L-arginine via
367 iNOS into NO and L-citrulline and orchestrate the first pro-inflammatory phase of the immune
368 response; instead, M2 macrophages metabolize L-arginine via Arg1 into L-ornithine and
369 urea and are mainly involved in anti-inflammatory responses (Thomas and Mattila, 2014,
370 Murray, 2017). The underlying mechanism involves the activation of iNOS expression in M1
371 macrophages by T helper 1 -derived cytokines (IL-1 β , TNF α) and IFN- γ induces iNOS
372 expression via activation of transcription factors like NF κ B, AP1 and drives the classical M1
373 activation pathway. T helper 2 cytokines like IL-4, IL-10, and IL-13 suppress iNOS activity
374 and promote Arg1 expression (Bronte and Zanovello, 2005, Thomas and Mattila, 2014, Martí
375 and Reith, 2021). Recently it was shown that Arg2 is present in the mitochondria of pro-
376 inflammatory M1 macrophages and is essential for IL-10 metabolic downregulations to
377 resolve the cell inflammatory status (Dowling et al., 2021). According to this view of M1
378 macrophages expressing iNOS and M2 macrophages expressing Arg1, it is tempting to
379 speculate that control of L-arginine bioavailability via these enzymes may also involve L-
380 arginine transporters like CAT1 and CAT2 and act via inter-cellular communication

381 In humans, the M1/M2 dichotomy is not well defined and controversially discussed in the
382 literature (Munder, 2009, Thomas and Mattila, 2014). In human blood circulating monocytes
383 do not express Arg1; instead, human Arg1 is constitutively expressed in PMN granules, is
384 released in response to pro-inflammatory stimuli and regulates immune T-cell responses
385 (Munder et al., 2005, Munder et al., 2006, Oberlies et al., 2009). Less is known about the
386 role of Arg1 in human tissue macrophages, and in general about the role of Arg2, which is
387 constitutively expressed in mitochondria and contributes to L-arginine metabolism (Martí and
388 Reith, 2021).

389 T lymphocytes play a central role in the adaptive immune response. It is well known that L-
390 arginine starvation impairs T cell functions by multiple mechanisms (Geiger et al., 2016,
391 Martí and Reith, 2021). T cell proliferation is dose-dependent on L-arginine, with maximal
392 proliferation occurring at plasma concentrations (~100 $\mu\text{mol/L}$) (Ochoa et al., 2001). CD8^+ T
393 cells show a more pronounced dependency on L-arginine availability than CD4^+ T cells.
394 Moreover, dietary L-arginine supplementation improves thymic weight and T-cell reactivity in
395 both rats and humans (Martí and Reith, 2021).

396 Mechanistically, L-arginine starvation impairs T cell function through the downregulation of
397 the $\text{CD3}\zeta$ subunit of the T cell receptor (TCR) complex, crucial for TCR assembly and
398 activation signaling (Munder et al., 2006, Munder, 2009). Additionally, L-arginine deprivation
399 disrupts TCR signaling, reduces IL-2 production, and affects cell cycle regulators, causing T
400 cell arrest in the G0-G1 phase (Martí and Reith, 2021). L-arginine starvation also inhibits
401 glycolysis in T cells without affecting mitochondrial function, although high L-arginine levels
402 can enhance CD8^+ T cell anti-tumor activity *in vivo* (Grzywa et al., 2020).

403 Human T cells constitutively express mitochondrial Arg2 (Lowe et al., 2019, Martí i Líndez et
404 al., 2019), while the constitutive expression of Arg1 is under debate (Martí and Reith, 2021)
405 (Murray, 2016). Therefore Arg2 regulates T-cell intracellular L-arginine metabolism and plays
406 a critical role in T cell function (Martí and Reith, 2021). Inhibition or deletion of Arg2
407 enhances T-cell activation and anti-tumor responses, independent of extracellular L-arginine
408 levels (Grzywa et al., 2020, Martí and Reith, 2021). Arg2 also supports regulatory T cell
409 (Treg) function and survival, indicating its potential as a therapeutic target in autoimmune
410 and neoplastic diseases (Grzywa et al., 2020). Based on the mechanism of arginase
411 inhibiting T cell function in the tumor microenvironment to promote cancer growth, novel
412 immunotherapy vaccines targeting Arg1 or Arg2 are developed and are now under clinical
413 trials (Martinenaite et al., 2019, Weis-Banke et al., 2020, Lorentzen et al., 2022, Niu et al.,
414 2022).

415 Human granulocytes subpopulations and especially polymorphonucleated neutrophils
416 express both isoforms of arginase. In these cells, Arg1 is not found in the cytoplasm, but
417 rather in the cytoplasmic granules and, as briefly mentioned before, Arg1 release in the
418 extracellular space exerts immunosuppressive functions by depletion of L-arginine and
419 inhibition of T effector cell responses (Munder et al., 2005, Munder et al., 2006, Oberlies et
420 al., 2009). Surprisingly the expression of Arg1 is not regulated by Th2-cytokines and other
421 stimuli in these cells (Munder, 2009, Murray, 2016). Similar T-cell immunosuppressive
422 activity of arginases is found in myeloid-derived suppressor cells (MDSCs). MDSCs are a
423 heterogeneous population of immature myeloid cells at different stages of myelopoiesis
424 exerting immunosuppressive function through their ability to metabolize and deplete L-
425 arginine, which is needed for T-cells-mediated responses (Bronte et al., 2016, Ostrand-
426 Rosenberg and Fenselau, 2018). Indeed MDSCs express high levels of both Arg1 and iNOS
427 (Gabrilovich and Nagaraj, 2009), and were described to inhibit T cells by high-output NO
428 production (Jia et al., 2010), and by inducing L-arginine starvation of T cells (Raber et al.,
429 2014). Arg1 is also crucial for the inhibition of allo-stimulated T cell inhibition by MDSCs
430 (Bronte et al., 2003). Hence, arginases and in general L-arginine metabolic enzymes in
431 MDSCs are considered as excellent molecular targets of immunoregulatory compounds in
432 infectious diseases and cancer (**Tab. 3**).

433 In the tumor microenvironment, abundant arginase activity is mainly related to the presence
434 of MDSCs and L-arginine metabolism is one of the metabolic pathways responsible for
435 tumor progression (Kim et al., 2018). Moreover, upregulation of either Arg1 or Arg2
436 expression/activity has been reported in several cancer types (Graboń et al., 2009, de
437 Boniface et al., 2012, Bedoya et al., 2014). Accumulating research indicates that inhibiting
438 the potent immunosuppressive mechanisms of MDSCs can be a therapeutic target to restore
439 T-cell activity and immunotherapy success in antifungal therapy (Law et al., 2020). Indeed,
440 pharmacological inhibition of MDSC-derived Arg1 expression by either SB202190, which is a
441 specific inhibitor of p38, or vandetanib, an orally available receptor tyrosine kinase inhibitor,

442 significantly enhanced T-cell-mediated antifungal responses against *C. neoformans* infection
443 (Li et al., 2022b). It has also been reported recently that by using the arginase inhibitor OAT-
444 1746, the negative effects of Arg1 in ovarian carcinoma can be mitigated (Czystowska-
445 Kuzmicz et al., 2019). Please refer also to Chapter IV and Table 3 and 4.

446 In conclusion, arginases significantly influence immune responses and inflammation, with
447 elevated activity linked to various pathological conditions such as immune dysfunction, tumor
448 progression, and immunosuppression. The roles of Arg1 and Arg2 differ between mice and
449 humans, in particular regarding their modulation of macrophage and T cell functions. The
450 use of pharmacological inhibitors to improve immunotherapy outcomes or recombinant
451 arginase to induce cancer cell L-arginine starvation is showing a great potential in cancer
452 therapy.

453 **C. Role of arginase in red blood cells**

454 It has long been known that Arg1 is present in circulating RBCs and that its protein level
455 differs considerably among species (Azizi et al., 1970, Spector et al., 1983). Humans and
456 primates have a high level/activity of arginase, while rodents, cats, and dogs have a rather
457 low arginase activity (which results often under the detection limits of common methods)
458 (Azizi et al., 1970, Spector et al., 1983).

459 In general, the proteome of circulating RBCs is made of proteins, which were synthesized
460 during their maturation from proerythroblasts to reticulocytes in the bone marrow. Human
461 erythroid cells express both Arg1 and Arg2 (Kim et al., 2002, Grzywa et al., 2021a). In
462 human erythroid cells, the expression of arginases starts during the late phase of
463 erythropoiesis, when the hematopoietic stem cell differentiates into proerythroblasts, while
464 the highest protein level is found in circulating human RBCs (Grzywa et al., 2021a, Grzywa
465 et al., 2021b). Importantly, Arg2 was found to be upregulated by 12-fold during erythroid
466 differentiation and remained elevated in late-stage erythroblasts, whereas Arg1 was
467 upregulated at very late-stage terminal differentiation (Grzywa et al., 2021a, Grzywa et al.,

468 2021b). Likely, Arg2 is lost when the mitochondria and the nucleus are extruded (Grzywa et
469 al., 2021a, Grzywa et al., 2021b). In human erythroid cells, there is also an alternatively
470 spliced variant of Arg1 with preserved activity (Kim et al., 2002).

471 The strong induction of Arg1 and Arg2 in human proerythroblasts was associated with a
472 continuous requirement for extracellular L-arginine throughout the erythroid differentiation
473 process. Notably, L-arginine in this context was not required for the synthesis of creatine or
474 NO, but rather for polyamine biosynthesis and the hypusination of the eIF5A transcription
475 factor (Shima et al., 2006, Gonzalez-Menendez et al., 2023). Interestingly, mouse
476 proerythroblasts express Arg1 at lower levels as compared to humans (Grzywa et al., 2021b,
477 Shahbaz et al., 2021).

478 There is compelling evidence that Arg1 levels in human RBCs are increased in people with
479 SCD (Iyamu et al., 2005, Morris et al., 2005a). SCD is caused by different mutations in the
480 β -globin chain of hemoglobin. Hypoxia induces sickling of RBCs due to polymerization of
481 abnormal hemoglobin (Pauling et al., 1949). Sickle cells are stiffer, more fragile, more prone
482 to rupture, and show an increased arginase activity (Iyamu et al., 2005). Specifically, it was
483 proposed that the release of RBC protein content due to cell rupture/damage induces an
484 increase of free hemoglobin and Arg1 in plasma. The increase in free hemoglobin in plasma
485 leads to systemic oxidative stress and NO scavenging, while the increased arginase activity
486 in plasma leads to reduced L-arginine bioavailability. Therefore, both free hemoglobin and
487 arginase in plasma may contribute to the pathophysiology of SCD by promoting endothelial
488 dysfunction and pulmonary hypertension. (Morris et al., 2005a). A similar pathophysiology
489 was also observed in the hemolytic uremic syndrome (Friberg et al., 2024).

490 Interestingly, other authors proposed that liberation of arginase from human RBCs into the
491 plasma may also exert immunosuppressive effects by L-arginine depletion (Bernard et al.,
492 2008, Munder, 2009). This immunosuppressive effect of arginase released from RBCs could

493 also be a possible explanation for the increased risk of invasive bacterial infection in humans
494 with SCD.

495 Another role attributed to Arg1 in RBCs is the control of systemic NO bioavailability and NO
496 release from RBCs (Yang et al., 2013). We and others have shown that eNOS is present in
497 RBCs (Kleinbongard et al., 2006, Cortese-Krott et al., 2012). In line with this finding, Yang et
498 al. showed that the inhibition of Arg1 in human RBCs regulates eNOS-dependent export of
499 NO-metabolites and contributes to cardioprotection in a Langendorff bioassay (Yang et al.,
500 2013). By comparing the cardiovascular hemodynamics and the outcome of acute
501 myocardial infarction in RBC- and EC-specific eNOS^{-/-} mice, we recently demonstrated that
502 eNOS present in RBCs regulates blood pressure, the levels of circulating NO metabolites
503 and is cardioprotective (Leo et al., 2021, Cortese-Krott et al., 2022). Recently, an erythroid
504 cell targeted Arg1^{-/-} mouse was generated by using mice expressing a Cre-recombinase
505 under the control of the promoter for erythropoietin receptor, and crossed on an apoE^{-/-}
506 background. These mice showed increased vascular calcification on high-fat diet and
507 increased S-nitrosoglutathione reductase activity in the vessels (Gogiraju et al., 2022).

508 It is important to point out that mice and rats are unlikely to be good models for studying the
509 role of Arg1 in RBCs *in vivo*. According to all studies investigating arginase activity
510 monitoring the conversion of isotopically labeled L-arginine into L-ornithine and urea, the
511 arginase activity in mouse and rat RBCs is very low or even undetectable under some
512 conditions (Azizi et al., 1970, Spector et al., 1983). Moreover, the expression and activity of
513 arginase in mouse monocytes is very high (Munder et al., 2005), which may contaminate
514 RBC samples. In addition, when considering the results of mouse studies obtained with the
515 loxP/Cre system, the specificity of the promoter and its regulation often also determine the
516 quality of the results. As pointed out before the Tie2 promoter drives gene expression in
517 both, ECs and cells of the myeloid cell lineage (leukocytes) (Payne et al., 2018), and the
518 phenotype may derive from vascular or immune cell dysfunction.

519 There is no doubt however that an increase in arginase activity in human RBCs has an
520 important pathophysiological role. Independent human studies found that the levels of L-
521 arginine in human RBCs correlated to the levels of Arg1 expression and activity in RBCs
522 (Spector et al., 1985, Morris et al., 2000, Morris et al., 2005a). As pointed out before, RBC
523 arginase activity was found to be elevated in hematological diseases (especially in mutations
524 of hemoglobin like SCD) and also in cardiovascular disease (CVD) (Azizi et al., 1970, Iyamu
525 et al., 2005, Morris et al., 2005b).

526 In the late '80s Cederbaum et al. proposed the absence of arginase in RBCs from lower
527 animals and its presence in RBCs from primates may be the results of an evolutionary
528 adaptation, rather than the “vestigial presence of an arcane function” (Spector et al., 1985).
529 It is unclear whether the presence of arginase expression in the RBCs confers any obvious
530 advantage or disadvantage on the animal who carries it. This interesting perspective was
531 sadly not followed further.

532 To summarize, while human RBCs carry high levels of Arg1, mice, and rats express Arg1 at
533 a very low level. An increase in RBC arginase activity plays a major role in SCD
534 pathophysiology and was proposed to be also immunomodulatory. More studies with human
535 erythroid precursor cells and human cohorts are required to understand the
536 pathophysiological role of arginase in RBCs and how its levels and activity may be
537 modulated under disease conditions.

538 **D. Role of arginase in the vasculature**

539 In the vasculature, L-arginine is mainly converted into NO by the eNOS (EC:1.14.13.39)
540 expressed in the ECs. NO is involved in the modulation of endothelial function, vascular
541 tone, organ perfusion, and blood pressure (Moncada et al., 1991, Farah et al., 2018,
542 Ostrand-Rosenberg and Fenselau, 2018, Lundberg and Weitzberg, 2022). Reduced
543 bioavailability of NO results in endothelial dysfunction and promote hypertension,
544 atherosclerosis, and myocardial infarction.

545 In the vascular wall ECs and vascular smooth muscle cells may express both isoforms of
546 arginase (although there are some species-specific patterns for Arg1 or Arg2, as carotid
547 porcine EC for example express Arg2 and not Arg1 (Thacher et al., 2010)) (**Fig. 7**).
548 Nevertheless, multiple papers describe arginase as a counterpart of eNOS in vascular ECs
549 for modulating endothelial function (Kim et al., 2009, Chung et al., 2014, Krause et al.,
550 2015). Thus, increased arginase activity in the vessel wall was proposed to limit the
551 bioavailability of L-arginine for eNOS and therefore decrease NO production resulting in
552 endothelial dysfunction and hypertension (Zhang et al., 2001, Toque et al., 2013, Caldwell et
553 al., 2018, Mahdi et al., 2020a, Li et al., 2022c).

554 Multiple pre-clinical studies in rodents showed that the oral administration of arginase
555 inhibitors, such as 2(S)-Amino-6-BoronoHexanoic acid (ABH) and N-hydroxy-nor-arginine
556 (nor-NOHA) improved eNOS dependent vasorelaxation, endothelial function, and decreased
557 blood pressure in spontaneously hypertensive rat, old rats or rats fed with high-fat diet (Kim
558 et al., 2009, Bagnost et al., 2010, Chung et al., 2014).

559 A similar phenotype was observed in EC-specific Arg1^{-/-} mice generated by using Cadherin-5
560 (Cdh5)-promoter Cre-recombinase mice and put on a high-fat and high-sucrose diet. In
561 these mice, the deletion of Arg1 in ECs protected mice from vascular dysfunction (Bhatta et
562 al., 2017, Yao et al., 2017). Interestingly, EC/myeloid cell-specific Arg1^{-/-} mice generated by
563 using Tie2-Cre-recombinase mice did not improve vasomotor function in diabetic mice
564 (Chennupati et al., 2018). It is important to point out, the Tie2-promoter drives Cre-
565 recombinase expression in all subtypes of ECs but Cre-expression was also found in the
566 hematopoietic cell lineage or, depending on the gene construct, also in the heart valves
567 (Payne et al., 2018). The Cdh5-promoter drives the expression of Cre-recombinase
568 specifically in ECs and it is generally considered as the most specific promoter, in particular
569 when the activity of the Cre-recombinase is also inducible by tamoxifen (Cdh5ET2-Cre
570 mice); however, in some models where Cdh5-Cre recombinase expression is constitutive,

571 the expression of Cre-recombinase was also observed in hematopoietic cells and the
572 cardiac valve.

573 Work from our own laboratory demonstrated that under homeostatic conditions EC Arg1^{-/-}
574 mice (tamoxifen-inducible Cdh5^{ET2}-Cre) show a downregulation of eNOS in the aorta and a
575 fully preserved vascular function and NO-metabolites under basal conditions (Heuser et al.,
576 2022). We also observed a compensatory upregulation of Arg1 in the aorta, which points to
577 an upregulation of Arg1 in vascular smooth muscle cells (Heuser et al., 2022). Therefore, the
578 relationship between eNOS and Arg1 in ECs *in vivo* is far more complex than a competition
579 for their common substrate. Accordingly, a recent study provided quantitative evidence that
580 in murine macrophages and human umbilical artery ECs, there was no direct competition
581 between Arg1 and the NOS enzymes if a constant flux of L-arginine is provided (Momma
582 and Ottaviani, 2022).

583 The role of Arg2 in vessels is less known. Arg2 expression in the mitochondria of ECs and
584 smooth muscle cells is lower as compared to Arg1, and their functions are difficult to
585 discern without genetic manipulation. There are few studies investigating the role of
586 mitochondrial Arg2 in the endothelium in mice. One animal study showed that Arg2 in aged
587 mice is the key isoform responsible for the total arginase activity in the aorta of aging mice
588 leading to eNOS uncoupling and endothelial dysfunction (Shin et al., 2012). This finding is
589 supported by another study showing that mice overexpressing Arg2 in the endothelium
590 showed endothelial dysfunction, hypertension, and enhanced atherosclerosis (Vaisman et
591 al., 2012). In addition, Arg2 is reported to promote a pro-inflammatory effect, contributing to
592 insulin resistance and atherogenesis (Ming et al., 2012, Yang and Ming, 2014). (Ming et al.,
593 2012, Yang and Ming, 2014). In addition, Arg2 is reported to promote inflammation,
594 contributing to insulin resistance and atherogenesis (Ming et al., 2012, Yang and Ming,
595 2014). Interestingly, in porcine carotid endothelial cell Arg2 was upregulated by oscillatory
596 shear stress; as a result, porcine carotid arteries subjected to oscillatory shear stress
597 showed a decreased bradykinin-induced vasorelaxation, which could be recovered by

598 treatment with the arginase inhibitor NorNOHA (Thacher et al., 2010). Interesting porcine
599 carotid arteries and their cellular components (ECs and SMCs) express Arg2, but not Arg1,
600 showing a further species-specificity feature of arginases in the vasculature.

601 Overall, these results indicate that Arg1 does not appear to be involved in the regulation of
602 NO-dependent vasorelaxation in homeostatic conditions and that increase in arginase
603 activity is correlated to regulation of vascular remodeling and stiffens probably via L-arginine
604 depletion and synthesis of polyamines.

605 Further studies are needed to understand whether and how arginase expression or activity
606 in the vascular endothelium is regulated by pathophysiological stimuli like shear stress or
607 turbulent flow and how this regulation is coordinated with eNOS activity.

608 **E. Role of arginase in the heart**

609 In the heart, Arg1 is expressed in coronary ECs and cardiomyocytes in a species-specific
610 way. The expression of Arg1 has been found to be upregulated in coronary arterioles in
611 humans with type 2 diabetes mellitus (T2DM) and in homogenate of the right atrial
612 appendage samples collected during cardiac surgery (Chen et al., 2006, Beleznai et al.,
613 2011). Arg1 is constitutively expressed in cardiomyocytes of felines and affects
614 cardiomyocyte NO signaling, whereas Arg2 is not constitutively expressed in feline
615 cardiomyocytes (Jung et al., 2006). Rat heart lysate shows expression of both Arg1 and
616 Arg2 but cardiomyocytes from rats express only Arg2 (Steppan et al., 2006).

617 Nor-NOHA-mediated arginase inhibition during ischemia-reperfusion (I/R)-injury in rats
618 resulted in reduced infarct size and elevated plasma nitrite levels *in vivo* (Jung et al., 2010,
619 Tratsiakovich et al., 2013). Furthermore, Arg1 expression was significantly increased in the
620 ischemic myocardium of rats (Jung et al., 2010). Whether these effects are due to the
621 expression of Arg1 in the myocardial cells (cardiomyocytes, vascular cells) or from infiltrated
622 neutrophils or other blood cells was not further investigated. Indeed infiltrated neutrophils
623 are known to contribute to the infarct size at least in rat (Williams et al., 1994). It has also

624 been shown that in pigs, Arg1 expressed in coronary arterioles modulates NO-mediated
625 vasorelaxation (Zhang et al., 2001). Furthermore, it has been proposed that coronary
626 endothelial cell dysfunction plays a role in the microvascular injury occurring after I/R injury.
627 This hypothesis is supported by the finding that mice overexpressing TNF- α show an
628 increase in arginase activity and the expression of Arg1 in ECs at basal conditions and after
629 I/R-injury as well (Gao et al., 2007). In addition, these mice show a significant reduction in
630 maximal vasodilation after I/R injury as well as a decrease in eNOS expression in coronary
631 arterioles.

632 To summarize, also in the heart, arginases show a species-specific and cell-specific
633 expression. It appears that Arg1 plays a role in the pathophysiology of myocardial infarction
634 whereas Arg2 plays an immunosuppressive and protective role, at least in rodents. The data
635 on the expression/activity and function of arginases in human heart tissue is still too sparse
636 to be able to make a clear conclusion about its role in the heart. More research is needed in
637 this direction, perhaps by using novel single cell sequencing and mapping in heart biopsies.

638 **F. L-Arginine metabolism and role of arginase in the kidney**

639 The kidney plays an essential role in the endogenous synthesis of L-arginine. L-Arginine is
640 synthesized by arginosuccinate synthetase and arginosuccinate lyase out of L-citrulline
641 (Szepesi et al., 1970, Morris et al., 1989). As mentioned in paragraph IV.A, there is a high
642 turnover of L-arginine through the urea cycle in the liver; however, the urea cycle is tightly
643 regulated in a way that L-arginine is promptly metabolized further, and thereby does not
644 contribute to the circulating levels of L-arginine under homeostatic conditions. In contrast, in
645 the kidney only a small part of the synthesized L-arginine is used for the production of
646 polyamines and creatine from L-ornithine, while most of it is released into the circulation,
647 making it available for other tissues (Rogers et al., 1972) (**Fig 8**).

648 L-Arginine is synthesized throughout the whole length of the proximal tubule by ASS and
649 ASL, but in the proximal convoluted tubule synthesis is the highest, which is consistent to the

650 highest expression of ASS and ASL in the nephron (Levillain et al., 1990, Levillain, 2012). L-
651 Arginine synthesis gradually decreases in the terminal part in the outer medulla, i.e. in the
652 proximal convoluted tubule, where a lower but significant synthesis takes place.

653 Notably, approximately 83% of L-citrulline released from the small intestine undergoes renal
654 metabolism. Thus, circulating L-citrulline availability is the limiting factor in renal L-arginine
655 production (Windmueller and Spaeth, 1981, Dhanakoti et al., 1990). At least in rats,
656 endogenous production of L-arginine from L-citrulline is necessary for normal growth and it
657 cannot be completely restored by the diet, demonstrating the importance of renal production
658 of L-arginine for the optimal growth in young animals (Hoogenraad et al., 1985). Surprisingly,
659 in rats, the level of L-arginine in plasma is normally stable even after chronic renal failure
660 due to the increased plasma concentration of L-citrulline and the rise of urea that may inhibit
661 the arginase activity (Moradi et al., 2006).

662 The total arginase activity is low in the kidney, and its function is still not fully understood.
663 The predominant arginase isoform expressed in the kidney is the mitochondrial isoenzyme
664 Arg2, which is also known as “the kidney arginase”. It is constitutively expressed in the
665 kidneys of humans, rodents, and likely in all mammals, whereas Arg1 is not expressed in the
666 kidney under homeostatic conditions (Spector et al., 1983, Morris et al., 1997, Miyanaka et
667 al., 1998, Morris et al., 2011). In rats, Arg2 is expressed mostly in the proximal straight
668 tubule (Miyanaka et al., 1998). Studies carried out on male and female mice showed that
669 female mice have a 3-fold higher Arg2 expression and activity as compared to male mice
670 (Levillain et al., 2005a). In rats, Arg2 is expressed at higher levels in the inner medullary
671 collecting ducts as compared to the thin descending and ascending limbs of Henle’s loop.
672 Accordingly, enzymatic activity of Arg2 is not homogenous in the whole kidney, but it occurs
673 mainly in the outer stripe of the outer medulla and inner medulla (Levillain et al., 1989).

674 Interestingly, there is evidence that all three NOS isoforms are expressed in the inner
675 medullary collecting duct (as summarized previously (LoBue et al., 2023)), which may

676 indicate a mutual regulation between these two enzyme classes in the metabolism of L-
677 arginine in the kidney (Wu et al., 1999, Levillain et al., 2005b, Hyndman et al., 2013). It has
678 been hypothesized that the renal arginase activity may be important for L-ornithine
679 production and subsequently polyamine metabolism for the maintenance of normal tissue
680 homeostasis and, only in small part, for producing urea, which may contribute to concentrate
681 the urine in the medulla (Levillain et al., 1989, Waddington et al., 1998, Brosnan and
682 Brosnan, 2004).

683 Interestingly, diabetic $Arg2^{-/-}$ mice chronically treated with streptozotocin (STZ) were
684 protected against diabetic nephropathy. The lack of Arg2 in these mice protected them
685 against STZ-induced albuminuria, macrophage recruitment, and histopathological changes,
686 leading to renal tissue protection and suggesting a role of Arg2 in diabetic nephropathy.
687 Moreover, the lack of Arg2 protected for a decrease in renal modular blood flow, which is
688 consistent with preserved renal NO production (Morris et al., 2011). Accordingly, it was
689 shown that a specific lack of Arg2 in ECs reduced renal fibrosis in mice by restoring NO
690 levels and mitochondrial function in the kidney (Wetzel et al., 2020). Another interesting
691 study indicates that Arg2 plays a role in the circadian clock. In this study, it was shown that
692 the lack of Bmal1 in the nephron led to increased urea levels in the plasma which correlated
693 with tubular dysfunction (Nikolaeva et al., 2016). The increase in urea could be explained by
694 an increase in the activity of Arg2 in the kidney.

695 Differently from Arg2, Arg1 expression in the kidney occurs only in pathological conditions,
696 mainly as a consequence of inflammation or tissue damage. For example, in nephritic
697 glomeruli in rats, arginase activity was found to be six-fold higher as compared to control
698 glomeruli due to the induction of Arg1 expression, while Arg2 was not upregulated
699 (Waddington et al., 1998). The expression of Arg1 is likely due to the presence of infiltrating
700 macrophages in the tissue. In fact, high expression of Arg1 was also found in the
701 macrophages located in the outer medulla after I/R injury in mice (Shin et al., 2022). In this

702 study, the authors proposed that Arg1 activity may contribute to stimulate the reparative
703 proliferative response to replace the cells in the medullary tubule.

704 To summarize, the kidney is a key organ involved in the synthesis of L-arginine and the
705 maintenance of L-arginine levels in plasma. Although expression of Arg2 is constitutive in
706 kidney cells, its function is not fully understood. The main role of Arg2 is likely to keep
707 normal tissue structure/homeostasis through the production of L-ornithine and the
708 subsequently metabolism of polyamines; however, this needs to be further investigated. In
709 contrast, the expression of Arg1 is mainly induced during tissue damage and inflammation
710 and contribute to immunomodulation and tissue repair.

711 **G. Summary and outlook**

712 In summary, Arg1 and Arg2 play multiple, often species-specific roles across cells and
713 tissues in the body. In this context, recent studies carried out with cell-specific transgenic
714 mice models are providing new and somehow unexpected information on the biological roles
715 of arginase in specific cells and compartments. Accumulating evidence also indicate that
716 there are important species-specific differences, in particular between rodents and humans,
717 regarding the role of arginases in immune cells and RBCs. These differences need to be
718 taken into account in pharmacological and translational studies, as well as in pre-clinical
719 testing.

720 In the liver, the cytosolic isoenzyme Arg1 is crucial for detoxifying ammonia via the urea
721 cycle, while the role of mitochondrial Arg2 appears to be mainly the synthesis of L-ornithine
722 as a precursor of L-proline and polyamines.

723 In the immune system, Arg1 is well known to modulate immune cell function and promote
724 immunosuppression, host protection, and resolution of inflammation, mainly by limiting L-
725 arginine bioavailability for downstream metabolic pathways and iNOS-mediated high-output
726 NO synthesis. In mouse, arginase expression in M2 macrophages drives the anti-
727 inflammatory responses, as well as participates in tissue repair via polyamine and proline

728 synthesis. In humans, Arg1 is constitutively expressed in granules of PMN cells and MDSCs,
729 and its L-arginine-depleting activity drives immunosuppression of T-cell responses. The
730 expression and function of Arg1 in monocytes/macrophages in humans is still debated. The
731 immunosuppressive role of arginases is part of the pathophysiology of chronic inflammatory
732 conditions, infections, and cancer; for example, some parasites and tumor cells express their
733 own arginase or induce arginase expression in the cells of the host. Also, Arg2 is emerging
734 as a further important regulator of the immune response and a possible pharmacological
735 target.

736 In the blood, Arg1 is also present at higher levels in human and primate RBCs, but its
737 presence in the RBCs of other mammals including mice and rats is very low. In humans,
738 arginase activity is increased in RBCs of people with SCD, thalassemia, and other
739 hemoglobinopathies, and it was shown to promote endothelial dysfunction and pulmonary
740 hypertension by hemolysis-induced arginase release into the plasma and systemic L-
741 arginine depletion. High levels of RBC arginase are also found in people with CVD and
742 diabetes and are proposed to contribute to endothelial dysfunction and cardiovascular
743 events. Interestingly, an immunosuppressive function of arginase release from RBCs has
744 been also proposed.

745 In the vasculature, arginase activity is increased under pathological conditions like diabetes
746 and atherosclerosis and promotes endothelial dysfunction mainly by competing with eNOS
747 for L-arginine and affecting endothelial NO production. The specific role of the cytoplasmic
748 Arg1 or the mitochondrial Arg2 in the vessel wall is not fully understood. Mice lacking EC
749 Arg1 show no changes in vascular endothelial function *ex vivo* or *in vivo* under homeostatic
750 conditions.

751 In the kidney, Arg2 is likely involved in L-arginine metabolism into L-ornithine and
752 polyamines, it is upregulated and exerts a protective function of the kidney tissue in diabetic
753 nephropathies, at least in the mouse.

754 These findings underscore the need for further research to reveal the complex roles of Arg1
755 and Arg2, by considering their cellular and subcellular localization and regulation, their
756 species specificity, and their significance in cellular processes. These differences need to be
757 taken into consideration when pharmacological therapies are tested in pre-clinical models.

758 **V. L-Arginine metabolism and arginase activity in human disease**

759 There are multiple human studies investigating L-arginine metabolism in human cohorts. L-
760 Arginine levels and metabolism in humans have been extensively studied to investigate the
761 role of arginase in the urea cycle and the consequences of genetic defects (like
762 hyperarginemia) in liver homeostasis, as well as in the immune system and cancer cells in
763 relationship to iNOS activity. Moreover, L-arginine bioavailability was studied in the context of
764 arginase as a counterpart of eNOS for endothelial dysfunction in CAD and diabetes.
765 Arginase has shown potential as a therapeutic target for various diseases and conditions,
766 and its inhibition has been explored in clinical trials to evaluate its efficacy and safety. Details
767 about the human studies discussed in the text are summarized in **Tab.5**.

768 **A. Measurements of arginase expression and activity in human disease**

769 The main pathophysiological consequence of autosomal ARG1 mutations in humans is
770 hyperargininemia, which leads to an autosomal inborn error in the urea cycle (Diez-
771 Fernandez et al., 2018). Other symptoms are progressive intellectual impairment and
772 neurological impairment, persistent growth retardation, and spastic paraparesis (Diez-
773 Fernandez et al., 2018). In a study, 66 mutations of the ARG1 gene have been identified in
774 112 humans with hyperargininemia, 30 of those were missense mutations, 15 deletions, 10
775 splicing, seven nonsense, one small insertion, and one translation initiation codon mutation.
776 The estimated incidence of this disease is around 1:726,000 (Catsburg et al., 2022). At the
777 beginning of this year, pegzilarginase, a recombinant, cobalt-substituted, and pegylated
778 human ARG1 enzyme therapy, received approval as an orphan drug in the EU for the
779 treatment of Arg1 deficiency (Russo et al., 2024). Interestingly, mutations of the ARG1 gene
780 could also play a role in other diseases. In subjects with erectile dysfunction (n=110), two
781 different polymorphisms in the ARG1 gene were associated with the severity of erectile
782 dysfunction, but there was no correlation with plasma Arg1 levels. (Lacchini et al., 2015).

783 It was proposed that an upregulation of Arg1 in the lungs leads to an imbalance in L-
784 arginine/NO availability resulting in pulmonary hypertension and/or smooth muscle
785 contraction as well as lung tissue remodeling of lung. In fact, an upregulation of Arg1 has
786 been found in pulmonary diseases, including chronic obstructive pulmonary disease,
787 pulmonary hypertension, pulmonary fibrosis, tuberculosis, and asthma. (North et al., 2009,
788 Henno et al., 2015, Monin et al., 2015, Lucca et al., 2018, Wu et al., 2019).

789 Increased levels of Arg1 in human RBCs and plasma were proposed to contribute to the
790 pathophysiology of hemoglobinopathies like SCD or thalassemia. It has been shown that
791 arginase activity in plasma is higher and L-arginine plasma level is lower in humans with
792 thalassemia (n=14) or SCD (n=140) (Morris et al., 2005a, Morris et al., 2005b). The authors
793 of these elegant studies proposed that intravascular hemolysis with release of hemoglobin
794 and arginase in plasma causes on one hand a reduction in L-arginine concentration in
795 plasma, and on the other hand scavenging of NO, leading to endothelial dysfunction and
796 pulmonary hypertension. Interestingly, the treatment of humans with SCD with hydroxyurea
797 (n=23) reduced arginase activity in the plasma (Iyamu et al., 2005).

798 In addition, there are first evidences that Arg1 present in RBCs can modulate endothelial
799 dysfunction and the outcome of I/R injury as tested in bioassays (Yang et al., 2018, Zhou et
800 al., 2018, Mahdi et al., 2020b). RBCs from humans with T2DM (n=20) showed an increased
801 arginase activity and arginase level in RBCs as compared to healthy individuals (n=15) (Zhou
802 et al., 2018). Furthermore, these authors showed in a bioassay that the co-incubation of
803 RBCs from humans with T2DM with rat aortas induces endothelial dysfunction, which can be
804 prevented by the *ex vivo* inhibition of arginase. In addition, RBCs from people with T2DM
805 also induced an increase in arginase activity in co-incubated human carotid arterial ECs. The
806 authors of the study proposed that this upregulation is induced by peroxynitrite (Mahdi et al.,
807 2020b). In another study, the same authors showed that RBCs from people with T2DM
808 (n=13) aggravate myocardial I/R injury (Yang et al., 2018). These studies indicate that Arg1

809 present in human RBCs play a role in the complex vascular and cardiac pathophysiological
810 consequences of T2DM in humans.

811 There are multiple studies showing an increased Arg1 activity/protein levels in serum of
812 humans with myocardial infarction (Porembaska and Kedra, 1975, Bekpinar et al., 2011), and
813 was linked to endothelial dysfunction via decrease of L-arginine bioavailability.

814 An interesting hypothesis that should be also taken into consideration is the release of
815 arginase and decrease of endogenous levels of L-arginine may also exert an
816 immunosuppressive effect as hypothesized by Munder et al. (Munder, 2009). The
817 immunosuppression may become pathophysiological in various infections with parasites and
818 viral infections. For example, in HIV-infected humans, a high expression of Arg1 in lymph
819 nodes correlated with an increase in HIV viral load whereas iNOS expression negatively
820 correlates with the HIV viral load (n=52) (Zhang et al., 2016). Such upregulation may
821 contribute to the suppression of antiviral immunity in HIV-infected humans, thus, Arg1
822 expression can be used as a parameter to predict disease progression.

823 There are no known genetic defects of Arg2 that cause human disease. However, it was
824 shown that Arg2 expression and activity were increased in pulmonary artery ECs of humans
825 with pulmonary arterial hypertension (PAH) (n=41 ± 3) (Xu et al., 2004). Similar to Arg1, Arg2
826 expression is increased in humans with asthma caused by chronic airway inflammation (Xu
827 et al., 2017).

828 In summary, both arginase isoforms play a crucial role in various disease conditions.
829 Mutations in the ARG1 gene lead to a defect of the urea cycle causing hyperargininemia and
830 leading to early death. Since the beginning of 2024, the first therapy using human
831 recombinant pegylated cobalt-substituted arginase enzyme is available. On the other hand,
832 the upregulation of arginase expression and activity seems to be involved in various
833 diseases like T2DM and SCD. In addition, arginase shows immunosuppressive properties
834 which is involved in infections with parasites and viral infection.

835 **B. Measurement of L-arginine bioavailability in human cohorts with cardiometabolic**
836 **disease**

837 The majority of the human studies having L-arginine bioavailability or metabolism as a
838 primary outcome measure is based on the hypothesis that arginase activity in the
839 vasculature contributes to the consumption of L-arginine, which contributes to endothelial
840 dysfunction. Consumption of L-arginine and the production of L-ornithine should affect GABR
841 in plasma, as an index of L-arginine bioavailability. Therefore, GABR was measured in the
842 plasma of humans with CAD (humans with no significantly obstructive CAD n=402 vs.
843 significantly obstructive CAD n=608) by monitoring the levels of free L-arginine, L-ornithine,
844 L-citrulline, and ADMA. GABR was lower in humans with obstructive CAD (>50% stenosis),
845 as compared to the humans without obstructive CAD, which implied that decreased GABR is
846 associated with obstructive CAD and subsequent increased incidence of major adverse
847 cardiovascular events (Tang et al., 2009). Similarly, the levels of L-arginine, L-ornithine, and
848 L-citrulline were determined in the serum of humans (n=2236) collected before coronary
849 angiography (Sourij et al., 2011). In this study, they found that GABR was significantly
850 decreased in humans with T2DM and also was inversely correlated with some known
851 biochemical markers of endothelial dysfunction such as the expression of intracellular
852 adhesion molecule-1, vascular adhesion molecule-1, and von Willebrand factor.
853 Furthermore, they also observed that decreased GABR and the arginine-to-ornithine ratio
854 were associated with increased cardiovascular mortality. A further study investigated the
855 changes of GABR in people with T2DM (n=41) after intensifying the therapy according to the
856 guideline for 3 months to reach therapy targets like, HbA_{1c}, LDL cholesterol 2.6, or blood
857 pressure (Tripolt et al., 2012). They showed that targeting those risk factors improves GABA
858 and arginine-to-ornithine ratio. It is important to note that this improvement was only found in
859 people with T2DM for less than 5 years.

860 L-arginine levels and metabolism were also determined in plasma samples from subjects
861 during the acute phase of myocardial infarction collected before percutaneous coronary

862 intervention and again 6 months after myocardial infarction (n=70) (Molek et al., 2021). L-
863 arginine, L-ornithine, and ADMA levels were determined and calculated into indexes of L-
864 citrulline/L-arginine, L-citrulline/L-ornithine, and L-arginine/ADMA. They observed that the
865 index of L-citrulline/L-arginine significantly decreased in the acute phase of MI but the
866 indexes of L-citrulline/L-ornithine and L-arginine/ADMA were unchanged. The authors
867 proposed that this may indicate a shift of L-arginine utilization from NOS towards arginase
868 and/or an increase in the activity of arginase.

869 The L-arginine and L-ornithine concentrations were also measured in the plasma from lean
870 and obese humans with asthma, obese humans without asthma, and also corresponding
871 healthy controls by using LC-MS/MS (Winnica et al., 2019). In this study they demonstrated
872 that the L-arginine levels in the plasma were decreased in both lean and obese humans with
873 asthma, and also obese humans without asthma as compared to healthy individuals.
874 Moreover, the L-arginine levels in obese humans with asthma were significantly lower than in
875 healthy lean controls.

876 Recently, L-arginine level, L-arginine-to-L-ornithine ratio, and GABR were analyzed in adult
877 humans diagnosed with COVID-19 (n=32) and pediatric humans with COVID-19/multisystem
878 inflammatory syndrome (n=20). They found that all these parameters were significantly lower
879 in COVID-19-positive adult and COVID-19/MIS-C pediatric groups as compared to the
880 COVID-19-negative controls. The authors proposed that low arginine-to-ornithine ratio in
881 these people might be due to an elevated arginase activity, and that low GABR may
882 contribute to immune dysregulation and endothelial dysfunction in COVID-19 (Rees et al.,
883 2021).

884 **C. Arginase as a pharmacological target**

885 Depending on the pathophysiological role of arginase and the specific type of disease
886 targeting arginase involves two possible strategies including arginase-mediated L-arginine

887 depletion or inhibition of arginase to restore L-arginine bioavailability. Established and
888 potential therapeutic applications are listed in table 3.

889 Administration of pegylated recombinant arginase has been recently approved by the EMEA
890 to treat humans with genetic hyperarginemia. Moreover, pegylated arginase has been
891 proposed as an anti-tumor agent (similar to the antileukemia agent L-asparaginase) for
892 tumors susceptible to L-arginine deprivation, like tumors lacking ASS enzymes (Cheng et al.,
893 2021). If properly targeted to the site of inflammation, another possible application of
894 recombinant Arg1 may be immunosuppression in autoimmunity and unwanted inflammatory
895 reactions (Munder, 2009).

896 Applications of arginase inhibitors were proposed against diseases with pathological
897 upregulation of arginase like specific infection diseases, cancer, or against endothelial
898 dysfunction in T2DM and CAD, and to treat pulmonary hypertension in SCD and
899 hemoglobinopathy. (see chapter IV paragraph B)

900 There are three generations of arginase inhibitors which are summarized in **Tab. 4**.

901 These inhibitors do not show isoform specificity, need to be administrated systemically via
902 i.p. or i.v injection, have a short half-life, and are rapidly eliminated by the kidney. A well-
903 known and often-used arginase inhibitor in cell culture, animal studies but also in human
904 studies is nor-NOHA. Nor-NOHA is a derivate of NOHA, a stable intermediate of NO
905 synthesis by NOS. It is a competitive non-specific inhibitor of arginase and is considered as
906 one of the most potent arginase inhibitors (Colleluori and Ash, 2001, Pudlo et al., 2017).
907 There are already numerous studies investigating the effect of arginase inhibitors in animals
908 (Kim et al., 2009, Jung et al., 2010, El-Bassossy et al., 2013, You et al., 2013, Pera et al.,
909 2014), and lately, in humans (**Tab. 4**).

910 There are very promising studies showing that arginase inhibition by nor-NOHA improves
911 endothelium-dependent vasodilation (EDV) (Shemyakin et al., 2012, Kövamees et al., 2014,
912 Kovamees et al., 2016a, Mahdi et al., 2018). In human studies, NorNOHA (0.1 mg/min for 2

913 hours) was administrated by infusion (Shemyakin et al., 2012, Kövamees et al., 2014,
914 Kovamees et al., 2016a, Mahdi et al., 2019). Administration of nor-NOHA improved
915 endothelial function in healthy elderly humans (n=21) as determined by forearm venous-
916 occlusion plethysmography (Mahdi et al., 2019).

917 Recently, a third generation of arginase inhibitors was developed and tested (**Tab.4**). One
918 notable compound from this generation is INCB001158 (formerly CB1158), an oral arginase
919 inhibitor that exhibits higher specificity for Arg1 ($IC_{50}=86$ nm) compared to Arg2 ($IC_{50}=296$
920 nm). INCB001158 has been evaluated in phase 1/2 clinical trials for the treatment of solid
921 tumors with increased arginase activity in combination with chemotherapy (Steggerda et al.,
922 2017, Kuboki et al., 2024, Naing et al., 2024). The most notable result of these studies is that
923 arginase inhibitors may be effective for therapies of specific tumors with up-regulation of
924 arginase activity as a mechanism for L-arginine depletion and immunosuppression.

925 In conclusion, pegylated arginase is an approved drug for hyperarginemia and genetic-
926 defect. Potentially for L-arginine auxotrophic tumors susceptible to L-arginine deprivation
927 and for immunosuppression.

928 Instead, the clinical applications of arginase inhibitors have shown potential to improve
929 endothelial function and vasodilation in individuals with T2DM, enhancing the effects of L-
930 arginine supplementation in individuals with heart failure and coronary artery diseases, and
931 serving as a promising therapeutic target for therapy of specific cancers. Further
932 pharmacological research focused on developing and testing arginase inhibitors will
933 contribute to the development of novel treatments and therapies in the future.

934 **D. L-arginine/L-arginine metabolites supplementation**

935 Oral supplementation of L-arginine was proposed as a way to increase L-arginine
936 bioavailability and to boost production of NOS-derived NO in humans (Girerd et al., 1990).
937 For example, L-arginine supplementation was proposed for alleviate endothelial dysfunction

938 (Lerman et al., 1998, Bai et al., 2009). However, the results of these studies are
939 controversial.

940 Oral L-arginine intake was shown to positively affect humans with heart failure and in
941 peripheral artery occlusive disease by increasing the distance in a 6-minute walk test,
942 increasing the forearm blood flow during forearm exercise, or reducing the symptom score
943 significantly (Rector et al., 1996, Lerman et al., 1998). On the other hand, oral administration
944 of L-arginine in healthy human (n=26) did not improve systemic hemodynamics *in vivo* or
945 vascular function of gluteal subcutaneous arteries assessed *in vitro* (Chin-Dusting et al.,
946 1996).

947 **E. Summary and outlook**

948 The involvement of arginases in the urea cycle, liver function, immune response, and cancer
949 cell dynamics, particularly in relation to iNOS activity, has been extensively examined. In
950 addition, arginase activity in the vessel wall has been studied in the context of endothelial
951 dysfunction in CAD and diabetes, revealing its potential as a therapeutic target. The GABR is
952 a measure of L-arginine bioavailability, which has been found to be lower in humans with
953 obstructive CAD and T2DM, correlating with major adverse cardiovascular events and
954 endothelial dysfunction markers. Pharmacological interventions that improve risk factors for
955 T2DM have been shown to improve GABR, particularly in humans recently diagnosed with
956 diabetes. Mutations in the ARG1 gene cause hyperargininemia, leading to various health
957 complications. Arginase activity is also increased in several pulmonary diseases and
958 hemolytic anemias, affecting NO availability and contributing to disease pathology. The
959 arginase inhibitor nor-NOHA has demonstrated efficacy in improving endothelial function in
960 people with T2DM and healthy elderly individuals. Supplementation with L-arginine or L-
961 citrulline has been explored to enhance L-arginine bioavailability and NO production, with
962 varying results depending on the health status of individuals.

963 **VI. Conclusion and outlook**

964 Arginases exhibit diverse functions across various tissues. In the liver, Arg1 is indispensable
965 for ammonia detoxification, while the specific role of mitochondrial Arg2 need further
966 investigation. It is important to point out that there are significant differences in Arg1 and
967 Arg2 expression, cellular localization, and activity in humans and primates as compared to
968 rodents (mice, rats) and other mammals, in particular in the blood and bone marrow, and
969 vascular endothelial cells.

970 In the immune system, the distribution and function of Arg1 are very different in mouse and
971 man. While in mice blood Arg1 is mainly expressed in myeloid cells and it is up-regulated by
972 Th2-cytokines, in humans Arg1 is constitutively expressed in PMN cells and is not regulated
973 by Th2 cytokines. In both species, arginase activity has an anti-inflammatory and
974 immunosuppressive effect on T cells.

975 In human and primate RBCs and proerythroblasts Arg1 expression and activity are high,
976 while in rats, mice, and other mammals it is very low and/or barely detectable. In humans,
977 elevated arginase activity in RBCs from individuals with SCD or hemoglobinopathies
978 suggests a contributory role in disease pathogenesis, with similar observations in CVD and
979 diabetes, underlining its fundamental importance in human disease.

980 In CVD conditions like diabetes and atherosclerosis, increased arginase activity can lead to
981 endothelial dysfunction by competing with eNOS for the bioavailability L-arginine, thus
982 impairing NO production and leading to endothelial dysfunction. Accordingly, administration
983 of arginase inhibitors in people with T2DM improve vascular function. Surprisingly, EC Arg1^{-/-}
984 revealed no changes in endothelial function or CV hemodynamics, and instead global Arg2^{-/-}
985 mice show hypertension. Indicating that at least *in vivo*, the role of vascular Arg1 in
986 maintaining endothelial function under homeostatic conditions in mice is limited.

987 Although the kidney plays a major role in the control of L-arginine synthesis, systemic levels
988 and bioavailability, the role of arginases in the kidney is not fully understood. The main

989 isoform expressed is Arg2 and appears to be crucial for tissue integrity and repair (at least in
990 rodents).

991 Clinical and translational studies have highlighted the therapeutic potential of targeting
992 arginase/L-arginine metabolism in various diseases. Clearly, the described multiple,
993 complex, species, cell-, and isoform-specific roles of arginase make pharmacological
994 targeting difficult. The only approved drug is pegylated recombinant arginase for the
995 treatment of humans with genetic hyperarginemia. However pegylated arginase was
996 proposed as a possible anti-tumor therapy for tumors sensitive to L-arginine deprivation. The
997 control of L-arginine bioavailability by arginases, as a key factor in endothelial dysfunction in
998 CVD, has been extensively studied and arginase is still considered as a promising
999 therapeutic target. The use of arginase inhibitors (e.g., nor-NOHA) was tested in small
1000 cohorts of humans with endothelial dysfunction due to CAD or T2DM. Moreover,
1001 administration of arginase inhibitors was proposed for blocking circulating arginase in
1002 hemoglobinopathies (SCD, thalassemia) and specific infection disease. Arginase inhibition
1003 has shown efficacy in improving endothelial function in subjects with T2DM and healthy
1004 elderly individuals, while L-arginine and L-citrulline supplementation have demonstrated
1005 potential benefits in heart failure and peripheral arterial occlusive disease. A strong limitation
1006 of the currently available inhibitors is that they do not show isoform specificity, need to be
1007 administrated systemically via i.p. or i.v injection, and have a short half-life, and are rapidly
1008 eliminated by the kidney. The third generation of arginase inhibitors can be administrated
1009 orally and have better pharmacodynamics and have been tested already in cancer therapy.

1010 More studies are needed to understand the complex biological and species-specific roles of
1011 Arg1 and Arg2, their importance in cellular processes, and their potential as therapeutic
1012 targets. The new pharmacological cell-specific targeting and the applicability of single-cell
1013 analysis for personalized medicine will allow better pharmacological strategies to target Arg1
1014 and Arg2 in humans.

1015 VII. References

- 1016 ADAMS, J. L., DUFFY, K. J., MOORE, M. L. & YANG, J. 2017. 5.11 - Cancer
1017 Immunotherapy—An Emerging Field That Bridges Oncology and Immunology
1018 Research. *In*: CHACKALAMANNIL, S., ROTELLA, D. & WARD, S. E. (eds.)
1019 *Comprehensive Medicinal Chemistry III*. Oxford: Elsevier.
- 1020 ANSERMET, C., CENTENO, G., LAGARRIGUE, S., NIKOLAEVA, S., YOSHIHARA, H. A.,
1021 PRADERVAND, S., BARRAS, J. L., DATTNER, N., ROTMAN, S., AMATI, F. &
1022 FIRSOV, D. 2020. Renal tubular arginase-2 participates in the formation of the
1023 corticomedullary urea gradient and attenuates kidney damage in ischemia-
1024 reperfusion injury in mice. *Acta Physiol (Oxf)*, 229, e13457.
- 1025 ARCHIBALD, R. M. 1945. COLORIMETRIC DETERMINATION OF UREA. *Journal of*
1026 *Biological Chemistry*, 157, 507-518.
- 1027 AZIZI, E., DROR, Y. & WALLIS, K. 1970. Arginase activity in erythrocytes of healthy and ill
1028 children. *Clin Chim Acta*, 28, 391-6.
- 1029 BAGNOST, T., BERTHELOT, A., ALVERGNAS, M., MIGUET-ALFONSI, C., ANDRE, C.,
1030 GUILLAUME, Y. & DEMOUGEOT, C. 2009. Misregulation of the arginase pathway in
1031 tissues of spontaneously hypertensive rats. *Hypertens Res*, 32, 1130-5.
- 1032 BAGNOST, T., MA, L., DA SILVA, R. F., REZAKHANIHA, R., HOUDAYER, C.,
1033 STERGIOPULOS, N., ANDRE, C., GUILLAUME, Y., BERTHELOT, A. &
1034 DEMOUGEOT, C. 2010. Cardiovascular effects of arginase inhibition in
1035 spontaneously hypertensive rats with fully developed hypertension. *Cardiovasc Res*,
1036 87, 569-77.
- 1037 BAI, Y., SUN, L., YANG, T., SUN, K., CHEN, J. & HUI, R. 2009. Increase in fasting vascular
1038 endothelial function after short-term oral L-arginine is effective when baseline flow-
1039 mediated dilation is low: a meta-analysis of randomized controlled trials. *Am J Clin*
1040 *Nutr*, 89, 77-84.
- 1041 BALLANTYNE, L. L., SIN, Y. Y., AL-DIRBASHI, O. Y., LI, X., HURLBUT, D. J. & FUNK, C. D.
1042 2016. Liver-specific knockout of arginase-1 leads to a profound phenotype similar to
1043 inducible whole body arginase-1 deficiency. *Molecular genetics and metabolism*
1044 *reports*, 9, 54-60.
- 1045 BARMORE, W., AZAD, F. & STONE, W. L. 2024. Physiology, Urea Cycle. *StatPearls*.
1046 Treasure Island (FL): StatPearls Publishing
- 1047 Copyright © 2024, StatPearls Publishing LLC.
- 1048 BARRA, V., KUHN, A. M., VON KNETHEN, A., WEIGERT, A. & BRUNE, B. 2011. Apoptotic
1049 cell-derived factors induce arginase II expression in murine macrophages by
1050 activating ERK5/CREB. *Cell Mol Life Sci*, 68, 1815-27.
- 1051 BEDOYA, A. M., TATE, D. J., BAENA, A., CÓRDOBA, C. M., BORRERO, M., PAREJA, R.,
1052 ROJAS, F., PATTERSON, J. R., HERRERO, R., ZEA, A. H. & SANCHEZ, G. I. 2014.
1053 Immunosuppression in cervical cancer with special reference to arginase activity.
1054 *Gynecol Oncol*, 135, 74-80.
- 1055 BEKPINAR, S., GURDOL, F., UNLUCERCI, Y., DEVELI, S. & YILMAZ, A. 2011. Serum
1056 levels of arginase I are associated with left ventricular function after myocardial
1057 infarction. *Clin Biochem*, 44, 1090-1093.
- 1058 BELEZNAI, T., FEHER, A., SPIELVOGEL, D., LANSMAN, S. L. & BAGI, Z. 2011. Arginase 1
1059 contributes to diminished coronary arteriolar dilation in patients with diabetes. *Am J*
1060 *Physiol Heart Circ Physiol*, 300, H777-83.
- 1061 BENITO, S., SANCHEZ, A., UNCETA, N., ANDRADE, F., ALDAMIZ-ECHEVARRIA, L.,
1062 GOICOLEA, M. A. & BARRIO, R. J. 2016. LC-QTOF-MS-based targeted
1063 metabolomics of arginine-creatine metabolic pathway-related compounds in plasma:
1064 application to identify potential biomarkers in pediatric chronic kidney disease. *Anal*
1065 *Bioanal Chem*, 408, 747-60.

- 1066 BERNARD, A., KASTEN, M., MEIER, C., MANNING, E., FREEMAN, S., ADAMS, W.,
1067 CHANG, P., BOULANGER, B. & KEARNEY, P. 2008. Red blood cell arginase
1068 suppresses Jurkat (T cell) proliferation by depleting arginine. *Surgery*, 143, 286-91.
- 1069 BHATTA, A., YAO, L., XU, Z., TOQUE, H. A., CHEN, J., ATAWIA, R. T., FOUA, A. Y.,
1070 BAGI, Z., LUCAS, R., CALDWELL, R. B. & CALDWELL, R. W. 2017. Obesity-
1071 induced vascular dysfunction and arterial stiffening requires endothelial cell arginase
1072 1. *Cardiovasc Res*, 113, 1664-1676.
- 1073 BRONTE, V., SERAFINI, P., DE SANTO, C., MARIGO, I., TOSELLO, V., MAZZONI, A.,
1074 SEGAL, D. M., STAIB, C., LOWEL, M., SUTTER, G., COLOMBO, M. P. &
1075 ZANOVELLO, P. 2003. IL-4-induced arginase 1 suppresses alloreactive T cells in
1076 tumor-bearing mice. *J Immunol*, 170, 270-8.
- 1077 BRONTE, V. & ZANOVELLO, P. 2005. Regulation of immune responses by L-arginine
1078 metabolism. *Nat Rev Immunol*, 5, 641-54.
- 1079 BRONTE, V., BRANDAU, S., CHEN, S.-H., COLOMBO, M. P., FREY, A. B., GRETEN, T. F.,
1080 MANDRUZZATO, S., MURRAY, P. J., OCHOA, A., OSTRAND-ROSENBERG, S.,
1081 RODRIGUEZ, P. C., SICA, A., UMANSKY, V., VONDERHEIDE, R. H. &
1082 GABRILOVICH, D. I. 2016. Recommendations for myeloid-derived suppressor cell
1083 nomenclature and characterization standards. *Nature Communications*, 7.
- 1084 BROSANAN, M. E. & BROSANAN, J. T. 2004. Renal arginine metabolism. *J Nutr*, 134, 2791S-
1085 2795S; discussion 2796S-2797S.
- 1086 BRUCH-GERHARZ, D., SCHNORR, O., SUSCHEK, C., BECK, K. F., PFEILSCHIFTER, J.,
1087 RUZICKA, T. & KOLB-BACHOFEN, V. 2003. Arginase 1 overexpression in psoriasis:
1088 limitation of inducible nitric oxide synthase activity as a molecular mechanism for
1089 keratinocyte hyperproliferation. *Am J Pathol*, 162, 203-11.
- 1090 BURRAGE, L. C., THISTLETHWAITE, L., STROUP, B. M., SUN, Q., MILLER, M. J.,
1091 NAGAMANI, S. C. S., CRAIGEN, W., SCAGLIA, F., SUTTON, V. R., GRAHAM, B.,
1092 KENNEDY, A. D., MEMBERS OF THE, U., MILOSAVLJEVIC, A., LEE, B. H. &
1093 ELSEA, S. H. 2019. Untargeted metabolomic profiling reveals multiple pathway
1094 perturbations and new clinical biomarkers in urea cycle disorders. *Genet Med*, 21,
1095 1977-1986.
- 1096 BUSNEL, O., CARREAUX, F., CARBONI, B., PETHE, S., GOFF, S. V., MANSUY, D. &
1097 BOUCHER, J. L. 2005. Synthesis and evaluation of new omega-borono-alpha-amino
1098 acids as rat liver arginase inhibitors. *Bioorg Med Chem*, 13, 2373-9.
- 1099 CALDWELL, R. B., TOQUE, H. A., NARAYANAN, S. P. & CALDWELL, R. W. 2015.
1100 Arginase: an old enzyme with new tricks. *Trends Pharmacol Sci*, 36, 395-405.
- 1101 CALDWELL, R. W., RODRIGUEZ, P. C., TOQUE, H. A., NARAYANAN, S. P. & CALDWELL,
1102 R. B. 2018. Arginase: A Multifaceted Enzyme Important in Health and Disease.
1103 *Physiol Rev*, 98, 641-665.
- 1104 CAMA, E., COLLELUORI, D. M., EMIG, F. A., SHIN, H., KIM, S. W., KIM, N. N., TRAISH, A.
1105 M., ASH, D. E. & CHRISTIANSON, D. W. 2003. Human arginase II: crystal structure
1106 and physiological role in male and female sexual arousal. *Biochemistry*, 42, 8445-51.
- 1107 CAMACHO, J. A. & RIOSECO-CAMACHO, N. 2009. The human and mouse SLC25A29
1108 mitochondrial transporters rescue the deficient ornithine metabolism in fibroblasts of
1109 patients with the hyperornithinemia-hyperammonemia-homocitrullinuria (HHH)
1110 syndrome. *Pediatr Res*, 66, 35-41.
- 1111 CATSBURG, C., ANDERSON, S., UPADHYAYA, N. & BECHTER, M. 2022. Arginase 1
1112 Deficiency: using genetic databases as a tool to establish global prevalence.
1113 *Orphanet J Rare Dis*, 17, 94.
- 1114 CHEN, X., NIROOMAND, F., LIU, Z., ZANKL, A., KATUS, H. A., JAHN, L. &
1115 TIEFENBACHER, C. P. 2006. Expression of nitric oxide related enzymes in coronary
1116 heart disease. *Basic Res Cardiol*, 101, 346-53.
- 1117 CHEN, Y. & TIAN, Z. 2021. Innate lymphocytes: pathogenesis and therapeutic targets of liver
1118 diseases and cancer. *Cell Mol Immunol*, 18, 57-72.
- 1119 CHENG, P. N. M., LIU, A. M., BESSUDO, A. & MUSSAI, F. 2021. Safety, PK/PD and
1120 preliminary anti-tumor activities of pegylated recombinant human arginase 1 (BCT-

- 1121 100) in patients with advanced arginine auxotrophic tumors. *Invest New Drugs*, 39,
1122 1633-1640.
- 1123 CHENNUPATI, R., MEENS, M. J., JANSSEN, B. J., VAN DIJK, P., HAKVOORT, T. B. M.,
1124 LAMERS, W. H., DE MEY, J. G. R. & KOEHLER, S. E. 2018. Deletion of endothelial
1125 arginase 1 does not improve vasomotor function in diabetic mice. *Physiol Rep*, 6,
1126 e13717.
- 1127 CHIN-DUSTING, J. P., ALEXANDER, C. T., ARNOLD, P. J., HODGSON, W. C., LUX, A. S.
1128 & JENNINGS, G. L. 1996. Effects of in vivo and in vitro L-arginine supplementation
1129 on healthy human vessels. *J Cardiovasc Pharmacol*, 28, 158-66.
- 1130 CHINARD, F. P. 1952. Photometric estimation of proline and ornithine. *J Biol Chem*, 199, 91-
1131 5.
- 1132 CHOI, S., PARK, C., AHN, M., LEE, J. H. & SHIN, T. 2012. Immunohistochemical study of
1133 arginase 1 and 2 in various tissues of rats. *Acta Histochem*, 114, 487-94.
- 1134 CHUNG, J. H., MOON, J., LEE, Y. S., CHUNG, H. K., LEE, S. M. & SHIN, M. J. 2014.
1135 Arginase inhibition restores endothelial function in diet-induced obesity. *Biochem
1136 Biophys Res Commun*, 451, 179-83.
- 1137 CLOOTS, R. H., SANKARANARAYANAN, S., DE THEIJE, C. C., POYNTER, M. E.,
1138 TERWINDT, E., VAN DIJK, P., HAKVOORT, T. B., LAMERS, W. H. & KOHLER, S. E.
1139 2013. Ablation of Arg1 in hematopoietic cells improves respiratory function of lung
1140 parenchyma, but not that of larger airways or inflammation in asthmatic mice. *Am J
1141 Physiol Lung Cell Mol Physiol*, 305, L364-76.
- 1142 CLOOTS, R. H. E., SANKARANARAYANAN, S., POYNTER, M. E., TERWINDT, E., VAN
1143 DIJK, P., LAMERS, W. H. & ELEONORE KOHLER, S. 2017. Arginase 1 deletion in
1144 myeloid cells affects the inflammatory response in allergic asthma, but not lung
1145 mechanics, in female mice. *BMC Pulm Med*, 17, 158.
- 1146 COLLELUORI, D. M. & ASH, D. E. 2001. Classical and slow-binding inhibitors of human type
1147 II arginase. *Biochemistry*, 40, 9356-62.
- 1148 CORRALIZA, I. M., CAMPO, M. L., SOLER, G. & MODOLELL, M. 1994. Determination of
1149 arginase activity in macrophages: a micromethod. *J Immunol Methods*, 174, 231-5.
- 1150 CORTESE-KROTT, M. M., RODRIGUEZ-MATEOS, A., SANSONE, R., KUHNLE, G. G.,
1151 THASIAN-SIVARAJAH, S., KRENZ, T., HORN, P., KRISP, C., WOLTERS, D.,
1152 HEISS, C., KRONCKE, K. D., HOGG, N., FEELISCH, M. & KELM, M. 2012. Human
1153 red blood cells at work: identification and visualization of erythrocytic eNOS activity in
1154 health and disease. *Blood*, 120, 4229-37.
- 1155 CORTESE-KROTT, M. M., SUVORAVA, T., LEO, F., HEUSER, S. K., LOBUE, A., LI, J.,
1156 BECHER, S., SCHNECKMANN, R., SRIVRASTAVA, T., ERKENS, R., WOLFF, G.,
1157 SCHMITT, J. P., GRANDOCH, M., LUNDBERG, J. O., PERNOW, J., ISAKSON, B.
1158 E., WEITZBERG, E. & KELM, M. 2022. Red blood cell eNOS is cardioprotective in
1159 acute myocardial infarction. *Redox Biol*, 54, 102370.
- 1160 CUNNINGHAM, R. P. & PORAT-SHLIOM, N. 2021. Liver Zonation - Revisiting Old
1161 Questions With New Technologies. *Front Physiol*, 12, 732929.
- 1162 CZYSTOWSKA-KUZMICZ, M., SOSNOWSKA, A., NOWIS, D., RAMJI, K., SZAJNIK, M.,
1163 CHLEBOWSKA-TUZ, J., WOLINSKA, E., GAJ, P., GRAZUL, M., PILCH, Z.,
1164 ZERROUQI, A., GRACZYK-JARZYNSKA, A., SOROCZYNSKA, K., CIERNIAK, S.,
1165 KOKTYSZ, R., ELISHAEV, E., GRUCA, S., STEFANOWICZ, A., BLASZCZYK, R.,
1166 BOREK, B., GZIK, A., WHITESIDE, T. & GOLAB, J. 2019. Small extracellular
1167 vesicles containing arginase-1 suppress T-cell responses and promote tumor growth
1168 in ovarian carcinoma. *Nature Communications*, 10, 3000.
- 1169 DAYOUB, R., THASLER, W. E., BOSSERHOFF, A. K., SINGER, T., JAUCH, K. W.,
1170 SCHLITT, H. J. & WEISS, T. S. 2006. Regulation of polyamine synthesis in human
1171 hepatocytes by hepatotrophic factor augments liver regeneration. *Biochem
1172 Biophys Res Commun*, 345, 181-7.
- 1173 DE BONIFACE, J., MAO, Y., SCHMIDT-MENDE, J., KIESSLING, R. & POSCHKE, I. 2012.
1174 Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph
1175 nodes and tumor tissue of early-stage breast cancer patients. *Oncoimmunology*, 1,
1176 1305-1312.

- 1177 DE SANTO, C., BOOTH, S., VARDON, A., COUSINS, A., TUBB, V., PERRY, T., NOYVERT,
1178 B., BEGGS, A., NG, M., HALSEY, C., KEARNS, P., CHENG, P. & MUSSAI, F. 2018.
1179 The arginine metabolome in acute lymphoblastic leukemia can be targeted by the
1180 pegylated-recombinant arginase I BCT-100. *Int J Cancer*, 142, 1490-1502.
- 1181 DEIGNAN, J. L., LIVESAY, J. C., YOO, P. K., GOODMAN, S. I., O'BRIEN, W. E., IYER, R.
1182 K., CEDERBAUM, S. D. & GRODY, W. W. 2006. Ornithine deficiency in the arginase
1183 double knockout mouse. *Mol Genet Metab*, 89, 87-96.
- 1184 DHANAKOTI, S. N., BROSNAN, J. T., HERZBERG, G. R. & BROSNAN, M. E. 1990. Renal
1185 arginine synthesis: studies in vitro and in vivo. *Am J Physiol*, 259, E437-42.
- 1186 DI COSTANZO, L., SABIO, G., MORA, A., RODRIGUEZ, P. C., OCHOA, A. C., CENTENO,
1187 F. & CHRISTIANSON, D. W. 2005. Crystal structure of human arginase I at 1.29-Å
1188 resolution and exploration of inhibition in the immune response. *Proc Natl Acad Sci U
1189 S A*, 102, 13058-63.
- 1190 DIEZ-FERNANDEZ, C., RUFENACHT, V., GEMPERLE, C., FINGERHUT, R. & HABERLE,
1191 J. 2018. Mutations and common variants in the human arginase 1 (ARG1) gene:
1192 Impact on patients, diagnostics, and protein structure considerations. *Hum Mutat*, 39,
1193 1029-1050.
- 1194 DIZIKES, G. J., GRODY, W. W., KERN, R. M. & CEDERBAUM, S. D. 1986. Isolation of
1195 human liver arginase cDNA and demonstration of nonhomology between the two
1196 human arginase genes. *Biochemical and biophysical research communications*, 141,
1197 53-59.
- 1198 DOWLING, J. K., AFZAL, R., GEARING, L. J., CERVANTES-SILVA, M. P., ANNETT, S.,
1199 DAVIS, G. M., DE SANTI, C., ASSMANN, N., DETTMER, K., GOUGH, D. J.,
1200 BANTUG, G. R., HAMID, F. I., NALLY, F. K., DUFFY, C. P., GORMAN, A. L.,
1201 LIDDICOAT, A. M., LAVELLE, E. C., HESS, C., OEFNER, P. J., FINLAY, D. K.,
1202 DAVEY, G. P., ROBSON, T., CURTIS, A. M., HERTZOG, P. J., WILLIAMS, B. R. G.
1203 & MCCOY, C. E. 2021. Mitochondrial arginase-2 is essential for IL-10 metabolic
1204 reprogramming of inflammatory macrophages. *Nat Commun*, 12, 1460.
- 1205 DURANTE, W., JOHNSON, F. K. & JOHNSON, R. A. 2007. Arginase: A Critical Regulator of
1206 Nitric Oxide Synthesis and Vascular Function. *Clinical and Experimental
1207 Pharmacology and Physiology*, 34, 906-911.
- 1208 EL-BASSOSSY, H. M., EL-FAWAL, R., FAHMY, A. & WATSON, M. L. 2013. Arginase
1209 inhibition alleviates hypertension in the metabolic syndrome. *Br J Pharmacol*, 169,
1210 693-703.
- 1211 EL KASMI, K. C., QUALLS, J. E., PESCE, J. T., SMITH, A. M., THOMPSON, R. W.,
1212 HENAO-TAMAYO, M., BASARABA, R. J., KÖNIG, T., SCHLEICHER, U., KOO, M.
1213 S., KAPLAN, G., FITZGERALD, K. A., TUOMANEN, E. I., ORME, I. M.,
1214 KANNEGANTI, T. D., BOGDAN, C., WYNN, T. A. & MURRAY, P. J. 2008. Toll-like
1215 receptor-induced arginase 1 in macrophages thwarts effective immunity against
1216 intracellular pathogens. *Nat Immunol*, 9, 1399-406.
- 1217 ELMS, S., CHEN, F., WANG, Y., QIAN, J., ASKARI, B., YU, Y., PANDEY, D., IDDINGS, J.,
1218 CALDWELL, R. B. & FULTON, D. J. 2013. Insights into the arginine paradox:
1219 evidence against the importance of subcellular location of arginase and eNOS. *Am J
1220 Physiol Heart Circ Physiol*, 305, H651-66.
- 1221 FAN, M., GAO, X., LI, L., REN, Z., LUI, L. M. W., MCINTYRE, R. S., TEOPIZ, K. M., DENG,
1222 P. & CAO, B. 2021. The Association Between Concentrations of Arginine, Ornithine,
1223 Citrulline and Major Depressive Disorder: A Meta-Analysis. *Front Psychiatry*, 12,
1224 686973.
- 1225 FARAH, C., MICHEL, L. Y. M. & BALLIGAND, J. L. 2018. Nitric oxide signalling in
1226 cardiovascular health and disease. *Nat Rev Cardiol*, 15, 292-316.
- 1227 FIERMONTE, G., DOLCE, V., DAVID, L., SANTORELLI, F. M., DIONISI-VICI, C.,
1228 PALMIERI, F. & WALKER, J. E. 2003. The mitochondrial ornithine transporter.
1229 Bacterial expression, reconstitution, functional characterization, and tissue distribution
1230 of two human isoforms. *J Biol Chem*, 278, 32778-83.

- 1231 FRIBERG, N., ARVIDSSON, I., TONTANAHAL, A., KRISTOFFERSSON, A. C., GRAM, M.,
1232 KAPLAN, B. S. & KARPMAN, D. 2024. Red blood cell-derived arginase release in
1233 hemolytic uremic syndrome. *J Transl Med*, 22, 17.
- 1234 GABRILOVICH, D. I. & NAGARAJ, S. 2009. Myeloid-derived suppressor cells as regulators
1235 of the immune system. *Nat Rev Immunol*, 9, 162-74.
- 1236 GAO, X., XU, X., BELMADANI, S., PARK, Y., TANG, Z., FELDMAN, A. M., CHILIAN, W. M.
1237 & ZHANG, C. 2007. TNF- α Contributes to Endothelial Dysfunction by Upregulating
1238 Arginase in Ischemia/Reperfusion Injury. *Arteriosclerosis, Thrombosis, and Vascular
1239 Biology*, 27, 1269-1275.
- 1240 GARGANTA, C. L. & BOND, J. S. 1986. Assay and kinetics of arginase. *Anal Biochem*, 154,
1241 388-94.
- 1242 GEIGER, R., RIECKMANN, J. C., WOLF, T., BASSO, C., FENG, Y., FUHRER, T.,
1243 KOGADEEVA, M., PICOTTI, P., MEISSNER, F., MANN, M., ZAMBONI, N.,
1244 SALLUSTO, F. & LANZAVECCHIA, A. 2016. L-Arginine Modulates T Cell Metabolism
1245 and Enhances Survival and Anti-tumor Activity. *Cell*, 167, 829-842.e13.
- 1246 GHOSH, I., SANKHE, R., MUDGAL, J., ARORA, D. & NAMPOOTHIRI, M. 2020. News and
1247 reviews spermidine, an autophagy inducer, as a therapeutic strategy in neurological
1248 disorders. *Neuropeptides*, 83, 102083.
- 1249 GIRERD, X. J., HIRSCH, A. T., COOKE, J. P., DZAU, V. J. & CREAGER, M. A. 1990. L-
1250 arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits.
1251 *Circ Res*, 67, 1301-8.
- 1252 GOGIRAJU, R., RENNER, L., BOCHENEK, M. L., ZIFKOS, K., MOLITOR, M.,
1253 DANCKWARDT, S., WENZEL, P., MUNZEL, T., KONSTANTINIDES, S. &
1254 SCHAFFER, K. 2022. Arginase-1 Deletion in Erythrocytes Promotes Vascular
1255 Calcification via Enhanced GSNOR (S-Nitrosoglutathione Reductase) Expression and
1256 NO Signaling in Smooth Muscle Cells. *Arterioscler Thromb Vasc Biol*, 42, e291-e310.
- 1257 GOLEBIEWSKI, A., WHITEHOUSE, D., BECKETT, R. P., VAN ZANDT, M., JI, M. K.,
1258 RYDER, T. R., JAGDMANN, E., ANDREOLI, M., LEE, Y., SHEELER, R., CONWAY,
1259 B., OLCZAK, J., MAZUR, M., CZESTKOWSKI, W., PIOTROWSKA, W., COUSIDO-
1260 SIAH, A., RUIZ, F. X., MITSCHLER, A., PODJARNY, A. & SCHROETER, H. 2013.
1261 Synthesis of quaternary alpha-amino acid-based arginase inhibitors via the Ugi
1262 reaction. *Bioorg Med Chem Lett*, 23, 4837-41.
- 1263 GONON, A. T., JUNG, C., KATZ, A., WESTERBLAD, H., SHEMYAKIN, A., SJOQUIST, P.
1264 O., LUNDBERG, J. O. & PERNOW, J. 2012. Local arginase inhibition during early
1265 reperfusion mediates cardioprotection via increased nitric oxide production. *PLoS
1266 One*, 7, e42038.
- 1267 GONZALEZ-MENENDEZ, P., PHADKE, I., OLIVE, M. E., JOLY, A., PAPOIN, J., YAN, H.,
1268 GALTIER, J., PLATON, J., KANG, S. W. S., MCGRAW, K. L., DAUMUR, M.,
1269 POUZOLLES, M., KONDO, T., BOIREAU, S., PAUL, F., YOUNG, D. J., LAMURE, S.,
1270 MIRMIRA, R. G., NARLA, A., CARTRON, G., DUNBAR, C. E., BOYER-CLAVEL, M.,
1271 PORAT-SHLIOM, N., DARDALHON, V., ZIMMERMANN, V. S., SITBON, M., DEVER,
1272 T. E., MOHANDAS, N., DA COSTA, L., UDESHI, N. D., BLANC, L., KINET, S. &
1273 TAYLOR, N. 2023. Arginine metabolism regulates human erythroid differentiation
1274 through hypusination of eIF5A. *Blood*, 141, 2520-2536.
- 1275 GOTOH, T., SONOKI, T., NAGASAKI, A., TERADA, K., TAKIGUCHI, M. & MORI, M. 1996.
1276 Molecular cloning of cDNA for nonhepatic mitochondrial arginase (arginase II) and
1277 comparison of its induction with nitric oxide synthase in a murine macrophage-like cell
1278 line. *FEBS letters*, 395, 119-122.
- 1279 GOTOH, T., ARAKI, M. & MORI, M. 1997. Chromosomal localization of the human arginase
1280 II gene and tissue distribution of its mRNA. *Biochem Biophys Res Commun*, 233,
1281 487-91.
- 1282 GRABOŃ, W., MIELCZAREK-PUTA, M., CHRZANOWSKA, A. & BARAŃCZYK-KUŹMA, A.
1283 2009. L-arginine as a factor increasing arginase significance in diagnosis of primary
1284 and metastatic colorectal cancer. *Clin Biochem*, 42, 353-7.

- 1285 GRANDVAUX, N., GABORIAU, F., HARRIS, J., TENOEVER, B. R., LIN, R. & HISCOTT, J.
1286 2005. Regulation of arginase II by interferon regulatory factor 3 and the involvement
1287 of polyamines in the antiviral response. *FEBS J*, 272, 3120-31.
- 1288 GRAY, M. J., POLJAKOVIC, M., KEPKA-LENHART, D. & MORRIS, S. M., JR. 2005.
1289 Induction of arginase I transcription by IL-4 requires a composite DNA response
1290 element for STAT6 and C/EBPbeta. *Gene*, 353, 98-106.
- 1291 GRZYWA, T. M., SOSNOWSKA, A., MATRYBA, P., RYDZYNSKA, Z., JASINSKI, M.,
1292 NOWIS, D. & GOLAB, J. 2020. Myeloid Cell-Derived Arginase in Cancer Immune
1293 Response. *Frontiers in Immunology*, 11.
- 1294 GRZYWA, T. M., NOWIS, D. & GOLAB, J. 2021a. The role of CD71(+) erythroid cells in the
1295 regulation of the immune response. *Pharmacol Ther*, 228, 107927.
- 1296 GRZYWA, T. M., SOSNOWSKA, A., RYDZYNSKA, Z., LAZNIEWSKI, M., PLEWCZYNSKI,
1297 D., KLICKA, K., MALECKA-GIELDOWSKA, M., RODZIEWICZ-LURZYNSKA, A.,
1298 CIEPIELA, O., JUSTYNIARSKA, M., POMPER, P., GRZYBOWSKI, M. M.,
1299 BLASZCZYK, R., WEGRZYNOWICZ, M., TOMASZEWSKA, A., BASAK, G., GOLAB,
1300 J. & NOWIS, D. 2021b. Potent but transient immunosuppression of T-cells is a
1301 general feature of CD71(+) erythroid cells. *Commun Biol*, 4, 1384.
- 1302 GZIK, A., BOREK, B., CHRZANOWSKI, J., JEDRZEJCZAK, K., DZIEGIELEWSKI, M.,
1303 BRZEZINSKA, J., NOWICKA, J., GRZYBOWSKI, M. M., REJCZAK, T., NIEDZIALEK,
1304 D., WIECZOREK, G., OLCZAK, J., GOLEBIEWSKI, A., ZASLONA, Z. &
1305 BLASZCZYK, R. 2024. Novel orally bioavailable piperidine derivatives as extracellular
1306 arginase inhibitors developed by a ring expansion. *Eur J Med Chem*, 264, 116033.
- 1307 HARAGUCHI, Y., TAKIGUCHI, M., AMAYA, Y., KAWAMOTO, S., MATSUDA, I. & MORI, M.
1308 1987. Molecular cloning and nucleotide sequence of cDNA for human liver arginase.
1309 *Proc Natl Acad Sci U S A*, 84, 412-5.
- 1310 HARDBOWER, D. M., ASIM, M., MURRAY-STEWART, T., CASERO, R. A., JR.,
1311 VERRIERE, T., LEWIS, N. D., CHATURVEDI, R., PIAZUELO, M. B. & WILSON, K. T.
1312 2016. Arginase 2 deletion leads to enhanced M1 macrophage activation and
1313 upregulated polyamine metabolism in response to Helicobacter pylori infection.
1314 *Amino Acids*, 48, 2375-88.
- 1315 HAYES, C. S., SHICORA, A. C., KEOUGH, M. P., SNOOK, A. E., BURNS, M. R. &
1316 GILMOUR, S. K. 2014. Polyamine-blocking therapy reverses immunosuppression in
1317 the tumor microenvironment. *Cancer Immunol Res*, 2, 274-85.
- 1318 HENNO, P., MAUREY, C., LE PIMPEC-BARTHES, F., DEVILLIER, P., DELCLAUX, C. &
1319 ISRAEL-BIET, D. 2015. Is arginase a potential drug target in tobacco-induced
1320 pulmonary endothelial dysfunction? *Respir Res*, 16, 46.
- 1321 HERESZTYN, T., WORTHLEY, M. I. & HOROWITZ, J. D. 2004. Determination of L-arginine
1322 and NG, NG - and NG, NG' -dimethyl-L-arginine in plasma by liquid chromatography
1323 as AccQ-Fluor fluorescent derivatives. *J Chromatogr B Analyt Technol Biomed Life
1324 Sci*, 805, 325-9.
- 1325 HEUSER, S. K., LOBUE, A., LI, J., ZHUGE, Z., LEO, F., SUVORAVA, T., OLSSON, A.,
1326 SCHNECKMANN, R., GUIMARAES BRAGA, D. D., SRIVRASTAVA, T., MONTERO,
1327 L., SCHMITZ, O. J., SCHMITT, J. P., GRANDOCH, M., WEITZBERG, E.,
1328 LUNDBERG, J. O., PERNOW, J., KELM, M., CARLSTRÖM, M. & CORTESE-
1329 KROTT, M. M. 2022. Downregulation of eNOS and preserved endothelial function in
1330 endothelial-specific arginase 1-deficient mice. *Nitric Oxide*, 125-126, 69-77.
- 1331 HEY, C., BOUCHER, J. L., VADON-LE GOFF, S., KETTERER, G., WESSLER, I. & RACKE,
1332 K. 1997. Inhibition of arginase in rat and rabbit alveolar macrophages by N omega-
1333 hydroxy-D,L-inospicine, effects on L-arginine utilization by nitric oxide synthase. *Br J
1334 Pharmacol*, 121, 395-400.
- 1335 HOFER, S. J., SIMON, A. K., BERGMANN, M., EISENBERG, T., KROEMER, G. & MADEO,
1336 F. 2022. Mechanisms of spermidine-induced autophagy and geroprotection. *Nat
1337 Aging*, 2, 1112-1129.
- 1338 HOLOWATZ, L. A., THOMPSON, C. S. & KENNEY, W. L. 2006. L-Arginine supplementation
1339 or arginase inhibition augments reflex cutaneous vasodilatation in aged human skin. *J
1340 Physiol*, 574, 573-81.

- 1341 HOOGENRAAD, N., TOTINO, N., ELMER, H., WRAIGHT, C., ALEWOOD, P. & JOHNS, R.
1342 B. 1985. Inhibition of intestinal citrulline synthesis causes severe growth retardation in
1343 rats. *Am J Physiol*, 249, G792-9.
- 1344 HUYNH, N. N., ANDREWS, K. L., HEAD, G. A., KHONG, S. M., MAYOROV, D. N.,
1345 MURPHY, A. J., LAMBERT, G., KIRIAZIS, H., XU, Q., DU, X. J. & CHIN-DUSTING,
1346 J. P. 2009. Arginase II knockout mouse displays a hypertensive phenotype despite a
1347 decreased vasoconstrictory profile. *Hypertension*, 54, 294-301.
- 1348 HYNDMAN, K. A., XUE, J., MACDONELL, A., SPEED, J. S., JIN, C. & POLLOCK, J. S.
1349 2013. Distinct regulation of inner medullary collecting duct nitric oxide production from
1350 mice and rats. *Clinical and experimental Pharmacology and Physiology*, 40, 233-239.
- 1351 IWATA, S., TSUJINO, T., IKEDA, Y., ISHIDA, T., UHEYAMA, T., GOTOH, T., MORI, M. &
1352 YOKOYAMA, M. 2002. Decreased expression of arginase II in the kidneys of Dahl
1353 salt-sensitive rats. *Hypertens Res*, 25, 411-8.
- 1354 IYAMU, E. W., CECIL, R., PARKIN, L., WOODS, G., OHENE-FREMPONG, K. & ASAKURA,
1355 T. 2005. Modulation of erythrocyte arginase activity in sickle cell disease patients
1356 during hydroxyurea therapy. *Br J Haematol*, 131, 389-94.
- 1357 IYAMU, E. W., ASAKURA, T. & WOODS, G. M. 2008. A colorimetric microplate assay
1358 method for high-throughput analysis of arginase activity in vitro. *Anal Biochem*, 383,
1359 332-4.
- 1360 IYER, R. K., YOO, P. K., KERN, R. M., ROZENGURT, N., TSOA, R., O'BRIEN, W. E., YU,
1361 H., GRODY, W. W. & CEDERBAUM, S. D. 2002. Mouse model for human arginase
1362 deficiency. *Mol Cell Biol*, 22, 4491-8.
- 1363 JAMES, C., ZHAO, T. Y., RAHIM, A., SAXENA, P., MUTHALIF, N. A., UEMURA, T.,
1364 TSUNEYOSHI, N., ONG, S., IGARASHI, K., LIM, C. Y., DUNN, N. R. & VARDY, L. A.
1365 2018. MINDY1 is a downstream target of the polyamines and promotes embryonic
1366 stem cell self-renewal. *Stem Cells*, 36, 1170-1178.
- 1367 JENKINSON, C. P., GRODY, W. W. & CEDERBAUM, S. D. 1996. Comparative properties of
1368 arginases. *Comparative Biochemistry and Physiology Part B: Biochemistry and*
1369 *Molecular Biology*, 114, 107-132.
- 1370 JIA, W., JACKSON-COOK, C. & GRAF, M. R. 2010. Tumor-infiltrating, myeloid-derived
1371 suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat
1372 glioma + vaccination model. *J Neuroimmunol*, 223, 20-30.
- 1373 JIANG, M., DING, Y., SU, Y., HU, X., LI, J. & ZHANG, Z. 2006. Arginase-flotillin interaction
1374 brings arginase to red blood cell membrane. *FEBS Lett*, 580, 6561-4.
- 1375 JUNG, A. S., KUBO, H., WILSON, R., HOUSER, S. R. & MARGULIES, K. B. 2006.
1376 Modulation of contractility by myocyte-derived arginase in normal and hypertrophied
1377 feline myocardium. *Am J Physiol Heart Circ Physiol*, 290, H1756-62.
- 1378 JUNG, C., GONON, A. T., SJOQUIST, P. O., LUNDBERG, J. O. & PERNOW, J. 2010.
1379 Arginase inhibition mediates cardioprotection during ischaemia-reperfusion.
1380 *Cardiovasc Res*, 85, 147-54.
- 1381 KANYO, Z. F., SCOLNICK, L. R., ASH, D. E. & CHRISTIANSON, D. W. 1996. Structure of a
1382 unique binuclear manganese cluster in arginase. *Nature*, 383, 554-7.
- 1383 KASTEN, J., HU, C., BHARGAVA, R., PARK, H., TAI, D., BYRNE, J. A., MARESCAU, B.,
1384 DE DEYN, P. P., SCHLICHTING, L., GRODY, W. W., CEDERBAUM, S. D. &
1385 LIPSHUTZ, G. S. 2013. Lethal phenotype in conditional late-onset arginase 1
1386 deficiency in the mouse. *Molecular genetics and metabolism*, 110, 222-230.
- 1387 KAYSEN, G. A. & STRECKER, H. J. 1973. Purification and properties of arginase of rat
1388 kidney. *Biochem J*, 133, 779-88.
- 1389 KIM, J. H., BUGAJ, L. J., OH, Y. J., BIVALACQUA, T. J., RYOO, S., SOUCY, K. G.,
1390 SANTHANAM, L., WEBB, A., CAMARA, A., SIKKA, G., NYHAN, D., SHOUKAS, A.
1391 A., ILIES, M., CHRISTIANSON, D. W., CHAMPION, H. C. & BERKOWITZ, D. E.
1392 2009. Arginase inhibition restores NOS coupling and reverses endothelial dysfunction
1393 and vascular stiffness in old rats. *J Appl Physiol (1985)*, 107, 1249-57.
- 1394 KIM, P. S., IYER, R. K., LU, K. V., YU, H., KARIMI, A., KERN, R. M., TAI, D. K.,
1395 CEDERBAUM, S. D. & GRODY, W. W. 2002. Expression of the liver form of arginase
1396 in erythrocytes. *Mol Genet Metab*, 76, 100-10.

- 1397 KIM, S. H., ROSZIK, J., GRIMM, E. A. & EKMEKCIOGLU, S. 2018. Impact of L-Arginine
1398 Metabolism on Immune Response and Anticancer Immunotherapy. *Front Oncol*, 8,
1399 67.
- 1400 KLEINBONGARD, P., SCHULZ, R., RASSAF, T., LAUER, T., DEJAM, A., JAX, T.,
1401 KUMARA, I., GHARINI, P., KABANOVA, S., OZUYAMAN, B., SCHNURCH, H. G.,
1402 GODECKE, A., WEBER, A. A., ROBENEK, M., ROBENEK, H., BLOCH, W., ROSEN,
1403 P. & KELM, M. 2006. Red blood cells express a functional endothelial nitric oxide
1404 synthase. *Blood*, 107, 2943-51.
- 1405 KOVAMEES, O., SHEMYAKIN, A., CHECA, A., WHEELLOCK, C. E., LUNDBERG, J. O.,
1406 OSTENSON, C. G. & PERNOW, J. 2016a. Arginase Inhibition Improves
1407 Microvascular Endothelial Function in Patients With Type 2 Diabetes Mellitus. *J Clin*
1408 *Endocrinol Metab*, 101, 3952-3958.
- 1409 KOVAMEES, O., SHEMYAKIN, A. & PERNOW, J. 2016b. Amino acid metabolism reflecting
1410 arginase activity is increased in patients with type 2 diabetes and associated with
1411 endothelial dysfunction. *Diab Vasc Dis Res*, 13, 354-60.
- 1412 KÖVAMEES, O., SHEMYAKIN, A. & PERNOW, J. 2014. Effect of arginase inhibition on
1413 ischemia-reperfusion injury in patients with coronary artery disease with and without
1414 diabetes mellitus. *PLoS One*, 9, e103260.
- 1415 KRAUSE, B. J., DEL RIO, R., MOYA, E. A., MARQUEZ-GUTIERREZ, M., CASANELLO, P.
1416 & ITURRIAGA, R. 2015. Arginase-endothelial nitric oxide synthase imbalance
1417 contributes to endothelial dysfunction during chronic intermittent hypoxia. *J*
1418 *Hypertens*, 33, 515-24; discussion 524.
- 1419 KREBS, H. A. & HENSELEIT, K. 1932. Untersuchungen über die Harnstoffbildung im
1420 Tierkörper. *Hoppe-Seyler's Zeitschrift für physiologische Chemie*, 210, 33-66.
- 1421 KROTOVA, K., PATEL, J. M., BLOCK, E. R. & ZHARIKOV, S. 2010. Hypoxic upregulation of
1422 arginase II in human lung endothelial cells. *Am J Physiol Cell Physiol*, 299, C1541-8.
- 1423 KUBOKI, Y., KOYAMA, T., MATSUBARA, N., NAITO, Y., KONDO, S., HARANO, K.,
1424 YONEMORI, K., YOH, K., GU, Y., MITA, T., CHEN, X., UEDA, E., YAMAMOTO, N.,
1425 DOI, T. & SHIMIZU, T. 2024. PD-1 inhibition with retifanlimab and/or arginase
1426 inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study.
1427 *Cancer Med*, 13, e6980.
- 1428 LACCHINI, R., MUNIZ, J. J., NOBRE, Y. T., COLOGNA, A. J., MARTINS, A. C. & TANUS-
1429 SANTOS, J. E. 2015. Relationship between Arginase 1 and Arginase 2 levels and
1430 genetic polymorphisms with erectile dysfunction. *Nitric Oxide*, 51, 36-42.
- 1431 LANGNER, M., MATESKA, I., BECHMANN, N., WIELOCKX, B., CHAVAKIS, T., ALEXAKI,
1432 V. I. & PEITZSCH, M. 2022. Liquid chromatography-tandem mass spectrometry
1433 based quantification of arginine metabolites including polyamines in different sample
1434 matrices. *J Chromatogr A*, 1671, 463021.
- 1435 LAW, A. M. K., VALDES-MORA, F. & GALLEGO-ORTEGA, D. 2020. Myeloid-Derived
1436 Suppressor Cells as a Therapeutic Target for Cancer. *Cells*, 9.
- 1437 LEO, F., SUVORAVA, T., HEUSER, S. K., LI, J., LOBUE, A., BARBARINO, F., PIRAGINE,
1438 E., SCHNECKMANN, R., HUTZLER, B., GOOD, M. E., FERNANDEZ, B. O.,
1439 VORNHOLZ, L., ROGERS, S., DOCTOR, A., GRANDOCH, M., STEGBAUER, J.,
1440 WEITZBERG, E., FEELISCH, M., LUNDBERG, J. O., ISAKSON, B. E., KELM, M. &
1441 CORTESE-KROTT, M. M. 2021. Red Blood Cell and Endothelial eNOS
1442 Independently Regulate Circulating Nitric Oxide Metabolites and Blood Pressure.
1443 *Circulation*, 144, 870-889.
- 1444 LERMAN, A., BURNETT, J. C., JR., HIGANO, S. T., MCKINLEY, L. J. & HOLMES, D. R.,
1445 JR. 1998. Long-term L-arginine supplementation improves small-vessel coronary
1446 endothelial function in humans. *Circulation*, 97, 2123-8.
- 1447 LEVILLAIN, O., HUS-CITHAREL, A., MOREL, F. & BANKIR, L. 1989. Production of urea
1448 from arginine in pars recta and collecting duct of the rat kidney. *Ren Physiol Biochem*,
1449 12, 302-12.
- 1450 LEVILLAIN, O., HUS-CITHAREL, A., MOREL, F. & BANKIR, L. 1990. Localization of arginine
1451 synthesis along rat nephron. *Am J Physiol*, 259, F916-23.

- 1452 LEVILLAIN, O., BALVAY, S. & PEYROL, S. 2005a. Localization and differential expression
1453 of arginase II in the kidney of male and female mice. *Pflugers Arch*, 449, 491-503.
- 1454 LEVILLAIN, O., BALVAY, S. & PEYROL, S. 2005b. Mitochondrial expression of arginase II in
1455 male and female rat inner medullary collecting ducts. *J Histochem Cytochem*, 53,
1456 533-41.
- 1457 LEVILLAIN, O. 2012. Expression and function of arginine-producing and consuming-
1458 enzymes in the kidney. *Amino Acids*, 42, 1237-52.
- 1459 LEWIS, N. D., ASIM, M., BARRY, D. P., SINGH, K., DE SABLET, T., BOUCHER, J. L.,
1460 GOBERT, A. P., CHATURVEDI, R. & WILSON, K. T. 2010. Arginase II restricts host
1461 defense to *Helicobacter pylori* by attenuating inducible nitric oxide synthase
1462 translation in macrophages. *J Immunol*, 184, 2572-82.
- 1463 LEWIS, N. D., ASIM, M., BARRY, D. P., DE SABLET, T., SINGH, K., PIAZUELO, M. B.,
1464 GOBERT, A. P., CHATURVEDI, R. & WILSON, K. T. 2011. Immune evasion by
1465 *Helicobacter pylori* is mediated by induction of macrophage arginase II. *J Immunol*,
1466 186, 3632-41.
- 1467 LI, M., QIN, J., XIONG, K., JIANG, B. & ZHANG, T. 2022a. Review of arginase as a
1468 promising biocatalyst: characteristics, preparation, applications and future challenges.
1469 *Crit Rev Biotechnol*, 42, 651-667.
- 1470 LI, Y.-N., WANG, Z.-W., LI, F., ZHOU, L.-H., JIANG, Y.-S., YU, Y., MA, H.-H., ZHU, L.-P.,
1471 QU, J.-M. & JIA, X.-M. 2022b. Inhibition of myeloid-derived suppressor cell arginase-
1472 1 production enhances T-cell-based immunotherapy against *Cryptococcus*
1473 *neoformans* infection. *Nature Communications*, 13, 4074.
- 1474 LI, Z., WANG, L., REN, Y., HUANG, Y., LIU, W., LV, Z., QIAN, L., YU, Y. & XIONG, Y.
1475 2022c. Arginase: shedding light on the mechanisms and opportunities in
1476 cardiovascular diseases. *Cell Death Discov*, 8, 413.
- 1477 LOBUE, A., HEUSER, S. K., LINDEMANN, M., LI, J., RAHMAN, M., KELM, M.,
1478 STEGBAUER, J. & CORTESE-KROTT, M. M. 2023. Red blood cell endothelial nitric
1479 oxide synthase: A major player in regulating cardiovascular health. *Br J Pharmacol*.
- 1480 LORENTZEN, C. L., MARTINENAITE, E., KJELDSSEN, J. W., HOLMSTROEM, R. B., MORK,
1481 S. K., PEDERSEN, A. W., EHRNROOTH, E., ANDERSEN, M. H. & SVANE, I. M.
1482 2022. Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors -
1483 A phase I trial. *Front Immunol*, 13, 1023023.
- 1484 LOWE, M. M., BOOTHBY, I., CLANCY, S., AHN, R. S., LIAO, W., NGUYEN, D. N.,
1485 SCHUMANN, K., MARSON, A., MAHURON, K. M., KINGSBURY, G. A., LIU, Z.,
1486 MUNOZ SANDOVAL, P., RODRIGUEZ, R. S., PAULI, M. L., TARAVATI, K., ARRON,
1487 S. T., NEUHAUS, I. M., HARRIS, H. W., KIM, E. A., SHIN, U. S., KRUMMEL, M. F.,
1488 DAUD, A., SCHARSCHMIDT, T. C. & ROSENBLUM, M. D. 2019. Regulatory T cells
1489 use arginase 2 to enhance their metabolic fitness in tissues. *JCI Insight*, 4.
- 1490 LUCCA, F., DA DALT, L., ROS, M., GUCCIARDI, A., PIRILLO, P., NATURALE, M.,
1491 PERILONGO, G., GIORDANO, G. & BARALDI, E. 2018. Asymmetric
1492 dimethylarginine and related metabolites in exhaled breath condensate of children
1493 with cystic fibrosis. *Clin Respir J*, 12, 140-148.
- 1494 LUK, G. D. 1986. Essential role of polyamine metabolism in hepatic regeneration. Inhibition
1495 of deoxyribonucleic acid and protein synthesis and tissue regeneration by
1496 difluoromethylornithine in the rat. *Gastroenterology*, 90, 1261-7.
- 1497 LUNDBERG, J. O. & WEITZBERG, E. 2022. Nitric oxide signaling in health and disease.
1498 *Cell*, 185, 2853-2878.
- 1499 MACKENZIE, A. & WADSWORTH, R. M. 2003. Extracellular L-arginine is required for
1500 optimal NO synthesis by eNOS and iNOS in the rat mesenteric artery wall. *Br J*
1501 *Pharmacol*, 139, 1487-97.
- 1502 MACPARLAND, S. A., LIU, J. C., MA, X. Z., INNES, B. T., BARTCZAK, A. M., GAGE, B. K.,
1503 MANUEL, J., KHUU, N., ECHEVERRI, J., LINARES, I., GUPTA, R., CHENG, M. L.,
1504 LIU, L. Y., CAMAT, D., CHUNG, S. W., SELIGA, R. K., SHAO, Z., LEE, E., OGAWA,
1505 S., OGAWA, M., WILSON, M. D., FISH, J. E., SELZNER, M., GHANEKAR, A.,
1506 GRANT, D., GREIG, P., SAPISOCHIN, G., SELZNER, N., WINEGARDEN, N.,
1507 ADEYI, O., KELLER, G., BADER, G. D. & MCGILVRAY, I. D. 2018. Single cell RNA

- 1508 sequencing of human liver reveals distinct intrahepatic macrophage populations. *Nat*
1509 *Commun*, 9, 4383.
- 1510 MAHDI, A., KÖVAMEES, O., CHECA, A., WHEELLOCK, C. E., VON HEIJNE, M.,
1511 ALVARSSON, M. & PERNOW, J. 2018. Arginase inhibition improves endothelial
1512 function in patients with type 2 diabetes mellitus despite intensive glucose-lowering
1513 therapy. *J Intern Med*, 284, 388-398.
- 1514 MAHDI, A., PERNOW, J. & KÖVAMEES, O. 2019. Arginase Inhibition Improves Endothelial
1515 Function in an Age-Dependent Manner in Healthy Elderly Humans. *Rejuvenation*
1516 *Res*, 22, 385-389.
- 1517 MAHDI, A., KOVAMEES, O. & PERNOW, J. 2020a. Improvement in endothelial function in
1518 cardiovascular disease - Is arginase the target? *Int J Cardiol*, 301, 207-214.
- 1519 MAHDI, A., TENGBOM, J., ALVARSSON, M., WERNLY, B., ZHOU, Z. & PERNOW, J.
1520 2020b. Red Blood Cell Peroxynitrite Causes Endothelial Dysfunction in Type 2
1521 Diabetes Mellitus via Arginase. *Cells*, 9.
- 1522 MARSELLI, L., BOSI, E., DE LUCA, C., DEL GUERRA, S., TESI, M., SULEIMAN, M. &
1523 MARCHETTI, P. 2021. Arginase 2 and Polyamines in Human Pancreatic Beta Cells:
1524 Possible Role in the Pathogenesis of Type 2 Diabetes. *Int J Mol Sci*, 22.
- 1525 MARTÍ I LÍNDEZ, A. A., DUNAND-SAUTHIER, I., CONTI, M., GOBET, F., NÚÑEZ, N.,
1526 HANNICH, J. T., RIEZMAN, H., GEIGER, R., PIERSIGILLI, A., HAHN, K., LEMEILLE,
1527 S., BECHER, B., DE SMEDT, T., HUGUES, S. & REITH, W. 2019. Mitochondrial
1528 arginase-2 is a cell-autonomous regulator of CD8+ T cell function and antitumor
1529 efficacy. *JCI Insight*, 4.
- 1530 MARTÍ, I. L. A. A. & REITH, W. 2021. Arginine-dependent immune responses. *Cell Mol Life*
1531 *Sci*, 78, 5303-5324.
- 1532 MARTINENAITE, E., AHMAD, S. M., BENDTSEN, S. K., JØRGENSEN, M. A., WEIS-
1533 BANKE, S. E., SVANE, I. M. & ANDERSEN, M. H. 2019. Arginase-1-based
1534 vaccination against the tumor microenvironment: the identification of an optimal T-cell
1535 epitope. *Cancer Immunol Immunother*, 68, 1901-1907.
- 1536 MING, X. F., RAJAPAKSE, A. G., YEPURI, G., XIONG, Y., CARVAS, J. M., RUFFIEUX, J.,
1537 SCERRI, I., WU, Z., POPP, K., LI, J., SARTORI, C., SCHERRER, U., KWAK, B. R.,
1538 MONTANI, J. P. & YANG, Z. 2012. Arginase II Promotes Macrophage Inflammatory
1539 Responses Through Mitochondrial Reactive Oxygen Species, Contributing to Insulin
1540 Resistance and Atherogenesis. *J Am Heart Assoc*, 1, e000992.
- 1541 MIYANAKA, K., GOTOH, T., NAGASAKI, A., TAKEYA, M., OZAKI, M., IWASE, K.,
1542 TAKIGUCHI, M., IYAMA, K. I., TOMITA, K. & MORI, M. 1998. Immunohistochemical
1543 localization of arginase II and other enzymes of arginine metabolism in rat kidney and
1544 liver. *Histochem J*, 30, 741-51.
- 1545 MIYAZAKI, K., MASAKI, N. & ADACHI, T. 2018. Arginine deficiency measured by global
1546 arginine bioavailability ratio in patients with acute coronary syndrome. *Vascular*
1547 *Failure*, 2, 80-87.
- 1548 MOLEK, P., ZMUDZKI, P., WLODARCZYK, A., NESSLER, J. & ZALEWSKI, J. 2021. The
1549 shifted balance of arginine metabolites in acute myocardial infarction patients and its
1550 clinical relevance. *Sci Rep*, 11, 83.
- 1551 MOMMA, T. Y. & OTTAVIANI, J. I. 2022. There is no direct competition between arginase
1552 and nitric oxide synthase for the common substrate L-arginine. *Nitric Oxide*, 129, 16-
1553 24.
- 1554 MONCADA, S., PALMER, R. M. & HIGGS, E. A. 1991. Nitric oxide: physiology,
1555 pathophysiology, and pharmacology. *Pharmacol Rev*, 43, 109-42.
- 1556 MONIN, L., GRIFFITHS, K. L., LAM, W. Y., GOPAL, R., KANG, D. D., AHMED, M.,
1557 RAJAMANICKAM, A., CRUZ-LAGUNAS, A., ZUNIGA, J., BABU, S., KOLLS, J. K.,
1558 MITREVA, M., ROSA, B. A., RAMOS-PAYAN, R., MORRISON, T. E., MURRAY, P.
1559 J., RANGEL-MORENO, J., PEARCE, E. J. & KHADER, S. A. 2015. Helminth-induced
1560 arginase-1 exacerbates lung inflammation and disease severity in tuberculosis. *J Clin*
1561 *Invest*, 125, 4699-713.
- 1562 MORADI, H., KWOK, V. & VAZIRI, N. D. 2006. Effect of chronic renal failure on arginase and
1563 argininosuccinate synthetase expression. *Am J Nephrol*, 26, 310-8.

- 1564 MORRIS, C. R., KUYPERS, F. A., LARKIN, S., VICHINSKY, E. P. & STYLES, L. A. 2000.
1565 Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-
1566 occlusive crisis and acute chest syndrome. *J Pediatr Hematol Oncol*, 22, 515-20.
- 1567 MORRIS, C. R., KATO, G. J., POLJAKOVIC, M., WANG, X., BLACKWELDER, W. C.,
1568 SACHDEV, V., HAZEN, S. L., VICHINSKY, E. P., MORRIS, S. M., JR. & GLADWIN,
1569 M. T. 2005a. Dysregulated arginine metabolism, hemolysis-associated pulmonary
1570 hypertension, and mortality in sickle cell disease. *JAMA*, 294, 81-90.
- 1571 MORRIS, C. R., KUYPERS, F. A., KATO, G. J., LAVRISHA, L., LARKIN, S., SINGER, T. &
1572 VICHINSKY, E. P. 2005b. Hemolysis-associated pulmonary hypertension in
1573 thalassemia. *Ann N Y Acad Sci*, 1054, 481-5.
- 1574 MORRIS, S. M., JR., MONCMAN, C. L., HOLUB, J. S. & HOD, Y. 1989. Nutritional and
1575 hormonal regulation of mRNA abundance for arginine biosynthetic enzymes in
1576 kidney. *Arch Biochem Biophys*, 273, 230-7.
- 1577 MORRIS, S. M., JR., BHAMIDIPATI, D. & KEPKA-LENHART, D. 1997. Human type II
1578 arginase: sequence analysis and tissue-specific expression. *Gene*, 193, 157-61.
- 1579 MORRIS, S. M., JR., KEPKA-LENHART, D. & CHEN, L. C. 1998. Differential regulation of
1580 arginases and inducible nitric oxide synthase in murine macrophage cells. *Am J*
1581 *Physiol*, 275, E740-7.
- 1582 MORRIS, S. M., JR., GAO, T., COOPER, T. K., KEPKA-LENHART, D. & AWAD, A. S. 2011.
1583 Arginase-2 mediates diabetic renal injury. *Diabetes*, 60, 3015-22.
- 1584 MUNDER, M., MOLLINEDO, F., CALAFAT, J., CANCHADO, J., GIL-LAMAIGNERE, C.,
1585 FUENTES, J. M., LUCKNER, C., DOSCHKO, G., SOLER, G., EICHMANN, K.,
1586 MULLER, F. M., HO, A. D., GOERNER, M. & MODOLELL, M. 2005. Arginase I is
1587 constitutively expressed in human granulocytes and participates in fungicidal activity.
1588 *Blood*, 105, 2549-56.
- 1589 MUNDER, M., SCHNEIDER, H., LUCKNER, C., GIESE, T., LANGHANS, C.-D., FUENTES,
1590 J. M., KROPF, P., MUELLER, I., KOLB, A., MODOLELL, M. & HO, A. D. 2006.
1591 Suppression of T-cell functions by human granulocyte arginase. *Blood*, 108, 1627-
1592 1634.
- 1593 MUNDER, M. 2009. Arginase: an emerging key player in the mammalian immune system. *Br*
1594 *J Pharmacol*, 158, 638-51.
- 1595 MURRAY, P. J. 2016. Amino acid auxotrophy as a system of immunological control nodes.
1596 *Nature immunology*, 17, 132-139.
- 1597 MURRAY, P. J. 2017. Macrophage Polarization. *Annual Review of Physiology*, 79, 541-566.
- 1598 NAING, A., PAPADOPOULOS, K. P., PISHVAIAN, M. J., RAHMA, O., HANNA, G. J.,
1599 GARRALDA, E., SAAVEDRA, O., GOGOV, S., KALLENDER, H., CHENG, L.,
1600 SMITH, M., CHEN, X., KURIAKOSE, E. & BAUER, T. 2024. First-in-human phase 1
1601 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in
1602 patients with advanced or metastatic solid tumours. *BMJ Oncology*, 3, e000249.
- 1603 NIESE, K. A., COLLIER, A. R., HAJEK, A. R., CEDERBAUM, S. D., O'BRIEN, W. E., WILLS-
1604 KARP, M., ROTHENBERG, M. E. & ZIMMERMANN, N. 2009. Bone marrow cell
1605 derived arginase I is the major source of allergen-induced lung arginase but is not
1606 required for airway hyperresponsiveness, remodeling and lung inflammatory
1607 responses in mice. *BMC Immunol*, 10, 33.
- 1608 NIKOLAEVA, S., ANSERMET, C., CENTENO, G., PRADERVAND, S., BIZE, V.,
1609 MORDASINI, D., HENRY, H., KOESTERS, R., MAILLARD, M., BONNY, O.,
1610 TOKONAMI, N. & FIRSOV, D. 2016. Nephron-Specific Deletion of Circadian Clock
1611 Gene *Bmal1* Alters the Plasma and Renal Metabolome and Impairs Drug Disposition.
1612 *J Am Soc Nephrol*, 27, 2997-3004.
- 1613 NIU, F., YU, Y., LI, Z., REN, Y., LI, Z., YE, Q., LIU, P., JI, C., QIAN, L. & XIONG, Y. 2022.
1614 Arginase: An emerging and promising therapeutic target for cancer treatment.
1615 *Biomed Pharmacother*, 149, 112840.
- 1616 NORTH, M. L., KHANNA, N., MARSDEN, P. A., GRASEMANN, H. & SCOTT, J. A. 2009.
1617 Functionally important role for arginase 1 in the airway hyperresponsiveness of
1618 asthma. *Am J Physiol Lung Cell Mol Physiol*, 296, L911-20.

- 1619 OBERLIES, J., WATZL, C., GIESE, T., LUCKNER, C., KROPF, P., MÜLLER, I., HO, A. D. &
1620 MUNDER, M. 2009. Regulation of NK cell function by human granulocyte arginase. *J*
1621 *Immunol*, 182, 5259-67.
- 1622 OCHOA, J. B., STRANGE, J., KEARNEY, P., GELLIN, G., ENDEAN, E. & FITZPATRICK, E.
1623 2001. Effects of L-arginine on the proliferation of T lymphocyte subpopulations. *JPEN*
1624 *J Parenter Enteral Nutr*, 25, 23-9.
- 1625 OKUMURA, S., TERATANI, T., FUJIMOTO, Y., ZHAO, X., TSURUYAMA, T., MASANO, Y.,
1626 KASAHARA, N., IIDA, T., YAGI, S., UEMURA, T., KAIDO, T. & UEMOTO, S. 2016.
1627 Oral administration of polyamines ameliorates liver ischemia/reperfusion injury and
1628 promotes liver regeneration in rats. *Liver Transpl*, 22, 1231-44.
- 1629 OSTRAND-ROSENBERG, S. & FENSELAU, C. 2018. Myeloid-Derived Suppressor Cells:
1630 Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by
1631 Their Environment. *J Immunol*, 200, 422-431.
- 1632 PARK, S. W., ZHEN, G., VERHAEGHE, C., NAKAGAMI, Y., NGUYENVU, L. T., BARCZAK,
1633 A. J., KILLEEN, N. & ERLE, D. J. 2009. The protein disulfide isomerase AGR2 is
1634 essential for production of intestinal mucus. *Proc Natl Acad Sci U S A*, 106, 6950-5.
- 1635 PATTERTON, D. & SHI, Y.-B. 1994. Thyroid hormone-dependent differential regulation of
1636 multiple arginase genes during amphibian metamorphosis. *Journal of Biological*
1637 *Chemistry*, 269, 25328-25334.
- 1638 PAULING, L., ITANO, H. A. & ET AL. 1949. Sickle cell anemia a molecular disease. *Science*,
1639 110, 543-8.
- 1640 PAYNE, S., DE VAL, S. & NEAL, A. 2018. Endothelial-Specific Cre Mouse Models.
1641 *Arterioscler Thromb Vasc Biol*, 38, 2550-2561.
- 1642 PELLE, J. W. 2012. 12 - Amino Acid and Heme Metabolism. *In: PELLE, J. W. (ed.)*
1643 *Elsevier's Integrated Review Biochemistry (Second Edition)*. Philadelphia: W.B.
1644 Saunders.
- 1645 PERA, T., ZUIDHOF, A. B., SMIT, M., MENZEN, M. H., KLEIN, T., FLIK, G., ZAAGSMA, J.,
1646 MEURS, H. & MAARSINGH, H. 2014. Arginase inhibition prevents inflammation and
1647 remodeling in a guinea pig model of chronic obstructive pulmonary disease. *J*
1648 *Pharmacol Exp Ther*, 349, 229-38.
- 1649 PEROZICH, J., HEMPEL, J. & MORRIS, S. M. 1998. Roles of conserved residues in the
1650 arginase family. *Biochimica et Biophysica Acta (BBA) - Protein Structure and*
1651 *Molecular Enzymology*, 1382, 23-37.
- 1652 POISSON, J., LEMOINNE, S., BOULANGER, C., DURAND, F., MOREAU, R., VALLA, D. &
1653 RAUTOU, P. E. 2017. Liver sinusoidal endothelial cells: Physiology and role in liver
1654 diseases. *J Hepatol*, 66, 212-227.
- 1655 PORCELLI, V., FIERMONTE, G., LONGO, A. & PALMIERI, F. 2014. The human gene
1656 SLC25A29, of solute carrier family 25, encodes a mitochondrial transporter of basic
1657 amino acids. *J Biol Chem*, 289, 13374-84.
- 1658 POREMBSKA, Z. & KEDRA, M. 1975. Early diagnosis of myocardial infarction by arginase
1659 activity determination. *Clin Chim Acta*, 60, 355-61.
- 1660 PUDEWELL, S., LISSY, J., NAKHAEIZADEH, H., TAHA, M. S., AKBARZADEH, M., REZAEI
1661 ADARIANI, S., NAKHAEI-RAD, S., LI, J., KORDES, C., HAUSSINGER, D.,
1662 PIEKORZ, R. P., CORTESE-KROTT, M. M. & AHMADIAN, M. R. 2022. Physical
1663 Interaction between Embryonic Stem Cell-Expressed Ras (ERas) and Arginase-1 in
1664 Quiescent Hepatic Stellate Cells. *Cells*, 11.
- 1665 PUDLO, M., DEMOUGEOT, C. & GIRARD-THERNIER, C. 2017. Arginase Inhibitors: A
1666 Rational Approach Over One Century. *Med Res Rev*, 37, 475-513.
- 1667 RABER, P. L., THEVENOT, P., SIERRA, R., WYCZECZOWSKA, D., HALLE, D., RAMIREZ,
1668 M. E., OCHOA, A. C., FLETCHER, M., VELASCO, C., WILK, A., REISS, K. &
1669 RODRIGUEZ, P. C. 2014. Subpopulations of myeloid-derived suppressor cells impair
1670 T cell responses through independent nitric oxide-related pathways. *Int J Cancer*,
1671 134, 2853-64.
- 1672 RACANELLI, V. & REHERMANN, B. 2006. The liver as an immunological organ.
1673 *Hepatology*, 43, S54-62.

- 1674 RATH, M., MÜLLER, I., KROPF, P., CLOSS, E. I. & MUNDER, M. 2014. Metabolism via
1675 Arginase or Nitric Oxide Synthase: Two Competing Arginine Pathways in
1676 Macrophages. *Front Immunol*, 5, 532.
- 1677 RECTOR, T. S., BANK, A. J., MULLEN, K. A., TSCHUMPERLIN, L. K., SIH, R., PILLAI, K. &
1678 KUBO, S. H. 1996. Randomized, double-blind, placebo-controlled study of
1679 supplemental oral L-arginine in patients with heart failure. *Circulation*, 93, 2135-41.
- 1680 RECZKOWSKI, R. S. & ASH, D. E. 1994. Rat liver arginase: kinetic mechanism, alternate
1681 substrates, and inhibitors. *Arch Biochem Biophys*, 312, 31-7.
- 1682 REES, C. A., ROSTAD, C. A., MANTUS, G., ANDERSON, E. J., CHAHROUDI, A., JAGGI,
1683 P., WRAMMERT, J., OCHOA, J. B., OCHOA, A., BASU, R. K., HEILMAN, S.,
1684 HARRIS, F., LAPP, S. A., HUSSAINI, L., VOS, M. B., BROWN, L. A. & MORRIS, C.
1685 R. 2021. Altered amino acid profile in patients with SARS-CoV-2 infection. *Proc Natl
1686 Acad Sci U S A*, 118.
- 1687 ROGERS, Q. R., FREEDLAND, R. A. & SYMMONS, R. A. 1972. In vivo synthesis and
1688 utilization of arginine in the rat. *Am J Physiol*, 223, 236-40.
- 1689 ROMERO, M. J., PLATT, D. H., TAWFIK, H. E., LABAZI, M., EL-REMESSY, A. B.,
1690 BARTOLI, M., CALDWELL, R. B. & CALDWELL, R. W. 2008. Diabetes-induced
1691 coronary vascular dysfunction involves increased arginase activity. *Circ Res*, 102, 95-
1692 102.
- 1693 ROMERO, M. J., IDDIGS, J. A., PLATT, D. H., ALI, M. I., CEDERBAUM, S. D., STEPP, D.
1694 W., CALDWELL, R. B. & CALDWELL, R. W. 2012. Diabetes-induced vascular
1695 dysfunction involves arginase I. *Am J Physiol Heart Circ Physiol*, 302, H159-66.
- 1696 ROTONDO, R., BERTOLOTTO, M., BARISIONE, G., ASTIGIANO, S., MANDRUZZATO, S.,
1697 OTTONELLO, L., DALLEGRI, F., BRONTE, V., FERRINI, S. & BARBIERI, O. 2011.
1698 Exocytosis of azurophil and arginase 1-containing granules by activated
1699 polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. *J
1700 Leukoc Biol*, 89, 721-7.
- 1701 RUEGG, U. T. & RUSSELL, A. S. 1980. A rapid and sensitive assay for arginase. *Anal
1702 Biochem*, 102, 206-12.
- 1703 RUSSO, R. S., GASPERINI, S., BUBB, G., NEUMAN, L., SLOAN, L. S., DIAZ, G. A., ENNS,
1704 G. M. & INVESTIGATORS, P. 2024. Efficacy and safety of pegzilarginase in arginase
1705 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled,
1706 multi-centre trial. *EClinicalMedicine*, 68, 102405.
- 1707 SAGAR, N. A., TARAFDAR, S., AGARWAL, S., TARAFDAR, A. & SHARMA, S. 2021.
1708 Polyamines: Functions, Metabolism, and Role in Human Disease Management. *Med
1709 Sci (Basel)*, 9.
- 1710 SAYERS, E. W., BOLTON, E. E., BRISTER, J. R., CANESE, K., CHAN, J., COMEAU, D. C.,
1711 CONNOR, R., FUNK, K., KELLY, C., KIM, S., MADEJ, T., MARCHLER-BAUER, A.,
1712 LANCZYCKI, C., LATHROP, S., LU, Z., THIBAUD-NISSEN, F., MURPHY, T., PHAN,
1713 L., SKRIPCHENKO, Y., TSE, T., WANG, J., WILLIAMS, R., TRAWICK, B. W.,
1714 PRUITT, K. D. & SHERRY, S. T. 2022. Database resources of the national center for
1715 biotechnology information. *Nucleic Acids Res*, 50, D20-d26.
- 1716 SCHMOK, E., ABAD DAR, M., BEHRENDTS, J., ERDMANN, H., RUCKERL, D.,
1717 ENDERMANN, T., HEITMANN, L., HESSMANN, M., YOSHIMURA, A., ROSE-JOHN,
1718 S., SCHELLER, J., SCHAIBLE, U. E., EHLERS, S., LANG, R. & HOLSCHER, C.
1719 2017. Suppressor of Cytokine Signaling 3 in Macrophages Prevents Exacerbated
1720 Interleukin-6-Dependent Arginase-1 Activity and Early Permissiveness to
1721 Experimental Tuberculosis. *Front Immunol*, 8, 1537.
- 1722 SHAHBAZ, S., XU, L., OSMAN, M., SLIGL, W., SHIELDS, J., JOYCE, M., TYRRELL, D. L.,
1723 OYEGBAMI, O. & ELAHI, S. 2021. Erythroid precursors and progenitors suppress
1724 adaptive immunity and get invaded by SARS-CoV-2. *Stem Cell Reports*, 16, 1165-
1725 1181.
- 1726 SHATANAWI, A., LEMTALSI, T., YAO, L., PATEL, C., CALDWELL, R. B. & CALDWELL, R.
1727 W. 2015. Angiotensin II limits NO production by upregulating arginase through a p38
1728 MAPK-ATF-2 pathway. *Eur J Pharmacol*, 746, 106-14.

- 1729 SHATANAWI, A., MOMANI, M. S., AL-AQTASH, R., HAMDAN, M. H. & GHARAIBEH, M. N.
1730 2020. L-Citrulline Supplementation Increases Plasma Nitric Oxide Levels and
1731 Reduces Arginase Activity in Patients With Type 2 Diabetes. *Front Pharmacol*, 11,
1732 584669.
- 1733 SHELDON, K. E., SHANDILYA, H., KEPKA-LENHART, D., POLJAKOVIC, M., GHOSH, A. &
1734 MORRIS, S. M., JR. 2013. Shaping the murine macrophage phenotype: IL-4 and
1735 cyclic AMP synergistically activate the arginase I promoter. *J Immunol*, 191, 2290-8.
- 1736 SHEMYAKIN, A., KÖVAMEES, O., RAFNSSON, A., BÖHM, F., SVENARUD, P.,
1737 SETTERGREN, M., JUNG, C. & PERNOW, J. 2012. Arginase inhibition improves
1738 endothelial function in patients with coronary artery disease and type 2 diabetes
1739 mellitus. *Circulation*, 126, 2943-50.
- 1740 SHI, O., MORRIS, S. M., JR., ZOGHBI, H., PORTER, C. W. & O'BRIEN, W. E. 2001.
1741 Generation of a mouse model for arginase II deficiency by targeted disruption of the
1742 arginase II gene. *Mol Cell Biol*, 21, 811-3.
- 1743 SHIMA, Y., MAEDA, T., AIZAWA, S., TSUBOI, I., KOBAYASHI, D., KATO, R. & TAMAI, I.
1744 2006. L-arginine import via cationic amino acid transporter CAT1 is essential for both
1745 differentiation and proliferation of erythrocytes. *Blood*, 107, 1352-6.
- 1746 SHIN, N. S., MARLIER, A., XU, L., DOILICHO, N., LINBERG, D., GUO, J. & CANTLEY, L. G.
1747 2022. Arginase-1 Is Required for Macrophage-Mediated Renal Tubule Regeneration.
1748 *J Am Soc Nephrol*, 33, 1077-1086.
- 1749 SHIN, S., MOHAN, S. & FUNG, H. L. 2011. Intracellular L-arginine concentration does not
1750 determine NO production in endothelial cells: implications on the "L-arginine
1751 paradox". *Biochem Biophys Res Commun*, 414, 660-3.
- 1752 SHIN, W. S., BERKOWITZ, D. E. & RYOO, S. W. 2012. Increased arginase II activity
1753 contributes to endothelial dysfunction through endothelial nitric oxide synthase
1754 uncoupling in aged mice. *Exp Mol Med*, 44, 594-602.
- 1755 SIN, Y. Y., BALLANTYNE, L. L., MUKHERJEE, K., ST. AMAND, T., KYRIAKOPOULOU, L.,
1756 SCHULZE, A. & FUNK, C. D. 2013. Inducible Arginase 1 Deficiency in Mice Leads to
1757 Hyperargininemia and Altered Amino Acid Metabolism. *PLOS ONE*, 8, e80001.
- 1758 SONOKI, T., NAGASAKI, A., GOTOH, T., TAKIGUCHI, M., TAKEYA, M., MATSUZAKI, H. &
1759 MORI, M. 1997. Coinduction of nitric-oxide synthase and arginase I in cultured rat
1760 peritoneal macrophages and rat tissues in vivo by lipopolysaccharide. *J Biol Chem*,
1761 272, 3689-93.
- 1762 SOURIJ, H., MEINITZER, A., PILZ, S., GRAMMER, T. B., WINKELMANN, B. R., BOEHM, B.
1763 O. & MARZ, W. 2011. Arginine bioavailability ratios are associated with
1764 cardiovascular mortality in patients referred to coronary angiography. *Atherosclerosis*,
1765 218, 220-5.
- 1766 SPARKES, R. S., DIZIKES, G. J., KLISAK, I., GRODY, W. W., MOHANDAS, T.,
1767 HEINZMANN, C., ZOLLMAN, S., LUSIS, A. J. & CEDERBAUM, S. D. 1986. The
1768 gene for human liver arginase (ARG1) is assigned to chromosome band 6q23. *Am J*
1769 *Hum Genet*, 39, 186-93.
- 1770 SPECTOR, E. B., KIERNAN, M., BERNARD, B. & CEDERBAUM, S. D. 1980. Properties of
1771 fetal and adult red blood cell arginase: a possible prenatal diagnostic test for arginase
1772 deficiency. *Am J Hum Genet*, 32, 79-87.
- 1773 SPECTOR, E. B., RICE, S. C. & CEDERBAUM, S. D. 1983. Immunologic studies of arginase
1774 in tissues of normal human adult and arginase-deficient patients. *Pediatr Res*, 17,
1775 941-4.
- 1776 SPECTOR, E. B., RICE, S. C., KERN, R. M., HENDRICKSON, R. & CEDERBAUM, S. D.
1777 1985. Comparison of arginase activity in red blood cells of lower mammals, primates,
1778 and man: evolution to high activity in primates. *Am J Hum Genet*, 37, 1138-45.
- 1779 STEGGERDA, S. M., BENNETT, M. K., CHEN, J., EMBERLEY, E., HUANG, T., JANES, J.
1780 R., LI, W., MACKINNON, A. L., MAKKOUK, A., MARGUIER, G., MURRAY, P. J.,
1781 NEOU, S., PAN, A., PARLATI, F., RODRIGUEZ, M. L. M., VAN DE VELDE, L. A.,
1782 WANG, T., WORKS, M., ZHANG, J., ZHANG, W. & GROSS, M. I. 2017. Inhibition of
1783 arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor
1784 microenvironment. *J Immunother Cancer*, 5, 101.

- 1785 STEPPAN, J., RYOO, S., SCHULERI, K. H., GREGG, C., HASAN, R. K., WHITE, A. R.,
1786 BUGAJ, L. J., KHAN, M., SANTHANAM, L., NYHAN, D., SHOUKAS, A. A., HARE, J.
1787 M. & BERKOWITZ, D. E. 2006. Arginase modulates myocardial contractility by a nitric
1788 oxide synthase 1-dependent mechanism. *Proc Natl Acad Sci U S A*, 103, 4759-64.
- 1789 STEPPAN, J., TRAN, H. T., BEAD, V. R., OH, Y. J., SIKKA, G., BIVALACQUA, T. J.,
1790 BURNETT, A. L., BERKOWITZ, D. E. & SANTHANAM, L. 2016. Arginase Inhibition
1791 Reverses Endothelial Dysfunction, Pulmonary Hypertension, and Vascular Stiffness
1792 in Transgenic Sickle Cell Mice. *Anesth Analg*, 123, 652-8.
- 1793 STONE, E. M., GLAZER, E. S., CHANTRANUPONG, L., CHERUKURI, P., BREECE, R. M.,
1794 TIERNEY, D. L., CURLEY, S. A., IVERSON, B. L. & GEORGIU, G. 2010. Replacing
1795 Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine
1796 auxotrophic cancer cell lines. *ACS Chem Biol*, 5, 333-42.
- 1797 STRONG, A., GOLD, J., GOLD, N. B. & YUDKOFF, M. 2021. Hepatic Manifestations of Urea
1798 Cycle Disorders. *Clin Liver Dis (Hoboken)*, 18, 198-203.
- 1799 STUEHR, D. J., CHO, H. J., KWON, N. S., WEISE, M. F. & NATHAN, C. F. 1991.
1800 Purification and characterization of the cytokine-induced macrophage nitric oxide
1801 synthase: an FAD- and FMN-containing flavoprotein. *Proc Natl Acad Sci U S A*, 88,
1802 7773-7.
- 1803 SZEPESEI, B., AVERY, E. H. & FREEDLAND, R. A. 1970. Role of kidney in gluconeogenesis
1804 and amino acid catabolism. *Am J Physiol*, 219, 1627-31.
- 1805 TANG, W. H., WANG, Z., CHO, L., BRENNAN, D. M. & HAZEN, S. L. 2009. Diminished
1806 global arginine bioavailability and increased arginine catabolism as metabolic profile
1807 of increased cardiovascular risk. *J Am Coll Cardiol*, 53, 2061-7.
- 1808 TEUPSER, D., BURKHARDT, R., WILFERT, W., HAFFNER, I., NEBENDAHL, K. & THIERY,
1809 J. 2006. Identification of macrophage arginase I as a new candidate gene of
1810 atherosclerosis resistance. *Arteriosclerosis, thrombosis, and vascular biology*, 26,
1811 365-371.
- 1812 THACHER, T. N., GAMBILLARA, V., RICHE, F., SILACCI, P., STERGIOPULOS, N. & DA
1813 SILVA, R. F. 2010. Regulation of arginase pathway in response to wall shear stress.
1814 *Atherosclerosis*, 210, 63-70.
- 1815 THOMAS, A. C. & MATTILA, J. T. 2014. "Of mice and men": arginine metabolism in
1816 macrophages. *Front Immunol*, 5, 479.
- 1817 TOMMASI, S., ELLIOT, D. J., DA BOIT, M., GRAY, S. R., LEWIS, B. C. & MANGONI, A. A.
1818 2018. Homoarginine and inhibition of human arginase activity: kinetic characterization
1819 and biological relevance. *Sci Rep*, 8, 3697.
- 1820 TOQUE, H. A., NUNES, K. P., ROJAS, M., BHATTA, A., YAO, L., XU, Z., ROMERO, M. J.,
1821 WEBB, R. C., CALDWELL, R. B. & CALDWELL, R. W. 2013. Arginase 1 mediates
1822 increased blood pressure and contributes to vascular endothelial dysfunction in
1823 deoxycorticosterone acetate-salt hypertension. *Front Immunol*, 4, 219.
- 1824 TRATSIKOVICH, Y., GONON, A. T., KROOK, A., YANG, J., SHEMYAKIN, A., SJOQUIST,
1825 P. O. & PERNOW, J. 2013. Arginase inhibition reduces infarct size via nitric oxide,
1826 protein kinase C epsilon and mitochondrial ATP-dependent K+ channels. *Eur J*
1827 *Pharmacol*, 712, 16-21.
- 1828 TRIPOLT, N. J., MEINITZER, A., EDER, M., WASCHER, T. C., PIEBER, T. R. & SOURIJ, H.
1829 2012. Multifactorial risk factor intervention in patients with Type 2 diabetes improves
1830 arginine bioavailability ratios. *Diabet Med*, 29, e365-8.
- 1831 UEMURA, T. & GERNER, E. W. 2011. Polyamine transport systems in mammalian cells and
1832 tissues. *Methods Mol Biol*, 720, 339-48.
- 1833 VAISMAN, B. L., ANDREWS, K. L., KHONG, S. M., WOOD, K. C., MOORE, X. L., FU, Y.,
1834 KEPKA-LENHART, D. M., MORRIS, S. M., JR., REMALEY, A. T. & CHIN-DUSTING,
1835 J. P. 2012. Selective endothelial overexpression of arginase II induces endothelial
1836 dysfunction and hypertension and enhances atherosclerosis in mice. *PLoS One*, 7,
1837 e39487.
- 1838 VAN DEN BOSSCHE, J., LAMERS, W. H., KOEHLER, E. S., GEUNS, J. M., ALHONEN, L.,
1839 UIMARI, A., PIRNES-KARHU, S., VAN OVERMEIRE, E., MORIAS, Y., BRYNS, L.,
1840 VEREECKE, L., DE BAETSELIER, P. & VAN GINDERACHTER, J. A. 2012. Pivotal

- 1841 Advance: Arginase-1-independent polyamine production stimulates the expression of
1842 IL-4-induced alternatively activated macrophage markers while inhibiting LPS-
1843 induced expression of inflammatory genes. *J Leukoc Biol*, 91, 685-99.
- 1844 VAN SLYKE, D. D. & ARCHIBALD, R. M. 1946. Gasometric and photometric measurement
1845 of arginase activity. *J Biol Chem*, 165, 293-309.
- 1846 VAN ZANDT, M. C., JAGDMANN, G. E., WHITEHOUSE, D. L., JI, M., SAVOY, J.,
1847 POTAPOVA, O., COUSIDO-SIAH, A., MITSCHLER, A., HOWARD, E. I., PYLE, A. M.
1848 & PODJARNY, A. D. 2019. Discovery of N-Substituted 3-Amino-4-(3-
1849 boronopropyl)pyrrolidine-3-carboxylic Acids as Highly Potent Third-Generation
1850 Inhibitors of Human Arginase I and II. *J Med Chem*, 62, 8164-8177.
- 1851 VOCKLEY, J. G., JENKINSON, C. P., SHUKLA, H., KERN, R. M., GRODY, W. W. &
1852 CEDERBAUM, S. D. 1996. Cloning and characterization of the human type II
1853 arginase gene. *Genomics*, 38, 118-123.
- 1854 WADDINGTON, S. N., MOSLEY, K., COOK, H. T., TAM, F. W. & CATTELL, V. 1998.
1855 Arginase AI is upregulated in acute immune complex-induced inflammation. *Biochem*
1856 *Biophys Res Commun*, 247, 84-7.
- 1857 WANG, W. W., JENKINSON, C. P., GRISCAVAGE, J. M., KERN, R. M., ARABOLOS, N. S.,
1858 BYRNS, R. E., CEDERBAUM, S. D. & IGNARRO, L. J. 1995. Co-induction of
1859 arginase and nitric oxide synthase in murine macrophages activated by
1860 lipopolysaccharide. *Biochem Biophys Res Commun*, 210, 1009-16.
- 1861 WEIS-BANKE, S. E., HÜBBE, M. L., HOLMSTRÖM, M. O., JØRGENSEN, M. A.,
1862 BENDTSEN, S. K., MARTINENAITE, E., CARRETTA, M., SVANE, I. M., ØDUM, N.,
1863 PEDERSEN, A. W., MET, Ö., MADSEN, D. H. & ANDERSEN, M. H. 2020. The
1864 metabolic enzyme arginase-2 is a potential target for novel immune modulatory
1865 vaccines. *Oncoimmunology*, 9, 1771142.
- 1866 WETZEL, M. D., STANLEY, K., WANG, W. W., MAITY, S., MADESH, M., REEVES, W. B. &
1867 AWAD, A. S. 2020. Selective inhibition of arginase-2 in endothelial cells but not
1868 proximal tubules reduces renal fibrosis. *JCI Insight*, 5.
- 1869 WIJNANDS, K. A., HOEKSEMA, M. A., MEESTERS, D. M., VAN DEN AKKER, N. M.,
1870 MOLIN, D. G., BRIEDE, J. J., GHOSH, M., KOHLER, S. E., VAN ZANDVOORT, M.
1871 A., DE WINTHER, M. P., BUURMAN, W. A., LAMERS, W. H. & POEZE, M. 2014.
1872 Arginase-1 deficiency regulates arginine concentrations and NOS2-mediated NO
1873 production during endotoxemia. *PLoS One*, 9, e86135.
- 1874 WILLIAMS, F. M., KUS, M., TANDA, K. & WILLIAMS, T. J. 1994. Effect of duration of
1875 ischaemia on reduction of myocardial infarct size by inhibition of neutrophil
1876 accumulation using an anti-CD18 monoclonal antibody. *Br J Pharmacol*, 111, 1123-8.
- 1877 WINDMUELLER, H. G. & SPAETH, A. E. 1981. Source and fate of circulating citrulline. *Am J*
1878 *Physiol*, 241, E473-80.
- 1879 WINNICA, D., COREY, C., MULLETT, S., REYNOLDS, M., HILL, G., WENDELL, S., QUE,
1880 L., HOLGUIN, F. & SHIVA, S. 2019. Bioenergetic Differences in the Airway
1881 Epithelium of Lean Versus Obese Asthmatics Are Driven by Nitric Oxide and
1882 Reflected in Circulating Platelets. *Antioxid Redox Signal*, 31, 673-686.
- 1883 WU, F., PARK, F., COWLEY, A. W., JR. & MATTSON, D. L. 1999. Quantification of nitric
1884 oxide synthase activity in microdissected segments of the rat kidney. *Am J Physiol*,
1885 276, F874-81.
- 1886 WU, G. & MORRIS, S. M., JR. 1998. Arginine metabolism: nitric oxide and beyond. *Biochem*
1887 *J*, 336 (Pt 1), 1-17.
- 1888 WU, Y. S., JIANG, J., AHMADI, S., LEW, A., LASELVA, O., XIA, S., BARTLETT, C., IP, W.,
1889 WELLHAUSER, L., OUYANG, H., GONSKA, T., MORAES, T. J. & BEAR, C. E. 2019.
1890 ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary
1891 Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and
1892 Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane
1893 Conductance Regulator Channel. *Mol Pharmacol*, 96, 515-525.
- 1894 XU, W., KANEKO, F. T., ZHENG, S., COMHAIR, S. A., JANOCHA, A. J., GOGGANS, T.,
1895 THUNNISSEN, F. B., FARVER, C., HAZEN, S. L., JENNINGS, C., DWEIK, R. A.,
1896 ARROLIGA, A. C. & ERZURUM, S. C. 2004. Increased arginase II and decreased

- 1897 NO synthesis in endothelial cells of patients with pulmonary arterial hypertension.
1898 *FASEB J*, 18, 1746-8.
- 1899 XU, W., COMHAIR, S. A. A., JANOSHA, A. J., LARA, A., MAVRAKIS, L. A., BENNETT, C.
1900 D., KALHAN, S. C. & ERZURUM, S. C. 2017. Arginine metabolic endotypes related
1901 to asthma severity. *PLoS One*, 12, e0183066.
- 1902 YANG, J., GONON, A. T., SJOQUIST, P. O., LUNDBERG, J. O. & PERNOW, J. 2013.
1903 Arginase regulates red blood cell nitric oxide synthase and export of cardioprotective
1904 nitric oxide bioactivity. *Proc Natl Acad Sci U S A*, 110, 15049-54.
- 1905 YANG, J., ZHENG, X., MAHDI, A., ZHOU, Z., TRATSIKOVICH, Y., JIAO, T., KISS, A.,
1906 KOVAMEES, O., ALVARSSON, M., CATRINA, S. B., LUNDBERG, J. O., BRISMAR,
1907 K. & PERNOW, J. 2018. Red Blood Cells in Type 2 Diabetes Impair Cardiac Post-
1908 Ischemic Recovery Through an Arginase-Dependent Modulation of Nitric Oxide
1909 Synthase and Reactive Oxygen Species. *JACC Basic Transl Sci*, 3, 450-463.
- 1910 YANG, Z. & MING, X. F. 2014. Functions of arginase isoforms in macrophage inflammatory
1911 responses: impact on cardiovascular diseases and metabolic disorders. *Front*
1912 *Immunol*, 5, 533.
- 1913 YAO, L., BHATTA, A., XU, Z., CHEN, J., TOQUE, H. A., CHEN, Y., XU, Y., BAGI, Z.,
1914 LUCAS, R., HUO, Y., CALDWELL, R. B. & CALDWELL, R. W. 2017. Obesity-induced
1915 vascular inflammation involves elevated arginase activity. *Am J Physiol Regul Integr*
1916 *Comp Physiol*, 313, R560-R571.
- 1917 YOU, H., GAO, T., COOPER, T. K., MORRIS, S. M., JR. & AWAD, A. S. 2013. Arginase
1918 inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide
1919 synthase 3-dependent mechanism. *Kidney Int*, 84, 1189-97.
- 1920 YU, H., YOO, P. K., AGUIRRE, C. C., TSOA, R. W., KERN, R. M., GRODY, W. W.,
1921 CEDERBAUM, S. D. & IYER, R. K. 2003. Widespread expression of arginase I in
1922 mouse tissues. Biochemical and physiological implications. *J Histochem Cytochem*,
1923 51, 1151-60.
- 1924 ZHANG, C., HEIN, T. W., WANG, W., CHANG, C. I. & KUO, L. 2001. Constitutive expression
1925 of arginase in microvascular endothelial cells counteracts nitric oxide-mediated
1926 vasodilatory function. *FASEB J*, 15, 1264-6.
- 1927 ZHANG, N., DENG, J., WU, F., LU, X., HUANG, L. & ZHAO, M. 2016. Expression of
1928 arginase I and inducible nitric oxide synthase in the peripheral blood and lymph
1929 nodes of HIVpositive patients. *Mol Med Rep*, 13, 731-43.
- 1930 ZHOU, Z., MAHDI, A., TRATSIKOVICH, Y., ZAHORAN, S., KOVAMEES, O., NORDIN, F.,
1931 URIBE GONZALEZ, A. E., ALVARSSON, M., OSTENSON, C. G., ANDERSSON, D.
1932 C., HEDIN, U., HERMESZ, E., LUNDBERG, J. O., YANG, J. & PERNOW, J. 2018.
1933 Erythrocytes From Patients With Type 2 Diabetes Induce Endothelial Dysfunction Via
1934 Arginase I. *J Am Coll Cardiol*, 72, 769-780.
- 1935 ZHU, M., GOETSCH, S. C., WANG, Z., LUO, R., HILL, J. A., SCHNEIDER, J., MORRIS, S.
1936 M., JR. & LIU, Z. P. 2015. FoxO4 promotes early inflammatory response upon
1937 myocardial infarction via endothelial Arg1. *Circ Res*, 117, 967-77.
- 1938

1939 **VIII. Tables**

1940 **Table 1: Characteristics of arginases in humans, rats, and mice. Please note that**
 1941 **according to NCBI, human proteins are abbreviated with ARG1 and ARG2 (with all**
 1942 **capital letters), for all other species abbreviation is Arg1 and Arg2. In the text, we use**
 1943 **Arg1 and Arg2 to indicated the Arg1 and Arg2 enzymes from all species.**

	Gene Name	Protein Names	Chromosome	Size	Uni-prot ID	Co-factors	Localization
Human	ARG1	Arginase 1 (ARG1) Arginase I (AI) Liver-Type Arginase Type I Arginase	6q23.2	322 aa (35 kDa)	P05089	Two Mn ²⁺ ions each Oligomerization (Homotrimer)	Cytosol
		Three identified isoforms by alternative splicing (Isoform 1: 322 aa / Isoform 2: 330 aa / Isoform 3: 236 aa)					
Rat	Arg1	Arg1	1p12	323 aa (35 kDa)	P07824		
Mouse	Arg1	Arg1	10 A4	323 aa (35 kDa)	Q61176		
Zebrafish	Sl:zC146F4.4	Arg	12	341 aa (37 kDa)	E7F8R4		
Human	ARG2	Arginase 2 (ARG2) Arginase II (AII) Kidney-type Arginase Non-hepatic Arginase Type II Arginase	14q.24.1	354 aa (39 kDa)	P78540		Mitochondria
Rat	Arg2	Arg2	6q24	354 aa (39 kDa)	O08701		
Mouse	Arg2	Arg2	12 C3	354 aa (39 kDa)	O08691		
Zebrafish	ARG2	Arg2	13	347 aa (38 kDa)	Q6PH54		

1944

Table 2: Summary of arginase specific knock out models

Mice Model	Targeted isoforms	Gene targeting strategy	Phenotype	Reference
Effect of genetic modification on home strain				
Global Arg1 ^{-/-}	Arg1	The replacement vector consisted of genomic sequences from exon 2 to exon 8, in which exon 4 was replaced by the neomycin resistance cassette (Neo ^R)	<ul style="list-style-type: none"> • Hyperammonaemia • Early lethal (between day 10 and 14) 	(Iyer et al., 2002)
Global Arg2 ^{-/-}	Arg2	Partly deletion of exons 4 and 5 of the Arg2 gene (by Sin et al.)	<ul style="list-style-type: none"> • Homozygous Arg2^{-/-} mice were viable • Plasma L-arginine level ↑ • Plasma norepinephrine turnover ↑ • Hypertension 	(Shi et al., 2001, Huynh et al., 2009)
Global Arg2 ^{-/-}	Arg2	Arg2 ^{fllox/fllox} (exon 2+3) FVB/NTgN(ACTB-Cre)2Mrt mice	<ul style="list-style-type: none"> • Arg2^{-/-} mice are unable to produce intestinal mucin • Arg2^{-/-} mice became highly susceptible to experimentally induced colitis 	(Park et al., 2009)
Inducible global Arg1 ^{-/-}	Arg1	Arg1 ^{fllox/fllox} (exons 7 and 8) CreER ^{T2}	<ul style="list-style-type: none"> • Lethal 2 weeks after Tamoxifen treatment • L-citrulline and guanidinoacetic acid ↑ • L-ornithine levels = • other amino acids ↓ 	(Sin et al., 2013)
Arg1 ^{-/-} Arg2 ^{-/-} mice	Arg1 Arg2	Arg1 ^{-/-} Arg2 ^{-/-} mice were generated by crossing Arg1 ^{+/-} mice (by Iyer et al.) with Arg2 ^{-/-} mice (by Sin et al.)	<ul style="list-style-type: none"> • L-arginine level ↑ • L-ornithine levels ↓ • Liver L-ornithine levels reduced to 2% with L-arginine very highly elevated. 	(Deignan et al., 2006)
Cell-specific arginase knockout models				
Liver-specific Arg1 ^{-/-}	Arg1	Deletion of exons 7 and 8 of the Arg1 gene after i.p. injection of Arg1 ^{fllox/fllox} (exons 7 and 8) mice with AAV-TBG-Cre-Promoter-Cre recombinase vector	<ul style="list-style-type: none"> • Lethal phenotype similar to the inducible Arg1^{-/-} mice phenotype • Delivery of Arg1-eGFP AAV vector prolongs lifespan 	(Ballantyne et al., 2016)

EC/HC Arg1 ^{-/-}	Arg1	Arg1 ^{fllox/fllox} (exon 4) Tie2-Cre deleter	<ul style="list-style-type: none"> • IL-4-induced polyamine production ↑ 	(Van den Bossche et al., 2012)
EC Arg1 ^{-/-}	Arg1	Arg1 ^{fllox/fllox} (exons 7 and 8) Cdh5-Cre/ERT2 ^{pos}	<ul style="list-style-type: none"> • Expression of eNOS in the aorta ↓ • L-arginine & NO bioavailability = • Vascular endothelial function in conductance and resistance arteries = • Preserved systemic hemodynamic and cardiac performance • Increased contractile response to phenylephrine in aorta rings 	(Heuser et al., 2022)
Microglial-specific Ar1 ^{-/-}	Arg1	Arg1 ^{fllox/fllox} (exons 7 and 8) Cx3cr1 ^{CreER}	<ul style="list-style-type: none"> • No notable morphological differences • Impaired cholinergic innervation and dendritic spine maturation in the hippocampus • Deficits in long-term memory acquisition in females 	
Effect of disease conditions (selected)				
<i>Infectious disease</i>				
Macrophage Arg1 ^{-/-} Toxoplasmid gonid/tuberculosis	Arg1	Arg ^{fllox/fllox} ; (exon 7 and 8) Tie2Cre ^{tg/-} Promoter LysMCre ^{tg/-} Promoter	<ul style="list-style-type: none"> • Knockout^{Tie2} showed complete Arg1 ablation in all macrophage types, knockout^{LysM} showed less deletion • Host survival in Toxoplasma gondii infection ↑ • Lung bacterial load in tuberculosis infection ↓ 	(El Kasmi et al., 2008)
Asthmatic Arg1 deficient BM chimeric mice	Arg1	Transfer Arg1 deficient BM into irradiated recipient mice Asthma model: OVA-induced or <i>Aspergillus fumigatus</i> -induced	<ul style="list-style-type: none"> • M-derived Arg1 is not required for baseline immune cell development and allergen-induced inflammation • BM-derived Arg1 is the main source of allergen-induced lung arginase 	(Niese et al., 2009)
Global Arg2 ^{-/-} mice Infected with <i>H. pylori</i>	Arg2	Partly deletion of exons 4 and 5 of the Arg2 gene (by Sin et al.)	<ul style="list-style-type: none"> • Macrophages of Arg2^{-/-} mice iNOS-protein levels & NO levels ↑ • Inhibition of arginase in Arg2^{-/-} mice did not have additional effects on iNOS or NO levels 	(Lewis et al., 2010)
Global Arg2 ^{-/-} mice infected with <i>H.pylori</i>	Arg2	Partly deletion of exons 4 and 5 of the Arg2 gene (by Sin et al.)	<ul style="list-style-type: none"> • Arg2^{-/-} macrophages undergo less apoptosis • Arg2^{-/-} macrophages more abundant • Arg2^{-/-} macrophages iNOS ↑ • Arg2^{-/-} macrophages nitrotyrosine staining ↑ 	(Lewis et al., 2011)
EC & HC Arg1 ^{-/-} in endotoxemia	Arg1	Arg1 ^{fllox/fllox} ; Exon 4 Tie2Cre ^{tg/-} Promoter	<ul style="list-style-type: none"> • Inflammatory response ↑ • NO production by iNOS ↑ • Depressed microcirculatory flow in the jejunal 	(Wijnands et al., 2014)
Double Arg2 ^{-/-} Nos2 ^{-/-} mice infected with <i>H. pylori</i>	Arg2	Double Arg2 ^{-/-} Nos2 ^{-/-} obtained by crossing Arg2 ^{-/-} mice (obtained by deletion of exons 4 and 5 of the Arg2 gene) and Nos2 ^{-/-}	<ul style="list-style-type: none"> • In Arg2^{-/-}, gastric polyamine synthesis and catabolism ↑ • Arg2^{-/-} and Arg2^{-/-};Nos2^{-/-}, gastritis ↑ colonization • In Arg2^{-/-}, M1 macrophage activation ↑, NOS2^{-/-} and Arg2^{-/-};Nos2^{-/-}, M1 macrophage activation = 	(Hardbower et al., 2016)



		mice obtained by deletion exons 12 and 13 of the NOS2 gene		
<i>Inflammatory disease/asthma</i>				
Asthmatic EC/HC Arg ^{-/-}	Arg1	Arg1 ^{fllox/fllox} : exon 4 Tie2Cre ^{tg/-} Promoter or LysMCre ^{tg/-} Promoter Asthma model: OVA-induced allergic asthma in female mice	<ul style="list-style-type: none"> Arg1 allele was virtually completely deleted in the lungs of knockout^{Tie2} mice, but incompletely in knockout^{LysM} mice Improved peripheral lung function in OVA-treated knockout^{Tie2} mice Knockout^{Tie2} mice did not alter air hyperreactivity and lung inflammation 	(Cloots et al., 2013)
Asthmatic Myeloid cell Arg1 ^{-/-} in female mice	Arg 1	Arg1 ^{fllox/fllox} : exon 4 Tie2Cre ^{tg/-} Promoter LysMCre ^{tg/-} Promoter Asthma model: OVA-induced allergic asthma in female mice	<ul style="list-style-type: none"> Arg1 positive cells completely absent from the lungs of OVA-treated knockout^{Tie2} mice, but only reduced in knockout^{LysM} mice Compared to male mice, females show more decline of arginine-metabolizing and -transporting genes, OVA-specific IgE ↓ methacholine responsiveness and accumulation of inflammatory cells = 	(Cloots et al., 2017)
<i>Diabetes/CVD</i>				
Diabetic Arg2 ^{-/-}	Arg2	Partly deletion of exons 4 and 5 of the Arg2 gene (by Sin et al.)	<ul style="list-style-type: none"> Albuminuria ↓ Macrophages recruitment ↓ Renal blood flow ↑ 	(Morris et al., 2011)
Diabetic Arg1 ^{+/-} Arg 2 ^{-/-}	Arg1 Arg2	Arg 1 -/- Arg 2 -/- mice were generated by crossing Arg 1 +/- mice (by Lyer et al.) with Arg 2 -/- mice (by Sin et al.) + STZ treatment	<ul style="list-style-type: none"> Impairment of EC-dependent vasodilation ↓ Tissue oxidation, vascular stiffness, and coronary fibrosis ↓ 	(Romero et al., 2012)
EC Arg1 ^{-/-} mice fed a high-fat/high-sucrose diet	Arg1	Arg ^{fllox/fllox} (exon 7&8) Cdh5-Cre ^{pos/neg}	<ul style="list-style-type: none"> Prevention of endothelial dysfunctions 	(Bhatta et al., 2017)
Diabetic EC/HC Arg1 ^{-/-}	Arg1	Arg1 ^{fllox/fllox} (exon 4) Tie2Cre ^{tg/-} mice Diabetic model, induced by STZ treatment	<ul style="list-style-type: none"> L- arginine concentration in plasma ↑ Diabetes-induced alterations in arterial smooth muscle reactivity and endothelium-dependent relaxations = 	(Chennupati et al., 2018)
<i>Renal disease</i>				





EC Arg2 ^{-/-} & proximal tubular cell Arg2 ^{-/-} with unilateral ureteral obstruction	Arg2	Arg2 ^{fllox/fllox} (exon 3) Tie2-Cre ^{pos/neg} Ggt1-Cre ^{pos/neg}	<ul style="list-style-type: none"> • EC Arg2 knockout, level of renal fibrosis ↓ • Proximal tubular epithelial cell Arg2 knockout, level of fibrosis = 	(Wetzel et al., 2020)
Renal tubular cells Arg2 ^{-/-}	Arg2	Arg2 ^{fllox/fllox} (exons 3, 4, 5 and 6) Pax8-rtTA/LC1 mice	<ul style="list-style-type: none"> • Urea concentration and os-molality gradients along the corticomedullary axis ↓ • Tissue damage after unilateral I/R-injury • Albuminuria and aminoaciduria 	(Ansermet et al., 2020)
<i>Atherosclerosis</i>				
Erythroid Arg1 ^{-/-} on apoE ^{-/-} background + HFD	Arg1	Arg ^{fllox/fllox} (exon 7&8) apoE ^{-/-} EpoR-Cre ^{pos/neg} mice + Western diet (high cholesterol)	<ul style="list-style-type: none"> • Atherosclerotic lesion size at the aortic root = • Vascular NO bioactivity, smooth muscle osteoblastic differentiation, and atherosclerotic lesion calcification ↑ • L-Ornithine, proline in vascular smooth muscle cells expression ↑ 	(Gogiraju et al., 2022)

Table 3 Established and potential therapeutic applications

Therapeutic intervention	Indication	Status	Reference
Pegylated arginase1	<ol style="list-style-type: none"> Arg1 deficiency Arginase auxotrophic tumors Immunosuppression 	<ol style="list-style-type: none"> Approved as orphan drug by the EMEA open-label Phase II trial Not tested 	<ol style="list-style-type: none"> (Russo et al., 2024) (Cheng et al., 2021) (Munder, 2009)
L-Arginine/L-Citrulline supplementation	<ol style="list-style-type: none"> Chest Pain T2DM Endothelia dysfunction 	<ol style="list-style-type: none"> Clinical trial Clinical trial Clinical trial 	<ol style="list-style-type: none"> (Lerman et al., 1998) (Sultanawi et al., 2020) (Chin-Dusting et al., 1996)
Arginase inhibitor	<ol style="list-style-type: none"> T2DM (+CVD) Advanced/metastatic solid tumors with upregulation of Arg1 Infection with parasites Pulmonary hypertension in SCD 	<ol style="list-style-type: none"> clinical tests/ Phase I clinical trial phase I clinical trial Mice studies Mice studies 	<ol style="list-style-type: none"> (Shemyakin et al., 2012, Kövamees et al., 2012) (Steggerda et al., 2017, Kuboki et al., 2023, Naing et al., 2024) (Li et al., 2022b) (Morris et al., 2005a, Steppan et al., 2016)

Table 4 arginase inhibitors used in human-based *in vitro/ex vivo* studies

Name	Structure	Test	U.S. National Clinical Trial number	Administration	application	Reference
First generation						
ABH (2-(S)-amino-6-borohexanoic acid)		In vitro	n.a.	n.a.	n.a.	(Van Zandt et al., 2019)
BEC (S-(2-boronoethyl)-L-cysteine)		In vitro/ex vivo/clinical trial	n.a.	Intradermal microdialysis in combination with NOHA	CVD	(Busnel et al., 2005, Holowatz et al., 2006)

nor-NOHA (N ω -hydroxy-nor-arginine)		In vitro/ex vivo/clinical trial	NCT 02009527 NCT 05536934 NCT 02687152 NCT 05806502	Intrabrachial infusion/ sublingual perfusion/ intradermal microdialysis/ intra-arterial infusion	CVD, D2TM, Obese	(Kövamees et al., 2014, Van Zandt et al., 2019)
Second generation						
ABH analogues (synthesized based on Ugi reaction)		In vitro/in vivo	n.a.	n.a.	n.a	(Golebiowski et al., 2013)
Third generation						
NED 3238		In vitro	n.a.	n.a.	n.a	(Van Zandt et al., 2019)
INCB001158 (formerly named as CB-1158)		Clinical trial phase 1/phase 2/in vitro	NCT 03314935 NCT 02903914 NCT 03910530 NCT 03361228 NCT 03837509	Oral application	Solid tumours	(Steggerda et al., 2017, Kuboki et al., 2024, Naing et al., 2024)

956 **Table 5. Summary of human studies on arginases and its substrates and products**

Study subjects Cohort (number of subjects)	Parameters	intervention	Main findings	Reference
Measurement of L-arginine bioavailability in human cohorts				
Subjects without significantly obstructive CAD (402) vs subjects with significantly obstructive CAD (608)	GABR in plasma	N.A.	<ul style="list-style-type: none"> GABR ↓ and L-citrulline level ↑ associated with the development of significantly obstructive atherosclerotic CAD and raise the risk of MACE 	(Tang et al., 2009)
CAD (2236)	GABR, L-arginine-to-L-ornithine ratio in serum	N.A.	<ul style="list-style-type: none"> GABR inversely correlated with endothelial markers such as ICAM-1 and VCAM-1 GABR ↓ and arginine-to-ornithine ratio ↓ are associated with a significant increase in cardiovascular mortality GABR ↓ in subjects with T2DM than subjects without diabetes 	(Sourij et al., 2011)
T2DM (41)	GABR In plasma	Intensified risk factor intervention	<ul style="list-style-type: none"> GABR and L-arginine-to-L-ornithine ratio ↑ after 3 months with intensified risk factor intervention such as glucose-lowering treatment, anti-hypertensive treatment, and lipid-lowering treatment 	(Tripolt et al., 2012)
adults with COVID-19 (32) and children with COVID-19/MIS-C (20) vs adult controls (28)	GABR, L-arginine-to-L-ornithine ratio in plasma	N.A.	<ul style="list-style-type: none"> L-arginine ↓, L-arginine-to-L-ornithine ratio ↓, and GABR ↓ in the COVID-19-positive adult and COVID-19/MIS-C pediatric group Low GABR might contribute to immune dysregulation and endothelial dysfunction in COVID-19 Low L-arginine-to-L-ornithine ratio might be due to the elevated arginase activity 	(Rees et al., 2021)
subjects with STEMI (70)	L-arginine metabolite levels in plasma	NOS inhibitor, L-NAME	<ul style="list-style-type: none"> Median concentration of L-arginine in acute phase of myocardial infarction > 6-month follow-up measurements correlated with ischemia risk area and infarct size Median L-citrulline/L-arginine ↓, L-citrulline/L-ornithine and arginine/ADMA = indicating a shift of L-arginine metabolism from NOS towards arginase Low L-arginine concentration associated with worse long-term outcomes 	(Molek et al., 2021)

Arginase expression and activity in human disease				
Early phase of myocardial infarction (100)	Arginase activity in serum after myocardial infarction (measured from a few hours after the first attack of coronary pain until 5 days)		<ul style="list-style-type: none"> Arginase activity ↑ in the 10-30 hours after the attack Normal values after 3-5 days No changes in individuals with angina pectoris, acute coronary insufficiency, left cardiac failure, right cardiac failure, or cardiac insufficiency 	(Poremska and Kedra, 1975)
PAH (41) vs controls (37)	L-arginine metabolites, arginase activity in pulmonary artery ECs	none	<ul style="list-style-type: none"> Arginase activity ↓ and Arg2 expression ↓ in the pulmonary artery ECs from the lung of individuals with PAH 	(Xu et al., 2004)
Sickle cell disease (228) vs controls (36)	Amino acid levels (Arg, Orn, Cit, and Pro) and arginase activity in plasma, pulmonary hypertension, Mortality	N.A.	<ul style="list-style-type: none"> Plasma arginase activity ↑ Correlation between arginase activity and L-arginine-to-L-ornithine ratio Correlation between arginase activity and increased intravascular hemolytic rate Low L-arginine-to-L-ornithine ratio associated with greater severity of pulmonary hypertension and mortality 	(Morris et al., 2005a)
Thalassemia (14) vs controls (36)	Amino acid levels (Arg, Orn, Cit, and Pro) and arginase activity in plasma	N.A.	<ul style="list-style-type: none"> L-arginine levels ↓, L-ornithine levels ↑, L-citrulline ↑ L-arginine-to-L-ornithine ratio ↓ arginase activity in plasma ↑ 	(Morris et al., 2005b)
Sickle cell disease (35) vs controls (10)	Arginase and NOS activity in plasma and RBCs, Fetal hemoglobin levels blood count	23 humans with SCD with hydroxyurea-therapy, 12 humans with SCD without HU-therapy	<ul style="list-style-type: none"> Arginase activity ↓ in individuals with hydroxyurea-therapy, a treatment with ribonucleotide reductase inhibitor Fetal hemoglobin levels ↑ NOS activity ↑ in subjects with hydroxyurea Therapy 	(Iyamu et al., 2005) (Iyamu et al., 2005)
Asthma (6) vs controls (7)	Arg1 expression in lung tissues	N.A.	<ul style="list-style-type: none"> Arg1 expression ↑ in subjects with asthma 	(North et al., 2009)
MI (43) vs controls (33)	Arg1 activity and expression in serum, L-arginine, and ADMA concentrations in plasma	N.A.	<ul style="list-style-type: none"> Arginase activity ↓ and arginase expression ↑ in blood serum from people with MI Arginase expression negatively associated with left ventricular ejection fraction Low L-arginine/ADMA ratio in plasma MI people 	(Bekpinar et al., 2011)

Endothelial dysfunction (110) vs controls (106)	Arg1 and Arg2 in plasma (levels and activities)	N.A.	<ul style="list-style-type: none"> Arg1 genetic variations affect ED severity Arg2 concentrations ↑ in plasma of people with ED 	(Lacchini et al., 2015)
HIV-asymptomatic (19), AIDS (33) vs controls lymph nodes (13), controls peripheral blood (20)	Arg1 expression in lymph nodes and peripheral blood	N.A.	<ul style="list-style-type: none"> Arg1 expression ↑ in the lymph nodes from HIV-infected people 	(Zhang et al., 2016)
Asthmatics (52) vs controls (51)	Arginase activity in serum, expression of Arg2 in airway epithelium	none	<ul style="list-style-type: none"> Arg2 expression ↑ in the airway of asthmatic human 	(Xu et al., 2017)
T2DM (46) vs controls (34)	Arginase activity in RBCs forearm blood flow, RBC (human)-aorta (rat) co-incubation	Incubation of RBC with ABH	<ul style="list-style-type: none"> Arginase activity in RBCs from subjects with T2DM ↑ RBC from subjects with T2DM-induced endothelial dysfunction Inhibition of ROS and arginase prevented endothelial dysfunction in <i>ex vivo</i> bioassay 	(Zhou et al., 2018)
T2DM (27) vs controls (23)	Arginase expression and activity in RBCs, effect of glucose on RBC arginase <i>ex vivo</i> , I/R on Langendorff heart		<ul style="list-style-type: none"> RBC arginase activity ↑ and production of ROS ↑ in RBCs RBCs from people with T2DM aggravate myocardial I/R injury in Langendorff heart Inhibition of arginase in RBCs improves post-ischemic myocardial recovery 	(Yang et al., 2018)
T2DM (18) vs controls (20)	RBC (individuals)-aorta (rat) co-incubation, arginase activity in aortic rings		<ul style="list-style-type: none"> Peroxynitrite scavenging with FeTTPS in RBCs reversed endothelial dysfunction in bioassay <i>ex vivo</i> Upregulation of arginase in T2D-RBCs and vasculature is peroxynitrite-dependent 	(Mahdi et al., 2020b)
Administration of arginase inhibitors				
CAD (16), CAD and T2DM (16) vs controls (16)	Arginase expression in the arteries, EDV	nor-NOHA	<ul style="list-style-type: none"> Inhibition of arginase significantly improves endothelial function in humans with CAD and T2DM Upregulation of arginase activity is a critical factor in endothelial dysfunction 	(Shemyakin et al., 2012)
CAD (12) vs CAD and T2DM (12)	EDV	nor-NOHA	<ul style="list-style-type: none"> Inhibition arginase provides protection against I/R-induced endothelial dysfunction in humans with CAD 	(Kövamees et al., 2014)
CAD (16), CAD and T2DM (16) vs controls (16)	EDV	arginase inhibitor nor-NOHA	<ul style="list-style-type: none"> Inhibition of arginase improves microvascular endothelial function in humans with T2DM and microvascular dysfunction Inhibition of arginase protects against I/R-induced endothelial dysfunction in humans with CAD 	(Kovamees et al., 2016a, Mahdi et al., 2018)

Controls (21)	EDV	Arginase inhibitor nor-NOHA	<ul style="list-style-type: none"> • Baseline EDV inversely associated with the age of the participants • Inhibition of arginase improves EDV, associated with the age of the participants • Inhibition of arginase improves endothelial function in elderly healthy subjects, age-dependent. 	(Mahdi et al., 2019)
Supplementation of L-arginine/L-citrulline				
Subjects referred to tertiary treatment for heart failure	Forearm blood flow, 6-minute walk test, symptom scores	supplementation of L-arginine	<ul style="list-style-type: none"> • Supplementation of L-arginine significantly increased the forearm blood flow during forearm exercises, the distance in 6-minute walk test, and lowered symptom scores 	(Rector et al., 1996)
Healthy individuals (26)	Forearm resistance arteries, major amino acids in plasma	28-day supplementation of L-arginine	<ul style="list-style-type: none"> • L-arginine led to no effect on endothelial function in healthy adults and changes in the total amino acid profile but not L-arginine concentration in plasma. 	(Chin-Dusting et al., 1996)
Subjects with chest pain and coronary endothelial dysfunction	Coronary blood flow	6-month supplementation of L-arginine	<ul style="list-style-type: none"> • Long-term supplementation of L-arginine increased the coronary blood flow, associated with improved symptom scores and a decrease in plasma endothelin concentrations 	(Lerman et al., 1998)
T2DM (25)	Arginase activity in plasma; levels of nitrite and nitrate in plasma	supplementation of L-citrulline	<ul style="list-style-type: none"> • Supplementation of L-citrulline reduced arginase activity and plasma NO levels in individuals of T2DM 	(Shatanawi et al., 2020)
Treatment with PEG-Arginase				
Arginase auxotrophic tumor (23)	L-arginine level in plasma, PEG-BCT-100 level in plasma, change in tumor size	Intravenous PEG-BCT-100	<ul style="list-style-type: none"> • Median L-arginine maintained at 2.5 μM after the second PEG-BCT-100 injection • Therapeutic L-arginine depletion found in 1.7 and 2.7 mg/kg/week cohorts with anti-tumor activities 	(Cheng et al., 2021)
Arg1 deficiency (32)	L-arginine level in plasma, functional mobility (Gross Motor Function Measure part E and 2-min walk test)	Intravenously/subcutaneously, one-weekly pegzilarginase treatment	<ul style="list-style-type: none"> • Pegzilarginase treatment lowered mean L-arginine in plasma from 354.0 μM to 86.4 μM as compared to patients treated with placebo from 464.7 μM to 426.6 μM • Patients treated with pegzilarginase observed clinically relevant functional mobility improvements 	(Russo et al., 2024)

958 **IX. Footnotes**

959 **Authorship contribution**

960 All authors contributed with manuscript writing, drafting of figures and editing the manuscript.

961 **Acknowledgements**

962 This research was funded by research grants from the German Research Council (DFG) (to
963 M.M.C.-K. and Dr. Johannes Stegbauer), grant number 263779315; and from DFG (to
964 M.M.C.-K.), grant number 521638178; from the Research Commission, Medical Faculty of
965 the Heinrich Heine University Duesseldorf (to M.C. K. and J.L.);

966 **Data Availability Statement**

967 This review article contains no datasets generated or analyzed during the current study

968 **Conflict-of-interest statement**

969 No author has an actual or perceived conflict of interest with the contents of this article.

970 X. Legend of figures

971 **Graphical Abstract:** Biochemistry, pharmacology, and in vivo function of arginases revisited: lessons
972 from cell-specific Arg1 and Arg2^{-/-} mice and human studies. Arginase converts L-arginine to L-
973 ornithine and urea and plays important roles in various biological processes, including the urea cycle
974 in the liver, the synthesis of polyamine and L-proline, and the control of L-arginine local bioavailability
975 for NO production in the vessel wall and inflammatory cells. Recent studies performed in cell-specific
976 transgenic mice and in human specimens indicate that the regulation and function of Arg1 and Arg2
977 appear to be cell type-specific, species-specific and profoundly different in mouse and human.
978 Specificity and availability of arginase inhibitors in human are still limited by their lack of isoform
979 specificity and for their poor pharmacodynamic properties, which means that they have to be
980 administrated i.v., or i.p. The only approved drug is so far a pegylated-arginase for the treatment of
981 hyperarginemia related to genetic defects of the ARG1 gene. Understanding the regulation of Arg1
982 and Arg2 in different cell types under consideration of their localization, species-specificity, and
983 multiple biochemical and physiological roles could lead to better pharmacological strategies to target
984 arginase in liver, cardiovascular, hematological, immune/infection diseases and cancer.

985 **Figure 1 Hydrolysis of L-arginine to L-ornithine and urea catalyzed by arginase**

986 **Figure 2 Synthesis of polyamines from L-ornithine**

987 **Figure 3 Domain organization of Arg1 and Arg2 in homo sapiens** – Arg1 comprises 322 aa and
988 exists as the canonical protein (isoform 1), a longer variant that includes the sequence VTQNFLIL
989 following Q43 (isoform 2) and an aa 204-289 depletion variant (isoform 3). Two substrate-binding
990 regions (dark blue) were identified as well as Mn²⁺ interacting aa that are not marked here. Arg2
991 sequence starts with a mitochondrial transit peptide (Marselli et al., 2021) followed by the main body of
992 the enzyme (blue) and closes of with a disordered region (yellow). The substrate binding regions are
993 marked in dark blue

994 **Figure 4 Active site of a monomer of Arg1 showing a binuclear manganese center coordinated**
995 **with 2 His and 4**

996 **Figure 5 Urea cycle in the liver.** The urea cycle is divided into five steps. The first two steps consist
997 in the generation of carbamoylphosphate from ammonia and synthesis of L-citrulline which takes place
998 in the mitochondria. L-Citrulline is transported to the cytosol and undergoes conversion into
999 argininosuccinate by argininosuccinate synthetase. Argininosuccinate is then cleaved into L-arginine and
1000 fumarate by the argininosuccinase, and then Arg1 in the cytosol hydrolyzes L-arginine to L-ornithine and
1001 urea in a final step. L-Ornithine is transported back into the mitochondria, where is transformed again
1002 into L-citrulline. Instead, urea is exported into the blood and is excreted in the urine via the kidney.

1003 **Figure 6 Arginase/iNOS pathway in mouse macrophages** (figure created with biorender.com)

1004 **Figure 7 L-arginine metabolism in endothelial cells.** In endothelial cells, L-arginine serves as a key
1005 substrate for both nitric oxide (NO) synthesis by endothelial nitric oxide synthase (eNOS) and
1006 catabolism by arginases 1 (Arg1) and arginase 2 (Arg2). eNOS is well-known to produce NO, which
1007 diffuses to vascular smooth muscle cells where it activates soluble guanylate cyclase (sGC), leading
1008 to vasorelaxation. Given the co-expression of both arginase isoforms within the endothelium, it is
1009 proposed that they act as functional counterparts to eNOS, indirectly regulating its activity. Data from
1010 cell-specific mice models reveal that this competition becomes only relevant in disease conditions
1011 leading to an increase in arginase activity, and instead is less relevant under homeostatic conditions.
1012 Abbreviations: cGMP, cyclic guanosine monophosphate; GTP, guanosine triphosphate; (figure created
1013 with biorender.com)

1014 **Figure 8 Synthesis of L-arginine in the kidney.** L-Arginine is endogenously synthesized in the
1015 kidney in a reaction catalyzed by argininosuccinate synthetase and argininosuccinate lyase by using
1016 circulating L-citrulline produced in the intestine. Synthesis occurs throughout the whole length of the
1017 proximal tubule, but is particularly high in the early part closest to the glomerulus, the proximal
1018 convoluted tubule (PCT), and gradually decreases in the terminal part in the outer medulla, the
1019 proximal straight tubule (PST). Only a small part of the L-arginine synthesized in the kidney is used for
1020 the production of polyamines and creatine from L-ornithine, while most of it is released into the
1021 circulation, making it available for other tissues (figure created with biorender.com).

Fig. 1







Fig. 2





Arginase





Ornithine aminotransferase

Ornithine decarboxylase



Spermidine synthase

P5C reductase



Spermine synthase






Fig.3

Arginase 1




Arginase 2



- Substrate binding
- Mitochondrial transit peptide
- Disordered region

Fig. 4






Fig.5

Fig. 6





Fig.7



Downloaded from <http://www.aspetjournals.org> at ASPET Journals on December 20, 2024

Fig. 8

